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Introduction and Outline of Thesis
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This thesis describes the use of operational research to identify programmatic challenges 
relating to Tuberculosis (TB) and the Human Immunodeficiency Virus (HIV) in order to 
provide evidence-based solutions for mitigating the high burden of TB in Zimbabwe. The 
chapters in this thesis explore issues such as time delays from symptom onset to treatment 
initiation, access to HIV testing and timely initiation of antiretroviral therapy (ART) and their 
relationship to TB treatment outcomes. The chapters also explore risk factors for TB case 
fatality and the national impact of ART scale-up on TB case notification rates in Zimbabwe. 
The study findings will help Zimbabwe begin to meet some of the targets of the World Health 
Organization’s (WHO) End TB Strategy and assist the country in reaching the goal of ending 
TB by 2030. 
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GLOBAL BURDEN AND RESPONSE TO TUBERCULOSIS, HIV/AIDS AND ASSOCIATED 
ILLNESS
TUBERCULOSIS
TB is an infectious disease with a high global burden, and is caused by the bacterium, 
Mycobacterium tuberculosis. Estimates published in 2014 suggest that 1.7 billion people 
are infected with Mycobacterium tuberculosis, which translates to about one quarter of the 
world’s population.1 The majority of these people with so called Latent TB infection (LTBI) 
never progress to active disease, with their immune systems able to keep multiplication 
of the organisms in check. However, between 5-10% of those with LTBI go on to develop 
active disease, with the risk being increased in early childhood and old age and by other 
determinants such as exposure to silicosis, tobacco or alcohol, malnutrition and co-infections 
/ co-morbidities such as HIV infection and diabetes mellitus.2,3,4 Active tuberculosis (TB) often 
presents as pulmonary disease with cough, chest pain, fever, night sweats and weight loss, 
but extra-pulmonary disease may also occur in up to one third of patients.5
According to the 2015 Global Burden of Disease Study, TB was ranked either 11th or 12th in 
1990, 2005 and 2015 in terms of leading causes of death in the world.6 According to the WHO, 
in 2015 there were an estimated 10.4 million new cases of TB and 1.8 million TB deaths; 
400,000 of which were associated with HIV infection and the acquired immune deficiency 
syndrome (AIDS).7 When disaggregated by gender and age group, 5.9 million cases of TB were 
among men, 3.5 million among women and 1.0 million among children (aged 0-14 years).7 
Despite the persisting high burden of TB, progress has been made over the last 25 years in 
mitigating this scourge. With the resurgence of TB in the 1980s, the WHO in 1993 declared 
TB as a global emergency and subsequently developed a framework for TB control. This 
framework, based on the pioneering work of Dr Karel Styblo,8 in Tanzania and elsewhere, 
was subsequently branded “DOTS” (Directly Observed Therapy, Short-Course) by WHO and 
incorporated an important five point policy package (Table 1).9 Between 1995 and 2005, 
DOTS was successfully expanded to 190 countries, and 26 million people, who were mostly 
poor, were successfully treated with standardised anti-TB treatment regimens.
CHAPTER 1
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Table 1: Five-Point Policy package of the DOTS Framework for Tuberculosis Control.
1. Government commitment to sustained TB control activities. 
2. Case detection by sputum smear microscopy among symptomatic patients self-reporting to health 
services.
3. Standardized treatment regimen of six to eight months for at least all confirmed sputum smear 
positive cases, with directly observed treatment (DOT) for at least the initial two months.
4. A regular, uninterrupted supply of all essential anti-TB drugs. 
5. A standardized recording and reporting system that allows assessment of treatment results for each 
patient and of the TB control programme overall.
In 2005, the Stop TB Strategy replaced the DOTS strategy as the mechanism to reduce the 
global burden of TB by 2015 in line with the Millennium Development Goals (MDG),10 and the 
Stop TB Partnership targets. Goal 6 of the MDG aimed to halt and reverse TB incidence by 
2015, while the Stop TB Partnership aimed to halve TB prevalence and deaths due to TB by 
2015 in comparison to the baseline of 1990 and to eliminate TB as a public health problem by 
2050.11 In order to achieve these goals and targets, the Stop TB strategy had six components 
which are outlined in the Table 2.
Table 2: Components of the Stop TB strategy.
Component Activities
Pursue high-quality 
DOTS expansion and 
enhancement
• Secure political commitment, with adequate and sustained financing
• Ensure early case detection, and diagnosis through quality-assured 
bacteriology
• Provide standardized treatment with supervision, and patient support
• Ensure effective drug supply and management
• Monitor and evaluate performance and impact 
Address TB-HIV, 
MDR-TB and the 
needs of poor and 
vulnerable populations
• Scale-up collaborative TB/HIV activities
• Scale-up prevention and management of multidrug-resistant TB (MDR-
TB)
• Address the needs of TB contacts, and of poor and vulnerable 
populations 
Contribute to health 
system strengthening 
based on primary 
health care 
• Help improve health policies, human resource development, financing, 
supplies, service delivery and information
• Strengthen infection control in health services, other congregate settings 
and households
• Upgrade laboratory networks, and implement the Practical Approach to 
Lung Health (PAL)
• Adapt successful approaches from other fields and sectors, and foster 
action on the social determinants of health
Engage all care 
providers
• Involve all public, voluntary, corporate and private providers through 
Public-Private Mix (PPM) approaches
• Promote use of the International Standards for Tuberculosis Care (ISTC)
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Empower people with 
TB and communities 
through partnership
• Pursue advocacy, communication and social mobilization
• Foster community participation in TB care, prevention and health 
promotion
• Promote use of the Patients' Charter for Tuberculosis Care
Enable and promote 
research
• Conduct programme-based operational research
• Advocate for and participate in research to develop new diagnostics, 
drugs and vaccines
There was considerable success as the target of halting and reversing TB incidence for Goal 
6 of the MDG was achieved. Between 1990 and 2015, the global TB prevalence fell by 42% 
with a 50% reduction being achieved in three WHO regions (the Region of the Americas, the 
South-East Asia Region and the Western Paciﬁc Region). Global TB mortality also fell by 47% 
with a 50% reduction being achieved in four WHO regions (the Region of the Americas, the 
Eastern Mediterranean Region, the South-East Asia Region and the Western Paciﬁc Region).12 
The WHO African region unfortunately failed on both counts. 
In the 13-year period from 2000 to 2013, an estimated 37 million lives were saved by TB 
prevention, diagnosis and treatment interventions. Furthermore, in 2013, 6.1 million people 
diagnosed with TB were officially reported to public health authorities. Of these, 5.7 million 
were people newly diagnosed, equivalent to approximately 64 per cent of estimated incident 
cases, and 400,000 were people already on treatment.12 According to the 2015 MDG report, 
the global number of people receiving TB treatment increased year on year from 2.9 million 
in 1995 to 5.8 million in 2012. The TB treatment success rate also improved over the years, 
with 86% of patients newly diagnosed in 2012 being successfully treated globally.12 The 
developing regions exceeded for the sixth year in succession the treatment success target of 
85%, which was set in 1991. 
This progress, however, has been bedevilled by many challenges. First, each year there are 
over 3 million people with TB who are missed by health systems, either because they are 
not diagnosed or because once diagnosed they are not notified  to national programmes 
and therefore potentially denied proper care and treatment.13 Second, multi-drug resistant 
TB (MDR-TB, which is defined as tuberculosis resistant to at least isoniazid and rifampicin) 
and extensively drug-resistant TB (XDR-TB, which is MDR-TB that is also resistant to 
fluoroquinolones and second-line injectable agents, which are used in the second line 
treatment regimens) have become a growing public health threat, with only 25% of these 
drug-resistant cases currently being detected, of whom only half are cured.14 Third, HIV 
infection has had a catastrophic effect, especially in sub-Saharan Africa, causing in some 
countries a five-fold or more increase in TB cases associated with high morbidity and 
mortality. Despite the availability of a sound TB/HIV response through an agreed global 
policy,15 its implementation was still sub-optimal in many countries with only one third of 
the estimated number of people with HIV-associated TB being on antiretroviral therapy 
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(ART) by the end of 2014.14 Finally, there have been budget shortfalls, with estimated funding 
deficits of US$1.4 billion and US$1.3 billion in 2014 for the implementation of existing TB 
interventions and TB research respectively.14
The continuing burden of TB, which takes its toll mainly on the world’s most poor and 
vulnerable populations, keeps the disease high on the international health priority agenda. 
December 2015 marked the end of the MDG and Stop TB Strategy eras and ushered in the 
post-2015 development framework (2016–2030) of the Sustainable Development Goals 
(SDGs) and the related WHO End TB strategy.16 The End TB Strategy is operational from 
2016 to 2035 and aims to end the global TB epidemic, defined as zero deaths, disease and 
suffering due to TB. Agreed targets under the End TB Strategy are to achieve by 2035: i) a 
95% reduction in the number of TB deaths compared to 2015, ii) a 90% reduction in the TB 
incidence rate compared to 2015, and iii) no TB-affected families having to face catastrophic 
costs due to TB.16 The key principles of the END TB Strategy are: i) Government stewardship 
and accountability, with monitoring and evaluation; ii) Strong coalitions with civil society 
organizations and communities; iii) Protection and promotion of human rights, ethics 
and equity; and iv) Adaptation of the strategy and targets at country level, with global 
collaboration. The pillars and components of the new strategy are shown in Table 3.
Table 3: Pillars and components of the End TB Strategy.
1. Integrated Patient-
centred care and 
prevention
A. Early diagnosis of TB including universal drug-susceptibility testing, 
and systematic screening of contacts and high-risk groups 
B. Treatment of all people with TB including drug-resistant TB, and 
patient support 
C. Collaborative TB/HIV activities, and management of co-morbidities 
D. Preventive treatment of persons at high risk, and vaccination against 
TB
2. Bold policies and 
supportive systems
A. Political commitment with adequate resources for TB care and 
prevention 
B. Engagement of communities, civil society organizations, and public 
and private care providers
C. Universal health coverage policy, and regulatory frameworks for case 
notification, vital registration, quality and rational use of medicines, 
and infection control
D. Social protection, poverty alleviation and actions on other 
determinants of TB 
3. Intensified Research 
and Innovation
A. Discovery, development and rapid uptake of new tools, interventions 
and strategies 
B. Research to optimize implementation and impact, and promote 
innovations
Source: Global Tuberculosis Report 2015
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HIV INFECTION, AIDS AND ART
HIV attacks the body’s immune system, specifically CD4-T cell lymphocytes, and if left 
untreated the infection progresses to AIDS and inevitable death. First recognised in 1981, 
the disease has killed almost 40 million people globally and, as of 2015, accounted for 36.7 
million people living with HIV/AIDS (PLHIV) with 2.1 million being newly infected and 1.1 
million dying from HIV/AIDS in that single year alone.17 Sub-Saharan Africa continues to bear 
the brunt of this epidemic with an estimated 25.5 million PLHIV (69% of global total) in 2015: 
in that same year, there were 1.4 million new HIV infections (65% of global total) and 800,000 
deaths (73% of global total).17 HIV/AIDS is unevenly distributed in sub-Saharan Africa, with 
southern Africa being the worst affected region on the continent. 
From the start of the AIDS epidemic, there has been a combination response, which over the 
years has grown to take on and incorporate new technologies and strategies as they have 
become available. The current response includes: HIV testing, antiretroviral therapy (ART), 
prevention of mother-to-child transmission (PMTCT), pre-exposure prophylaxis (PrEP) with 
antiretroviral drugs, voluntary medical male circumcision, condom promotion, behaviour 
change programmes, opioid drug substitution, needle and exchange programmes and 
outreach programmes for men who have sex with men and sex workers.18 The priority 
accorded to each of these components depends on country and context. 
The key biomedical measures are the diagnosis of HIV infection and the sustained provision 
of ART to all those diagnosed with HIV. The advent of ART has been a game changer, improving 
clinical, immunological and virological outcomes as well as prolonging survival.19 By the end 
of 2015, there were 17 million people globally receiving ART, representing 46% of PLHIV.17 This 
was two million more than the 15 million target set by the United Nations General Assembly. 
In sub-Saharan Africa, there has been excellent progress, with over 12 million people on ART 
by 2015. In the world’s most affected region, Eastern and Southern Africa, the number on 
treatment has more than doubled since 2010, reaching nearly 10.3 million, thus representing 
54% of PLHIV.17 This remarkable increase in ART coverage is largely responsible for the 27% 
decline in AIDS-related deaths globally since 2010, from an estimated 1.5 million in 2010 to 
1.1 million in 2015.17
Thresholds for starting ART have gradually loosened over the last 15 years. In 2003, PLHIV 
could start ART if their CD4-cell count fell  <200 cells/uL, but gradually this cut-off has risen to 
350 cells/uL to 500 cells/uL to the current WHO recommendation that ART be offered to all 
PLHIV regardless of their clinical stage or CD4 cell count.20 This loosening of the ART initiation 
thresholds has been well informed by high quality randomised controlled trials; the two most 
recent being INSIGHT START and TEMPRANO which both showed that early start of ART was 
associated with significant reductions in the risk of serious HIV-related disease or death.21, 22 
The benefits of ART also go beyond those for individual patients. ART, especially if given early 
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in the course of HIV infection, reduces the risk of sexual transmission of HIV with this benefit 
having been demonstrated not only in clinical trials but also in the real world setting.23, 24 
ART also reduces the risk of acquiring herpes simplex type- 2 infection,25 decreases the risk 
of TB,26 and provides concurrent treatment for hepatitis B infection.27 Option B+, the current 
recommended strategy for PMTCT, has immediate ART at its core, and, by offering lifelong 
treatment to HIV-infected pregnant and breast feeding mothers regardless of CD4 cell count 
or WHO clinical stage, has significant benefits for HIV transmission prevention and maternal 
health.28 
This body of knowledge prompted the Joint United Nations Program on HIV/AIDS (UNAIDS) 
to release the new 90-90-90 treatment targets for HIV.29 These targets specify that by 2020, 
90% of individuals living with HIV will know their HIV status, 90% of people diagnosed with 
HIV infection will receive sustained ART and 90% of those on ART will be virally suppressed. 
If this three-part strategy is achieved, nearly three quarters of all PLHIV will be on treatment 
and virally suppressed by 2020. Modelling studies suggest that this outcome will enable the 
world to end the AIDS epidemic by 2030, defined as a 90% reduction in both incidence of HIV 
and AIDS-related mortality.29  
HIV-ASSOCIATED TUBERCULOSIS 
HIV is the most important risk factor for the development of TB in persons infected with 
Mycobacterium tuberculosis. HIV targets the host cell-mediated immune response to 
Mycobacterium tuberculosis,30 and, as a result, the risk of TB increases 2-3 times within 
the first two years after HIV seroconversion and continues to rise as the CD4 cell counts 
decrease.31 HIV-infected individuals with Mycobacterium tuberculosis infection have an 
average annual risk of developing TB of approximately 10% per year, with the risk heavily 
dependent on the degree of immune deficiency, the amount of Mycobacterium tuberculosis 
transmission in the community and the prevailing socio-economic conditions.32, 33 Those with 
advanced immunodeficiency have an increasing risk of extra-pulmonary, disseminated and 
smear-negative TB. This pattern of TB is difficult to diagnose in most health care facilities in 
resource-poor settings where HIV-TB flourishes and is associated with high mortality, much 
of which is not recognised or identified during life.34
As a result of HIV/AIDS, between 1990 and 2000, there was an enormous increase in the burden 
of TB in countries with generalized HIV epidemics, especially in the severely affected countries 
of Eastern and Southern Africa.32, 35, 36 Not only was there an increase in case numbers and 
case notification rates, but there was an increase in morbidity, risk of adverse drug reactions, 
case fatality and recurrent tuberculosis after successful completion of treatment.36 
In 2004, in response to this burgeoning epidemic of HIV-associated TB, the WHO released 
an interim policy for collaborative TB/HIV activities.37 The policy goal was to decrease the 
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burden of TB and HIV in dually affected populations. The objectives of the collaborative TB/
HIV activities were: (1) to establish the mechanisms for collaboration between TB and HIV/
AIDS programmes; (2) to decrease the burden of TB in PLHIV; and (3) to decrease the burden 
of HIV in TB patients. The recommendations in this policy are outlined in Table 4.
Table 4: Recommendations for 2004 WHO Interim Policy on TB/HIV collaborative activities.
A. Establish the mechanisms for collaboration
A.1 Set up a coordinating body for TB/HIV activities effective at all levels 
A.2 Conduct surveillance of HIV prevalence among tuberculosis patients 
A.3 Carry out joint TB/HIV planning 
A.4 Conduct monitoring and evaluation
B. Decrease the burden of tuberculosis in people living with HIV/AIDS
B.1 Establish intensified tuberculosis case-finding 
B.2 Introduce isoniazid preventive therapy 
B.3 Ensure tuberculosis infection control in health care and congregate settings
C. Decrease the burden of HIV in tuberculosis patients
C.1 Provide HIV testing and counselling 
C.2 Introduce HIV prevention methods 
C.3 Introduce co-trimoxazole preventive therapy 
C.4 Ensure HIV/AIDS care and support 
C.5 Introduce antiretroviral therapy
Source: 2004 Interim Policy on Collaborative TB/HIV Activities1.
Although it was estimated that one million lives were saved between 2005 and 2010 as a result 
of implementing key activities of the 2004 interim policy, 38 the burden of TB/HIV coinfection 
and related mortality remained high. This paved the way for the release of an updated policy 
of TB/HIV collaborative activities in March 2012 which combined evidence attained in the 
previous eight years through randomized clinical trials, observational studies, operational 
research and best practices from programme implementation.15 These guidelines followed 
the same framework as the 2004 policy, with additional elements emphasizing the timely 
initiation of ART in TB/HIV co-infected patients and HIV screening in presumptive TB patients 
as opposed to focusing on confirmed TB patients only. Revised recommendations for the 
2012 interim policy are outlined in Table 5.
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Table 5: Recommendations for the 2012 WHO Interim Policy on TB/HIV collaborative activities.
A. Establish and strengthen the mechanisms for delivering integrated TB and HIV services
A.1. Set up and strengthen a coordinating body for collaborative TB/HIV activities functional at all 
levels 
A.2. Determine HIV prevalence among TB patients and TB prevalence among people living with 
HIV 
A.3. Carry out joint TB/HIV planning to integrate the delivery of TB and HIV services 
A.4. Monitor and evaluate collaborative TB/HIV activities
B. Reduce the burden of TB in people living with HIV and initiate early antiretroviral therapy 
(the Three I’s for HIV/TB)
B.1. Intensify TB case-finding and ensure high quality anti-tuberculosis treatment 
B.2. Initiate TB prevention with Isoniazid preventive therapy and early antiretroviral therapy 
B.3. Ensure control of TB Infection in health-care facilities and congregate settings
C. Reduce the burden of HIV in patients with presumptive and diagnosed TB
C.1. Provide HIV testing and counselling to patients with presumptive and diagnosed TB 
C.2. Provide HIV prevention interventions for patients with presumptive and diagnosed TB 
C.3. Provide co-trimoxazole preventive therapy for TB patients living with HIV 
C.4. Ensure HIV prevention interventions, treatment and care for TB patients living with HIV 
C.5. Provide antiretroviral therapy for TB patients living with HIV
Source: 2012 WHO policy on collaborative TB/HIV activities. Guidelines for national programmes and other 
stakeholders2.
ART has played a key role in tackling HIV-associated TB. ART not only reverses the 
immune dysfunction associated with HIV, but it also facilitates rapid functional recovery 
of mycobacteria-specific immune responses which results in enhanced capacity to restrict 
mycobacterial growth.39, 40 As a result, ART has a potent TB preventive effect. A systematic 
review and meta-analysis of 11 studies from 2002 to 2011 showed that ART was associated 
with a 65% reduction in TB incidence across all baseline CD4 counts in PLHIV.26 The effects of 
ART appear to be stronger in those with more advanced HIV-disease or with the lowest CD4 
cell counts, but are also apparent in patients with CD4 counts > 350 cells/µL. 
Despite the progress made in the response to HIV-associated TB, in 2015 1.2 million (12%) of 
all estimated new TB cases were among PLHIV.7 Of the 1.8 million global TB deaths in 2015, 
400,000 deaths occurred in those with HIV-associated TB while TB was also a leading cause of 
death among PLHIV with 35% of HIV-related deaths in 2015 being attributed to this disease.7 
The WHO Africa region with 47 member states continues to have the world’s highest TB/HIV 
co-infection rates and constitutes 24 of the 30 high burden TB/HIV countries of the world. In 
2015, 36% of TB patients with known HIV status were HIV-positive in this region, compared 
to 10% in other regions of the world. The highest proportions of TB/HIV co-infected patients 
were found particularly in Southern Africa where HIV coinfection exceeded 50% in certain 
countries     (Figure 1). TB-related mortality stood at 45 deaths /100,000 population and 
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30 cases/100,000 population for HIV-positive and HIV-negative TB patients’ respectively.7 
Therefore there is much more work still to be done. 
Figure 1. Estimated HIV prevalence in new and relapse TB cases, 2015.
Source: Global Tuberculosis Report 2016
ZIMBABWE
GENERAL FEATURES
Zimbabwe is a land-locked country located in the southern part of Africa with a surface 
area of 390,580 km2. It is bordered by South Africa (south), Botswana (southwest), Zambia 
(northwest) and Mozambique (northeast) as shown in Figure 2. Zimbabwe is a low income 
country and has a population of 13 million.41 Of this population, 6.3 million (48%) are males 
and 6.8 million (52%) are females. Seventy percent (70%) of Zimbabwe’s population are 
women and children. The population aged less than 15 years contributes 41% of the total. 
Sixty seven percent (67%) of the population lives in rural areas.41
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Figure 2. Map of Zimbabwe on the African continent and neighbouring southern African countries.
Source: Ontheworldmap.com
In 2015, Zimbabwe had a gross domestic product (GDP) per capita of US$924.10 compared 
to US$1,588.4 for Sub-Saharan Africa as a whole.42 The country has experienced a protracted 
socio- economic crisis since early 2000 with a contracting negative economic growth, a 
high unemployment rate of more than 60% and a recurrent food crisis.43 The declining GDP 
income has resulted in reduced health expenditure which stood at 6.4% in 2014.42
The Zimbabwe Ministry of Health and Child Care, through the national health strategy as its 
guiding tool,44 promotes equity and high quality health care, and does this by implementing 
health care services using the primary health care concept as the cornerstone of service 
delivery. A clear referral system exists along the different levels of care, with referrals made 
from community level to a primary health care clinic to district, provincial and tertiary level. 
At each of these levels, a management structure coordinates the provision of health care 
services.
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The country is divided into 10 administrative provinces, two of which are cities. There are 
63 health districts, which are further subdivided into 1,963 wards.41 A ward is the smallest 
administrative subdivision by geographic area with an average population size of 5,000 
people. There are also 31,519 enumeration areas with an approximate adult population (≥15 
years) per enumeration area of 160 to 240 people.
TB BURDEN AND TB CONTROL EFFORTS
TB is a major public health burden in Zimbabwe with the country being ranked among the 
22 high burden TB countries during the MDG and Stop TB Strategy era. In 2015, overall TB 
incidence was 242 cases per 100,000 people, with HIV-TB incidence being at 167 cases per 
100,000 people.7 The TB epidemic in Zimbabwe has been fuelled by the HIV epidemic with 
the TB/HIV co-infection rate being 70% in 2015.7 The advent of the SDGs and the End TB 
strategy led to the reclassification of the high burden countries for TB, HIV/TB and MDR-TB: 
Zimbabwe is now one of the 14 countries that is classified in the top 30 high priority burden 
countries for all three categories.7 
According to the recently concluded TB prevalence survey in 2014,45 the prevalence of 
bacteriologically-confirmed TB was 344 cases (275-430) per 100,000 people. Furthermore, 
the TB prevalence was observed as increasing in a linear trend by age from approximately 
230/100,000 in the 15-34 year age group to approximately 420/100,000 and 500/100,000 in 
the 35-54 and 55+ year age groups respectively.45 Anti-TB treatment coverage was estimated 
at 72% (55%-97%) in 2015, meaning that about three in every ten TB cases went undiagnosed 
and untreated. TB treatment coverage among new and relapse TB cases in 2014 stood at 
81% and 51% respectively, meaning that almost half of the patients with recurrent TB did 
not make it to treatment. However, despite the high TB incidence and the shortfalls in anti-
TB treatment coverage, Zimbabwe has the highest decline in TB incidence among the high 
burden TB countries, estimated at 11% decline between 2010 and 2015.7
The National TB Programme (NTP), which falls under the AIDS and TB Directorate of the 
Ministry of Health, is responsible for coordinating TB control efforts in the country at national 
level. The programme is represented at the national level by a central unit and at the provincial 
and district levels by provincial TB coordinators and district TB coordinators respectively, 
who are responsible for coordinating TB programme activities. TB treatment is offered only 
in public health facilities through integration with general health services, while TB diagnosis 
can be found in the private sector with confirmed TB cases being referred to the public sector 
for treatment. Zimbabwe has been compliant with the DOTS, Stop TB and, of late, the End 
TB strategies. Similarly, the country has adopted all previous and current WHO TB guidelines 
in its national TB guidelines and has taken up all other WHO-TB policies. Adoption of global 
guidance at country level has largely contributed to the observed declines in TB incidence 
over the years, despite TB remaining a high burden disease.
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HIV BURDEN AND HIV CONTROL EFFORTS 
Zimbabwe has a generalized HIV prevalence rate, currently estimated at 14.6% with an 
annual HIV incidence of 0.45% among the 15-64 year old adult population according to the 
recently concluded Zimbabwe Population-based HIV Impact Assessment (ZIMPHIA) survey.46 
HIV prevalence rose from 15% in 1990 to a peak of 26% in 1996 before steadily declining to 
the current levels (Figure 3). There are differences in HIV prevalence by gender, with women 
in the 15-49 year old age group having HIV-prevalence rates of 16.6% compared to 11.2% 
among men. Similarly, annual HIV incidence is higher among 15-49 year old women at 0.67% 
compared to 0.28% among men.46 According to the Zimbabwe Demographic Health Surveys, 
HIV-testing in the general population has improved over the years increasing amongst 
women from 7% in 2005-06 to 49% in 2015 and amongst men from 7% in 2005-06 to 36% 
in 2015. More importantly, according to the ZIMPHIA, 74% of PLHIV know their HIV status, 
87% of those diagnosed with HIV are receiving ART and 87% of those on ART are virally 
suppressed. This is good progress in terms of meeting the UNAIDS 90-90-90 targets, although 
the largest gap to be bridged is to increase the proportion of PLHIV who know their HIV status, 
particularly among men.
Figure 3. HIV Prevalence in Zimbabwe among 15-49 year olds (1990-2015).
ART was introduced in the public health sector in Zimbabwe in 2004 when 5,000 people 
were initiated on ART. This absolute number of people accessing ART has increased 
tremendously over the years to the current number of 915,486 as of December 2016 (National 
ART Programme, Ministry of Health and Child Care, Zimbabwe). The ART programme was 
implemented in a phased approach starting with five ART learning sites in 2004 followed 
INTRODUCTION AND OUTLINE OF THESIS
25
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
by a rapid expansion to 1,545 health facilities (92% of all health facilities in the country) by 
June, 2015. This rapid expansion was in line with the country’s thrust towards providing 
decentralized ART services close to where people live. Along with the scale-up of ART, the CD4 
cell count threshold for starting ART has gradually changed from 200 cells/uL to 350 cells/uL 
to 500 cells/uL and finally to the HIV treat all approach in line with WHO guidance.47, 48, 49, 20 
Simultaneously, ART has become more effective and less toxic in line with the transition from 
a stavudine-based ARV regimen to a tenofovir-based ARV regimen.
TB/HIV COLLABORATIVE CARE
Zimbabwe has a largely HIV-driven TB epidemic given the high HIV prevalence which stands at 
14.6%. In line with the WHO 2004 interim policy on TB/HIV collaborative activities, the country 
has over the years routinely monitored the prevalence of HIV/TB co-infection among patients 
receiving TB treatment. HIV testing rates of TB patients have increased from 26% in 2007 to 
96% in 2015. The HIV/TB co-infection rate has consistently stood at 70%, although it did peak 
in 2009 at 79% before gradually coming down to 70% as reported in 2015. Other policies 
adopted in line with this interim policy were TB screening in ART settings using the WHO 
recommended TB symptom checklist followed by TB investigations among presumptive TB 
cases. Uptake of ART among co-infected TB/HIV cases has also been scaled up over the years 
from a low of 23% in 2007 to 72% in 2015.
The revised WHO 2012 policy on TB/HIV collaborative activities brought increased 
emphasis on integrating TB and HIV services and offering these as a “one-stop shop” as well 
as initiating ART in a timely way among HIV/TB co-infected patients. In 2013, Zimbabwe 
also adopted guidance on provision of isoniazid preventive therapy (IPT) among eligible 
HIV-positive clients in order to lessen their risk of acquiring TB. From an initial 10 pilot sites 
offering IPT in January 2013, this service had expanded to 340 sites as of June 2016. Despite 
the expansion of IPT services, the coverage of IPT among newly enrolled HIV-positive clients 
is still very low, estimated at 31% by the end of 2016.7
CHALLENGES FOR TB/HIV COLLABORATIVE CARE
From 2010 onwards, in addition to the broad challenges in TB/HIV collaborative care, 
outlined earlier in Table 4 and Table 5, there were a number of specific challenges that were 
encountered by the AIDS and TB department in Zimbabwe in terms of implementing TB/HIV 
collaborative activities. 
First, it was known anecdotally that there were often delays in patients starting 
anti-TB treatment and more information was needed on this particular challenge. There were 
reports of problems with the sputum specimen transportation system due to lack of vehicles 
or shortages of fuel affecting the timely movement of sputum specimens from peripheral 
primary health care centres to centralised TB diagnosing centres. These delays, which could 
lead to individual progression of disease and on-going TB transmission in the community, 
became a high priority research area for the NTP.
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Second, despite HIV testing among TB patients increasing to 86% with a TB/HIV 
coinfection rate of 78%, there was little information in the country about whether HIV testing 
uptake and HIV-status differed amongst those with different types and categories of TB or 
whether anti-TB treatment outcomes differed significantly in terms of HIV status (HIV-positive, 
HIV-negative or HIV-not known). This became an area of research interest for the NTP.    
Third, treatment success rates at the national level were consistently below the 
85% target set by the WHO. For instance in 2013, the national TB treatment success rate was 
81% among registered drug-susceptible TB cases with case fatality rates being about 8% 
regardless of type and category of TB. High case fatality was judged to be an important cause 
of poor treatment outcomes and a better documentation and understanding of the causes 
of this mortality was needed. 
Fourth, amongst the TB/HIV co-infected patients there was a relatively low uptake 
of ART of about 45%. Furthermore, although the global guidance from the 2012 policy on TB/
HIV collaborative activities to initiate ART within 2 to 4 weeks of starting TB treatment had 
been adopted in the country, information about how well this was implemented was not 
being routinely tracked through TB and HIV monitoring and evaluation tools. Both national 
programmes wanted to know more detail about this and whether ART and its timely initiation 
was having any impact on TB treatment outcomes for new and for previously treated TB.
Finally, while the TB preventive effects of ART in PLHIV were recognised at the 
individual level, 50 there was little information in Zimbabwe about whether ART scale up 
at the national level was having any effect on TB case notifications at the population level. 
Using data from the southern African HIV/AIDS epidemic, mathematical models had indicated 
that a strategy of universal and annual HIV testing of adults with immediate start of ART in 
those diagnosed HIV-positive might be expected to halve the incidence of HIV-associated 
TB within a 5 year period.51  At the programme level, despite PLHIV routinely initiating ART 
at low CD4 counts, it had been shown in Malawi and Swaziland that when ART coverage in 
the HIV-infected populations reached a high level, TB case notification rates decreased.52,53 
The most significant declines in TB cases in Malawi and Swaziland were observed in patients 
with smear-negative pulmonary TB, a disease type strongly associated with HIV, and in 
Malawi significant declines were also documented in patients with recurrent TB, which is 
also strongly associated with HIV. No such information had been collected or analysed in 
Zimbabwe, and both national programmes for HIV/AIDS and TB wanted to document the 
effects of ART scale up on the national TB burden.
OPERATIONAL RESEARCH WITHIN THE HIV/AIDS AND TB PROGRAMMES
It was agreed that operational research was needed to address the above challenges in TB/
HIV collaborative care. At the time, there were no trained people within the HIV/AIDS and 
TB Departments of the Ministry of Health and Child Care to undertake the work, so in May 
2010 an operational research (OR) fellow from the Centre for Operational Research, The 
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International Union Against Tuberculosis and Lung Disease, Paris, France, was appointed 
within the departments to promote and lead a TB/HIV operational research agenda. 
The OR fellow (KCT, the primary author of this thesis) underwent a formal training 
at the Union-MSF run Structured Operational Research and Training Initiative (SORT IT) 
Course.54 Following this, he started to work with government colleagues to conduct and 
publish research into strategies, interventions, tools and new knowledge around TB/HIV 
with the aim of helping the programmes to better understand the challenges and identify 
solutions. The OR fellow’s specific responsibilities were to:- i) design and write up protocols 
for research projects under the mentorship of staff at the Centre for Operational Research 
and in collaboration with AIDS and TB Department programme managers; ii) submit research 
protocols for ethics clearance to ensure that the standards of research ethics are met; iii) 
ensure that research protocols once approved, were implemented in the field within a 
reasonable time frame; iv) ensure that within 3 months of completion of any research project, 
that a paper was prepared and made ready for submission to a peer-reviewed scientific 
journal; v) present the results of the research work at relevant national and international 
conferences; and vi) be proactive in getting research findings to inform policy and practice at 
either national, provincial or district level.
AIMS, OBJECTIVES AND RATIONALE FOR THESE STUDIES
AIM:
The aim of the thesis is to document and reduce the burden of tuberculosis in the high HIV-
prevalence setting of Zimbabwe. 
OBJECTIVES:
Specific objectives of the thesis are as follows:
Objective 1: To determine treatment delays and their associated factors in patients with 
tuberculosis registered within the Zimbabwe national tuberculosis control programme 
(Chapter 2)
Objective 2: To determine treatment outcomes of adult patients with new and recurrent 
tuberculosis in relation to HIV status in Zimbabwe (Chapters 3 and 4).
Objective 3: To assess case fatality among patients on anti-TB treatment in the southern 
region of Zimbabwe and the associated factors (Chapter 5)
Objective 4: To document the uptake of ART amongst patients with TB/HIV co-infection, the 
timing of ART in relation to start of anti-TB treatment and how ART influences TB treatment 
outcomes (Chapter 6)
Objective 5: To report on tuberculosis case notification rates in relation to the scale up of 
ART in Zimbabwe (Chapter 7).  
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RATIONALE FOR THE STUDIES AND OUTLINE OF THE THESIS
This thesis thus consists of six studies that were performed in line with the Zimbabwe AIDS 
and TB Programme research priorities that in turn were aligned with National TB Programme 
objectives as derived from the WHO STOP TB strategy and of late, the WHO End TB Strategy. 
The goal of the End TB Strategy, moreover, is in line with SDG 3.3 which aims “By 2030, to end 
the epidemics of AIDS, TB, malaria and neglected tropical diseases and combat hepatitis, 
water-borne diseases and other communicable diseases.” 
People in the community with latent TB infection may develop active TB disease, and if 
this occurs they are expected to present to the public health system in Zimbabwe as early 
as possible for diagnosis and treatment. Delays at the patient level from the onset of TB 
symptoms and health institutional delays in making a diagnosis of TB are therefore detrimental 
to affected individuals because of disease progression and they also result in continued TB 
transmission in the community. Because TB in Zimbabwe is so strongly associated with HIV, 
access to HIV testing is vital as it provides the gateway for life-saving ART and CPT among HIV 
infected patients thus reducing adverse TB treatment outcomes, especially mortality. Not 
only is it important for HIV-TB patients to receive ART, but it is necessary for them to start 
ART in a timely way as this further reduces the risk of death. Attention to all these aspects of 
care should help to reduce TB-associated mortality. However, the largest impact would be 
to prevent TB occurring in the first place. ART has a TB protective effect when given to PLHIV, 
and the national scale up of ART in Zimbabwe may therefore have significantly reduced TB 
case notifications. These six studies are therefore connected mainly around the theme of 
reducing TB-associated mortality and relate to the 90-90-90 people centred global targets for 
TB. (i.e. reach and treat at least 90% of all people with TB; as a part of this approach, reach 
and treat at least 90% of key populations; achieve at least 90% treatment success for all 
people diagnosed with TB). Figure 4 outlines how these aims and objectives (indicated by 
numbers in the left and right boxes) and associated studies in this PhD thesis are interlinked 
and connected with national TB and HIV priorities in Zimbabwe.
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Figure 4. Conceptual framework that links the PhD objectives to Zimbabwe’s national TB/HIV priorities.
In Chapter 2, we explore the extent of time delays from self-reported initiation of any TB 
symptoms to start of anti-TB treatment among those diagnosed with active TB. This area 
was of top priority to the National TB Programme that believed there were long delays in 
patients between becoming ill and presenting to health facilities for investigation combined 
with health system delays in TB diagnosis. Timely diagnosis and start of treatment for TB 
are an important programmatic aspect to assess since delays cause patients to have more 
advanced disease, more complications, higher mortality and worse TB treatment outcomes 
especially when associated with HIV infection. TB treatment delays also have the potential 
of contributing to on-going TB transmission in the community, and this applies to untreated 
smear-positive pulmonary TB 55 and also smear-negative pulmonary TB.56, 57 This research 
objective was of high priority within Zimbabwe and also in line with priorities of the Stop TB11 
and End TB13 strategies which advocate for early diagnosis of TB.
In Chapters 3 and 4, we set out to assess whether there are differences in TB treatment 
outcomes by HIV testing status among confirmed TB cases that were started on anti-TB 
treatment, and we assess this for both new TB and recurrent TB respectively. The hypothesis 
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is that access to HIV testing among TB patients in this setting, where HIV-TB co-infectivity 
is high, is beneficial as it paves the way for access to cotrimoxazole preventive therapy and 
life-saving ART in those diagnosed as HIV-positive,  both of these interventions reducing 
mortality and improving survival.58-60 This information was not available in the public domain 
at the time because in the initial years of the ART programme, there was poor collaboration 
between the National TB and ART programmes. This was also an area of national and 
international importance and in line with one of the components of the Stop TB strategy 
which called for integrated patient-centred care through collaborative TB/HIV activities and 
the management of comorbidities.11 
In Chapter 5, we explore the determinants of mortality in the southern region of Zimbabwe 
where TB treatment outcomes have been consistently low due to high case fatality during 
treatment. This research question was highlighted as being of high priority in one of the 
National TB Review meetings and at one of the management meetings of the country’s 
Provincial Medical Directors and National TB Programme management. At a point when 
HIV testing and ART provision among the largely HIV co-infected cohort of TB patients had 
increased, this research question required further investigation to identify the characteristics 
and determinants associated with these case fatalities during TB treatment. This was also 
interconnected with the study in Chapter 6, where we explore the coverage and timely 
initiation of ART uptake among TB/HIV co-infected patients and its association with TB 
treatment outcomes. Appropriate timing of ART among HIV-TB patients has been shown 
through clinical trials to be critical to reducing mortality, especially in those with advanced 
immunosuppression.61-63 This evidence led to WHO recommending ART initiation within 2 
to 8 weeks after commencement of TB treatment, 48 and hence the National ART and TB 
programmes were interested in knowing how this was operationalized within the routine 
programme setting and its impact, if any, on TB treatment outcomes.   
Finally, based on the knowledge that the burden of TB, especially in eastern and southern 
Africa, increased dramatically in association with HIV infection,32, 64 there appears to have 
been a decline in TB cases related to the exponential increase of PLHIV accessing ART which 
has a TB-protective effect. This prompted the work in Chapter 7 to assess the impact of ART 
scale-up on the trend in TB case notification rates in Zimbabwe, which has been one of the 
countries with a high burden of both HIV and TB. Given the well-known TB protective effect 
of ART, we hypothesized that the rapid scale-up of ART has resulted in a decline in TB case 
notifications.
Chapter 1 (this chapter) and Chapter 8 (the final chapter) provide the Introduction and the 
Discussion / Conclusion of this thesis. 
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ABSTRACT
BACKGROUND
Delayed presentation of pulmonary TB (PTB) patients for treatment from onset of symptoms 
remains a threat to controlling individual disease progression and TB transmission in the 
community. Currently, there is insufficient information about treatment delays in Zimbabwe, 
and we therefore determined the extent of patient and health systems delays and their 
associated factors in patients with microbiologically confirmed PTB.
METHODS
A structured questionnaire was administered at 47 randomly selected health facilities in 
Zimbabwe by trained health workers to all patients aged ≥18 years with microbiologically 
confirmed PTB who were started on TB treatment and entered in the health facility TB 
registers between 01 January and 31 March 2013. Multivariate logistic regression was used 
to calculate adjusted odds ratios (aOR) and 95% confidence intervals (CIs) for associations 
between patient/health system characteristics and patient delay >30 days or health system 
delay >4 days.
RESULTS
Of the 383 recruited patients, 211(55%) were male with an overall median age of 34 years 
(IQR, 28-43). There was a median of 28 days (IQR, 21-63) for patient delays and 2 days (IQR, 
1-5) for health system delays with 184 (48%) and 118 (31%) TB patients experiencing health 
system delays >30 days and health system delays >4 days respectively. Starting TB treatment 
at rural primary healthcare vs district/mission facilities [aOR 2.70, 95% CI 1.27-5.75, p = 
0.01] and taking self-medication [aOR 2.33, 95% CI 1.23-4.43, p = 0.01] were associated with 
encountering patient delays. Associated with health system delays were accessing treatment 
from lower level facilities [aOR 2.67, 95% CI 1.18-6.07, p = 0.019], having a Gene Xpert TB 
diagnosis [aOR 0.21, 95% CI 0.07-0.66, p = 0.008] and >4 health facility visits prior to TB 
diagnosis [(aOR) 3.34, 95% CI 1.11-10.03, p = 0.045].
CONCLUSION
Patient delays were longer and more prevalent, suggesting the need for strategies aimed 
at promoting timely seeking of appropriate medical consultation among presumptive TB 
patient. Health system delays were uncommon, suggesting a fairly efficient response to 
microbiologically confirmed PTB cases. Identified risk factors should be explored further and 
specific strategies aimed at addressing these factors should be identified in order to lessen 
patient and health system delays.
KEYWORDS
Tuberculosis, Treatment, Delay, Zimbabwe
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BACKGROUND
Tuberculosis remains an infectious disease of public health concern with the World Health 
Organisation (WHO) declaring it a global public health emergency in 1993.1 There has been 
a global increase in notified TB cases since then from an estimated 7-8 million cases to 9 
million cases in 2013.1 In sub-Saharan Africa, the resurgence of TB has been attributed 
mostly to the HIV pandemic, and this has been felt most strongly in the southern part of the 
continent.2 Providing treatment with anti-tuberculosis drugs through the directly observed 
treatment short course (DOTS) has greatly assisted most national tuberculosis control 
programmes in curing TB, and as a result it is estimated that from 2000 to 2013, 37 million 
lives have been saved.1 However, the continued spread of TB can partly be attributed to 
delayed or undiagnosed TB and this in turn has also been shown to be associated with 
increased mortality.3
The severity of disease and the likelihood of a TB infected individual infecting 
another person is highest in those with microbiologically confirmed pulmonary TB (PTB) 
in comparison with other types of TB such as smear-negative pulmonary TB and extra-
pulmonary TB.4 Moreover, the high burden of HIV co-infection results in a rapid increase in 
the number of tuberculosis patients in the community.4 Zimbabwe has a high burden of TB/
HIV co-infection, which was recorded at 69% in 2013.1 In 2013 prevalence estimates of TB 
morbidity (including HIV/TB co-infections) were 409 (235-630) cases per 100,000 population 
whilst mortality estimates (including HIV/TB deaths) were 153 (121-189) cases per 100,000 
population.1
Given this, early diagnosis and immediate initiation of TB treatment are therefore 
essential for an effective TB control programme in order to prevent further disease progression 
at the individual level and transmission within the community. A systematic review of 52 
studies on the length of treatment delays by Sreeramareddy et al5 showed that average 
patient delays and health system delays were similar (28.7 versus 25 days) and the trend 
was similar when stratified into low and high income countries. Other systematic reviews by 
Storla et al6 and Finnie et al7 showed varying factors associated with TB treatment delays 
but both highlighted the importance of how uptake of measures to shorten these delays may 
reduce infectious cases and improve TB control. In Finnie et al’s7 systematic review which 
was specific to sub-Saharan Africa, consulting traditional leaders first and longer travel time 
were consistently associated with patient health system delays among other factors. In the 
Zimbabwe National TB programme, there is insufficient knowledge on the extent of total 
TB treatment delay and whether such delay is mostly attributable to patient delay or health 
system delay. The aim of this study was therefore to assess the length of patient and health 
system delays among TB patients in Zimbabwe and their associated risk factors.
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METHODS
STUDY DESIGN
This was a descriptive cross-sectional study.
STUDY PARTICIPANTS AND SAMPLING
We used a two-stage random sampling design. In the first stage, 4 of the country’s 10 
provinces were randomly selected, whilst in the second stage, 3 districts were randomly 
selected in each province. In the third stage, 4 health facilities were randomly selected from 
all health facilities that registered ≥30 smear-positive PTB cases per month in each district. In 
total, 47 health facilities were included in the study of which 3 were provincial hospitals, 15 
were district/mission hospitals, 10 were urban clinics and 19 were rural primary health care 
facilities.
All patients aged ≥ 18 years with microbiologically confirmed PTB and who were 
started on TB treatment and entered in the TB registers from these facilities between 01 
January and 31 March 2013 were sequentially recruited in the study after verbal consent. 
The diagnosis and confirmation of TB was either by sputum-smear microscopy for acid-fast 
bacilli or GeneXpert MTB/RIF assay. Using Dobson’s formula, a minimum sample size of 260 
study participants was required to estimate the proportion with patient delays >30 days 
given a 95% confidence interval (CI) with a 5% margin of error, based on 83% of patients 
experiencing patient delay >30 days as derived from a study by Odusanya et al8 and an 80% 
response rate.
TB DIAGNOSIS UNDER THE NATIONAL TB PROGRAM
In Zimbabwe, TB treatment services are integrated with general health services at all health 
facilities in the country. When patients present with TB symptoms at a health facility, they 
are recorded in the TB suspect register and have their sputum examined by direct smear 
microscopy looking for acid-fast bacilli with a Ziehl-Neelsen stain. Sputum specimens are sent 
to TB diagnosing centres for sputum-smear microscopy which are often located at selected 
primary level health facilities (microscopy centres) and all secondary level health facilities 
(district or mission hospitals) in each district and all tertiary level (provincial) hospitals at 
the provincial level. In urban areas, TB diagnosing centres are located at selected municipal 
polyclinics. Smear-positive PTB cases are those with sputum smears positive for acid-fast 
bacilli.9 Recently, Gene Xpert is being recommended as the initial TB diagnosis among 
presumptive TB patients who are HIV-infected or who have risk factors for drug-resistant TB 
although it is not available at all TB diagnosing centres. In patients who are known to be 
HIV-negative and/or who have no risk factors for DR-TB, sputum smear microscopy remains 
the diagnostic method of choice. Patients with smear-positive sputum or a positive result 
from Gene Xpert are classified as having microbiologically confirmed PTB and have their 
results communicated to their respective health facilities by telephone. Upon receiving this 
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communication, these patients are traced in the community by a village health worker (VHW) 
or an environmental health technician (EHT).
Once traced, these patients are referred back to their nearest health facility where 
they are registered in the health facility daily observed treatment (DOT) register and care 
started on anti-TB treatment. All presumptive and confirmed TB patients are offered HIV 
counselling and testing (opt-out provider-initiated) and those confirmed HIV-positive are 
provided with10 HIV treatment and care in the form of cotrimoxazole preventive therapy 
(CPT) and antiretroviral therapy (ART), provided there is no contra-indication.11
DATA VARIABLES, SOURCE OF DATA AND DATA COLLECTION
A one-day data collection training exercise was conducted prior to piloting of the 
questionnaire. Data were collected using a structured questionnaire adapted from WHO,12 
and this was administered by selected health workers in the selected health facilities. Prior 
to data collection, a one-day data collection training exercise was conducted followed by 
piloting of the questionnaire. Variables that were abstracted from TB registers included: 
date of collection of the sputum specimens, type of TB, name of referring health facility, TB 
treatment start date, sex and age of the patient. TB registration numbers and TB suspect 
numbers were collected as patient identifiers in place of patient names. The structured 
questionnaires were administered to all microbiologically confirmed PTB patients upon 
commencing TB treatment or during review visits within 1 week of commencing TB treatment. 
Questionnaires were also translated into the 2 local languages (Shona and Ndebele) for 
those who were not conversant with English. Informed verbal consent was sought prior to 
the interview and participants were allowed to withdraw from the interviews whenever they 
pleased.
Variables collected in the questionnaire about timing and treatment delays 
included:- date of onset of any TB symptoms, date of first encounter with a health worker 
and number of visits to a health facility prior to starting treatment. Information on the first 
encounter with a health worker and the number of visits to the health facility was verified 
wherever possible by looking through the patient’s case notes and their TB treatment card.
STUDY DEFINITIONS
This study focused on total delay which was stratified into patient delay and health care 
system delay. These terms were defined as follows:
PATIENT DELAY
The time period in days between the onset of TB symptoms and the patient’s first contact with 
a health worker of >30 days.7, 13, 14 Contact with a health worker refers to a nurse or medical 
doctor at a public health facility (which are the only institutions providing TB treatment) and 
this excludes pharmacists, private practitioners or traditional healers. Onset of TB symptoms 
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was defined as the first experience of any symptoms suggestive of TB (cough, fever, weight 
loss, haemoptysis, fatigue, night sweats).
HEALTH CARE SYSTEM DELAY
The time period in days between the date of first contact with a health worker and the date 
of start of TB treatment of >4 days. This is under the assumption that laboratory turn-around 
times for sputum samples are expected to be less than 72 hours and are coupled with 
immediate tracing of patients for start of TB treatment for purposes of infection control.
STATISTICAL ANALYSIS
Patient data collected in the structured report form were coded and double entered by 
three independent data entry clerks into EpiData version 3.1 and later cleaned for errors 
and analysed using STATA, version 12.1 (Stata Corporation, College Station, Texas). Data 
were weighted prior to analysis to account for unequal probabilities of selection and to also 
account for the clustering effect of the sample design. Patient and health care system delays 
were first summarised and presented as the median (interquartile range) number of days. 
Patient delay was then categorised as patient delay >30 days whilst health system delay was 
categorised as health system delay >4 days and these were used for the univariate analysis. 
Associations between patient characteristics and both types of delay were determined by 
the chi-square test or alternatively the Fischer’s Exact test if numbers were small. Logistic 
regression was used to calculate adjusted odds ratios (aOR) and their respective 95% 
confidence intervals for factors associated with patient delay and health system delay. All 
patient characteristics with p-values < 0.25 or those thought to be biologically plausible were 
included in both the univariate and multivariate logistic regression models. P-values of less 
than 0.05 were considered statistically significant.
ETHICS AND APPROVAL
Ethics approval was obtained locally from the Medical Research Council of Zimbabwe (MRCZ) 
and also the Ethics Advisory Group (EAG) for The International Union Against Tuberculosis 
and Lung Disease (IUATLD).
RESULTS
PATIENT CHARACTERISTICS
During the 3-month study period, all 383 interviewed patients gave voluntary consent to 
participate in the survey of whom the majority, 211 (55%) were male (Table 1). Overall median 
age of study participants was 34 years (IQR, 28-43). Most patients (62%) were recruited upon 
starting TB treatment from either district or mission hospitals. The majority of these patients, 
280 (75%), started TB treatment at TB diagnosing centres were they had also been diagnosed. 
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Tuberculosis diagnosis was mainly by sputum-smear microscopy (95%). Nearly all patients 
(98%) had been HIV-tested: there were 230 (62%) who were HIV-infected. Most patients (70%) 
resided in rural areas, unemployment was high (62%) and more than half (55%) had attained 
secondary school education or higher.
Table 1: Characteristics of tuberculosis patients in Zimbabwe.
Characteristics (N = 383) N N Weighted percent 
(95%CI)
Age in years
    18 – 25
    26 – 44
    45 – 54
    ≥55
53
244
54
31
383
383
383
383
13.9% (10.5-18.2)
63.8% (58.3-69.0)
14.2% (10.6-18.6)
8.1 (5.7-11.6)
Sex
    Female
    Male
172
211
383
383
45.0% (39.5-50.6)
55.0% (49.4-60.5)
Type of diagnostic test
    Sputum microscopy
    Gene Xpert
363
20
383
383
94.8% (93.0-96.2)
5.2% (3.8-7.0)
Type of health facility
    Provincial hospital
    District/mission hospital
    Urban municipal
    Rural primary healthcare facility
18
237
73
55
383
383
383
383
4.7% (3.1-6.9)
61.8% (58.5-64.9)
19.1% (16.7-21.8)
14.5% (11.4-18.2)
Diagnosing centre
    Same as DOT facility
    Different from DOT facility
    Missing
280
93
10
373
373
383
75.1% (71.8-78.2)
24.9% (21.8-28.3)
2.6%
HIV tested
    No
    Yes
    Missing
6
370
7
376
376
383
1.6% (0.8-3.4)
98.4% (96.6-99.2)
1.9%
HIV status
    HIV-negative
    HIV-positive
140
230
370
370
37.9% (32.6-43.6)
62.1% (56.4-67.4)
HIV + ve patient on CPT/ART prior to TB treatment
    No
    Yes
72
158
230
230
31.2% (25.4-37.6)
68.8 (62.4-74.7)
Staying with anyone currently on TB treatment
    No
    Yes
348
35
383
383
90.9% (86.3-95.3)
9.1% (6.3-13.1)
Education
    More than secondary
    Secondary
    Primary
    No education
    Missing
20
192
145
25
1
382
382
382
382
383
5.3% (3.3-8.4)
50.3% (45.0-55.6)
38.0% (33.1-43.1)
6.5% (4.2-9.8)
0.4%
Employment status
    Formal employment
    Informal employment
    Unemployed
    Missing
40
105
234
4
379
379
379
383
10.7% (8.0-14.2)
27.6% (23.1-32.6)
61.8% (56.7-66.6)
1.0%
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Residence
    Urban
    Rural
    Missing
114
264
5
378
378
383
30.1% (26.1-34.5)
69.9% (65.6-73.9)
1.3%
History of smoking
    Never smoked
    Current smoker
    Quit smoking
    Missing
269
26
86
3
380
380
380
383
70.7% (65.3-75.5)
6.8% (4.3-10.6)
22.5% (18.3-27.4)
0.8%
History of alcohol use
    Never
    Current drinker
    Quit alchohol use
    Missing
213
29
132
10
373
373
373
383
57.0% (51.4-62.4)
7.7% (5.5-10.6)
35.3% (30.2-40.9)
2.6%
Previous contact with TB patient
    No
    Yes
210
173
383
383
54.8% (48.4-62.1)
45.2% (39.8-50.6)
Marital status
    Married
    Single
    Divorced/separated
    Widowed
    Missing
225
67
35
52
3
380
380
380
380
383
59.3% (53.6-64.7)
17.6% (13.7-22.4)
9.3% (6.6-12.9)
13.8% (10.2-18.4)
0.8%
Took self-medication from pharmacy
    No
    Yes
335
48
383
383
87.5% (84.0-90.3)
12.5% (9.7-16.0)
Took traditional medicine
    No
    Yes
348
35
383
383
90.8% (87.3-93.4)
9.2% (6.6-12.7)
Visited a private practitioner
    No
    Yes
354
29
383
383
92.4% (89.4-94.7)
7.6% (5.4-10.6)
Health care visits prior to diagnosis
    1
    2
    3
    ≥4
    Missing
173
121
40
45
5
378
378
378
378
383
45.6% (40.2-51.1)
31.9% (26.9-37.3)
10.5% (7.6-14.4)
12.0% (9.1-15.7)
1.2%
Time taken to reach health facility
    <30 minutes
    30mins - 1 hour
    >1 hour
    Missing
150
101
126
6
377
377
377
383
39.9% (35.1-44.8)
26.7% (21.9-32.0)
33.5% (28.6-38.8)
1.5%
Distance to health facility(in km)
    ≤5
    6 – 15
    16 – 30
    ≥30
Missing
122
64
55
90
52
331
331
331
331
383
36.8% (32.3-41.6)
19.5% (15.4-24.3)
16.5% (12.3-21.8)
27.2% (22.4-32.5)
13.7%
Difficulty in accessing transport to health centre
    No
    Yes
322
61
383
383
84.2% (78.9-89.5)
15.8% (12.1-20.5)
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Ever heard of TB before diagnosis
    Yes
    No
    Missing
43
322
18
365
365
383
88.1% (83.6-91.5)
11.9% (8.5-16.4)
4.8%
NB: Percentages may not always add up to 100 because of rounding off error.
DOT = directly observed treatment; HIV = human immunodeficiency virus; CPT = cotrimoxazole preventive 
therapy; ART = antiretroviral therapy, TB = tuberculosis.
PATIENT DELAYS AND ASSOCIATED FACTORS
There was a median of 28 days for patient delays (IQR, 21-63). Of all recruited study 
participants, 184 (48%) experienced patient delays >30 days in seeking TB treatment services.
Table 2 shows factors associated with patient delay. In comparison to patients starting TB 
treatment at district or mission hospitals, those starting treatment at rural primary health 
facilities were more likely [adjusted odds ratio (aOR) 2.70, 95% confidence interval (CI) 1.27-
5.75, p = 0.01] to experience patient delays. On further analysis, those patients who started TB 
treatment at rural facilities accessed traditional healers first more than those accessing other 
types of health facilities although the association was not statistically significant (14.2% vs. 
8.4%, p = 0.192). The seeking of treatment first at private practitioners was also similar for 
both those who were treated at rural facilities and other types of health facilities (7.8% vs. 
7.5%, p = 0.937).
Table 2: Factors associated with patient delay in accessing TB treatment services.
Patient delay > 30 days*
Characteristic (N = 383) n (%) OR (95% CI) Adjusted OR 
(95%CI)
Age in years
    18 – 25
    26 – 44
    45 – 54
    ≥55
30 (55.8)
122 (50.0)
24 (43.9)
9 (29.4)
Reference
0.79 (0.41-1.53)
0.62 (0.26-1.46)
0.33 (0.12-0.88)
Reference
0.55 (0.25-1.19)
0.55 (0.21-1.43)
0.35 (0.10-1.24)
Sex
    Female
    Male
80 (46.5)
105 (49.7)
Reference
1.13 (0.72-1.78)
Reference
1.07 (0.59-1.96)
Type of health facility
    District/mission hosp
    Provincial hospital
    Urban municipal clinic
    Rural PHC
95 (51.2)
10 (5.2)
45 (24.6)
35 (19.0)
Reference
1.77 (0.64-4.86)
2.45 (1.42-4.22)
2.61 (1.36-5.01)
Reference
1.82 (0.53-6.30)
1.78 (0.88-3.60)
2.70 (1.27-5.75)
HIV status
    Not tested
    HIV negative
    HIV positive, not on ART
    HIV positive, on ART/CPT
2 (40.0)
63 (44.6)
36 (51.0)
80 (50.5)
Reference
1.21 (0.25-5.81)
1.56 (0.32-7.66)
1.53 (0.32-7.30)
Reference
1.01 (0.16-6.51)
1.38 (0.22-8.77)
1.68 (0.26-
10.77)
Staying with anyone currently on TB treatment
    No
    Yes
170 (48.9)
15 (41.7)
Reference
0.75 (0.35-1.61)
Reference
0.99 (0.79-1.23)
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Education
    More than secondary
    Secondary
    Primary
No education
10 (48.2)
101 (52.7)
66 (44.8)
9 (36.7)
Reference
1.20 (0.43-3.31)
0.87 (0.31-2.45)
0.62 (0.17-2.29)
Reference
1.40 (0.45-4.37)
1.35 (0.39-4.74)
1.10 (0.23-5.33)
Employment status
    Formal employment
    Informal employment
    Unemployed
25 (61.2)
54 (51.5)
104 (44.3)
Reference
0.67 (0.33-1.39)
0.50 (0.26-1.00)
Reference
0.92 (0.37-2.27)
0.74 (0.30-1.85)
Residence
    Urban
    Rural
60 (52.8)
119 (46.2)
Reference
0.82 (0.53-1.26)
Reference
1.04 (0.80-1.33)
History of smoking
    Never
    Current smoker
    Quit smoking
131 (48.8)
10 (36.8)
43 (50.3)
Reference
0.61 (0.24-1.57)
1.06 (0.63-1.80)
Reference
0.59 (0.20-1.78)
0.75 (0.35-1.62)
History of alcohol use
    Never
    Current drinker
    Quit alcohol use
98 (46.2)
12 (43.0)
69 (52.3)
Reference
0.88 (0.40-1.91)
1.28 (0.78-2.08)
Reference
1.19 (0.39-3.57)
1.26 (0.61-2.64)
Previous contact with TB patient
    No
    Yes
100 (47.8)
84 (48.8)
Reference
1.03 (0.66-1.59)
Reference
0.96 (0.79-1.16)
Took traditional medicine
    No
    Yes
163 (46.8)
22 (62.4)
Reference
1.88 (0.84-4.20)
Reference
1.80 (0.76-4.28)
Took self-medication from pharmacy
    No
    Yes
140 (44.5)
45 (65.4)
Reference
2.35 (1.35-4.11)
Reference
2.33 (1.23-4.43)
First consulted private practitioner
    No
    Yes
166 (46.9)
19 (65.3)
Reference
2.14 (0.95-4.81)
Reference
1.47 (0.56-3.87)
Time taken to reach health facility
    <30 minutes
    30mins - 1 hour
    >1 hour
89 (59.3)
40 (39.9)
54 (42.5)
Reference
0.45 (0.26-0.81)
0.51 (0.31-0.82)
Reference
0.43 (0.22-0.83)
0.47 (0.24-0.94)
Distance to health facility (in km)
    ≤5
    6 – 15
    16 – 30
    ≥30
66 (54.1)
28 (43.8)
27 (50.1)
39 (43.0)
Reference
0.66 (0.36-1.21)
0.85 (0.41-1.76)
0.64 (0.35-1.18)
Reference
1.14 (0.52-2.47)
1.85 (0.79-4.37)
1.39 (0.60-3.23)
Difficulty in accessing transport to health centre
    No
    Yes
150 (46.6)
35 (57.3)
Reference
1.51 (0.80-2.85)
Reference
0.66 (0.40-1.08)
Ever heard of TB before diagnosis?
    No
    Yes
Total
18 (40.4)
156 (48.7)
184 (48.3)
Reference
1.40 (0.63-3.13)
-
Reference
1.16 (0.97-1.40)
-
*Patient delay was defined as a period >30 days from onset of any TB symptom to date of first encounter 
with health worker. HIV = human immunodeficiency virus; CPT = cotrimoxazole preventive therapy; 
ART = antiretroviral therapy; TB = tuberculosis; VCT = voluntary counseling and testing; OR = odds ratio; 
CI = confidence interval.
TUBERCULOSIS TREATMENT DELAYS AND ASSOCIATED FACTORS 
WITHIN THE ZIMBABWE NATIONAL TUBERCULOSIS PROGRAMME
47
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
The likelihood of patient delays was higher for those who took self-medication when 
experiencing cough symptoms [aOR 2.33, 95% CI 1.23-4.43, p = 0.01]. Those taking between 
30 minutes to an hour to reach their DOT facility [aOR 0.43, 95% CI 0.22-0.83, p = 0.013] and >1 
hour [aOR 0.47, 95% CI 0.24-0.94, p = 0.032] were both less likely to experience patient delays 
when compared to those reaching the DOT facility in less than 30 minutes.
HEALTH SYSTEM DELAYS AND ASSOCIATED FACTORS
There was a median of 2 days for health system delays (IQR, 1-5). There were only 118 (31%) of 
all study participants who encountered health system delays >4 days. Table 3 shows factors 
associated with health system delay >4 days. Health system delays were higher among those 
26-44 years old [aOR 3.30, 95% CI 1.16-9.37, p = 0.025] and aged 45-54 years [aOR 3.57, 95% CI 
1.09-11.72, p = 0.036]. Being male and having TB diagnosis done using GeneXpert were also 
associated with less odds of health system delays i.e. [aOR 0.47, 95% CI 0.23-0.96, p = 0.038] 
and [aOR 0.21, 95% CI 0.07-0.66, p = 0.008] respectively. All those who had a GeneXpert test 
done were HIV-infected individuals.
Table 3: Factors associated with Health system delays in accessing TB treatment services.
Health system delay > 4 days
Characteristic (N = 383) n (%) OR (95% CI) Adjusted OR 
(95% CI)
Age in years
    18 – 25
    26 – 44
    45 – 54
    ≥55
9 (17.3)
84 (34.4)
18 (32.4)
7 (20.9)
reference
2.51 (1.08-5.84)
2.30 (0.85-6.22)
1.26 (0.38-4.18)
reference
3.30 (1.16-9.37)
3.57 (1.09-11.72)
2.66 (0.61-11.57)
Type of diagnostic test
    Direct smear microscopy
    Gene Xpert
110 (30.4)
7 (35.6)
reference
1.27 (0.56-2.85)
reference
0.21 (0.07-0.66)
Sex
    Female
    Male
61 (35.6)
56 (26.6)
reference
0.66 (0.41-1.06)
reference
0.47 (0.23-0.96)
Type of health facility
    District/mission hospital
    Provincial hospital
    Urban municipal
    Rural primary healthcare facility
48 (20.5)
12 (64.6)
37 (50.1)
21 (37.6)
reference
7.08 (2.81-17.88)
3.89 (2.21-6.86)
2.33 (1.19-4.58)
reference
14.15 (4.58-43.69)
6.9 (2.41-19.82)
2.67 (1.18-6.07)
TB Diagnosing centre on site
    Yes
    No
71 (25.5)
43 (45.8)
reference
2.48 (1.53-4.02)
reference
1.41 (0.59-3.36)
HIV status
    Not tested
    HIV-negative
    HIV-positive, not yet on ART
    HIV-positive, on ART/CPT
2 (33.5)
38 (27.0)
20 (28.0)
55 (34.5)
reference
0.73 (0.13-4.11)
0.77 (0.13-4.52)
1.04 (0.19-5.78)
reference
0.72 (0.06-8.97)
0.70 (0.06-8.99)
1.37 (0.11-17.04)
Residence
    Urban
    Rural
43 (37.6)
74 (27.9)
reference
0.81 (0.54-1.22)
reference
0.95 (0.71-1.29)
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History of smoking
    Never
    Current smoker
    Quit smoking
80 (29.9)
7 (25.1)
29 (34.2)
reference
0.79 (0.29-2.14)
1.22 (0.70-2.12)
reference
1.58 (0.45-5.63)
0.86 (0.39-1.89)
History of alcohol use
    Never
    Current drinker
    Quit alcohol use
64 (30.1)
5 (18.6)
46 (34.7)
reference
0.53 (0.20-1.37)
1.23 (0.74-2.05)
reference
0.40 (0.11-1.42)
1.50 (0.69-3.26)
Took traditional medicine
    No
    Yes
109 (31.3)
9 (24.6)
reference
0.72 (0.31-1.65)
reference
0.66 (0.28-1.57)
Took self-medication from pharmacy
    No
    Yes
98 (29.2)
20 (41.3)
reference
1.71 (0.90-3.23)
reference
1.68 (0.72-3.93)
Health care visits prior to diagnosis
    1
    2
    3
    ≥4
46 (26.8)
40 (33.5)
10 (25.2)
20 (43.9)
reference
1.38 (0.79-2.41)
0.92 (0.39-2.15)
2.14 (1.06-4.34)
reference
1.82 (0.93-3.53)
0.99 (0.33-2.96)
2.24 (1.02-4.94)
Time taken to reach health facility
    <30 minutes
    30mins - 1 hour
    >1 hour
52 (34.3)
33 (33.1)
32 (25.4)
reference
0.95 (0.52-1.71)
0.65 (0.37-1.15)
reference
1.38 (0.65-2.93)
1.03 (0.46-2.27)
Distance to health facility (in km)
    ≤5
    6 – 15
    16 – 30
    ≥30
44 (36.4)
17 (26.7)
18 (32.9)
15 (16.5)
reference
0.64 (0.32-1.27)
0.86 (0.41-1.78)
0.35 (0.16-0.75)
reference
0.78 (0.32-1.88)
1.84 (0.68-4.98)
0.51 (0.20-1.29)
Difficulty in accessing transport to health centre
    No
    Yes
Total
21 (32.6)
96 (30.3)
118 (30.7)
reference
1.14 (0.60-2.19)
-
reference
1.00 (0.64-1.57)
-
*Health system delay was defined as a period >4 days from first encounter with health worker to date of 
starting TB treatment.
DOT = directly observed treatment; HIV = human immunodeficiency virus; CPT = cotrimoxazole preventive 
therapy; ART = antiretroviral therapy; TB = tuberculosis, VCT = voluntary counseling and testing.
In addition, the odds of health system delays were higher when starting treatment at 
urban municipal clinics [aOR 6.9, 95% CI 2.41-19.82, p = 0.03] and rural clinics [aOR 
2.67, 95% CI 1.18-6.07, p = 0.019] although these delays were not significantly higher for 
those accessing treatment from non-TB diagnosing facilities after multivariate analysis. 
Lastly, there were higher odds of health system delays associated with encountering ≥4 
health care visits in comparison to one healthcare visit prior to starting TB treatment 
[aOR 2.24, 95% CI 1.02-4.94, p = 0.045]. Further stratification of those with ≥4 
healthcare visits by type of health-worker seen among those experiencing health system 
delays showed that 8 (42%) had seen different health workers in the same facility and 11 
(58%) had seen different health workers in different health facilities.
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TOTAL DELAYS
Total delay among all recruited study participants was a median of 36 days (IQR, 23-68). 
Figure 1 shows the distribution of total delays in weeks.
Figure 1. Total delay in weeks between onset of Tb-related symptoms and treatment of TB
DISCUSSION
In this study, we assessed the extent of both patient and health system delays in accessing 
TB treatment within public health facilities under the Zimbabwe National Tuberculosis 
Programme. The median patient delay was 28 days and this is similar to findings from other 
African countries such as Ghana15 and South Africa16 and slightly lower than reported findings 
from other low income countries as reported in a systematic review by Sreeramareddy et al.5 
The taking of self-medication for TB-related symptoms, as has been found in other studies,17, 18 was 
associated with patient delay, although in general this practice was uncommon amongst this 
patient population. Also uptake of traditional medicine was not significantly associated with 
patient or health system delays and assuming there was no under-reporting, this practice 
was uncommon despite the fact that more than two thirds of study participants resided in a 
rural setting. This finding differs from findings from a meta-analysis by Finnie et al7 of other 
sub-Saharan African countries where taking of traditional medicine was consistently found 
to be associated with patient delays.
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Patients who started TB treatment at rural primary healthcare facilities were more 
likely to experience patient delays when compared to those who started at district or mission 
hospitals. Literature from other countries also indicates that an initial visit to a government 
low-level health care facility19–21 and rural residence14, 16, 22 are both associated with increased 
patient delays in seeking TB treatment services. Whilst the majority of our study participants 
were rural patients, distance to a DOT facility was not associated with patient delay and in fact 
those taking a longer time to reach a DOT facility were less likely to experience patient delays. 
The reasons for this finding are not clear as other studies have found that long distances to 
health facilities7 and absence of transport have contributed to poor and delayed uptake of 
HIV care and treatment in co-infected patients.23
It is likely that the patient delays among those with shorter travel time to a health 
facility and accessing treatment at lower-level health facilities are attributed to these 
patients being less health conscious and seeking treatment late in comparison to those who 
are more health conscious who seek services sooner at higher-level hospitals even though 
they may be further away. Zimbabwe has a four-tiered referral health system and district/
mission hospitals which are at the second level may be preferable to patients since they 
manage referral cases not managed at primary care facilities which are at the first level, 
as they have a staff complement of medical doctors in addition to nursing staff. They also 
provide specialized services to periphery first-level health facilities within their district such 
as laboratory services and ART initiation prior to decentralization of ART initiations to lower-
level health facilities. These district/mission hospitals are also centrally located within the 
district and therefore usually better resourced and managed and generally further away from 
patients in comparison to primary facilities, particularly in rural settings.
Contrary to other published studies, gender,24 education level13 and old age25, 26 
were not associated with patient delays. In our study, HIV status showed no association with 
patient or health system delays, as has been found elsewhere.16, 27
In this study, the greater proportion of delay in seeking TB treatment was a result 
of patient-related factors rather than health system factors, a finding that is similar to that 
of other countries.8,17,28,29 The median health system delay was just 2 days, which is low in 
comparison to findings from other studies done in both intermediate30, 31 and high-burden 
TB settings.14,16,19 This encouraging finding highlights the efficiency within the national 
TB programme of processes that exist from sputum collection to sputum examination 
to diagnosis and the return of results to the health worker and eventual transmission 
of information to the patient which is followed by the initiation of the patient on anti-TB 
treatment among microbiologically confirmed PTB cases.
Of note were the higher health system delays among those receiving treatment at 
lower-level health facilities and those with four or more health facility visits prior to starting 
TB treatment. Primary health-care facilities usually do not have TB diagnosing facilities on 
site and therefore refer sputum samples to TB diagnosing centres at second-level health 
facilities thereby increasing sputum turnaround times, especially in rural settings. Whilst 
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sputum transportation using motorbikes has been established in some districts ranging from 
2-day to 1-week intervals, it remains ad-hoc in some places and this needs improvement. 
In Zimbabwe, Gene Xpert which is a more accurate and rapid diagnostic test,32 has recently 
been recommended33 and piloted as the initial diagnostic test for HIV-infected persons in 
addition to those with drug resistant TB risk factors as recommended by WHO.34 This explains 
why fewer health system delays were noted for those HIV-infected patients with TB diagnosed 
using the Gene Xpert MTB/RIF assay compared to the conventional smear microscopy.
Those who had four or more visits had either seen different health workers in the 
same facility or different health workers in different health facilities and this finding may 
highlight an important barrier to early diagnosis and treatment of TB, especially among 
mobile populations where each consecutive visit to a different health care worker may be like 
a first time visit if the hospital or patient records are not properly scrutinised. This calls for an 
important need to strengthen TB case diagnosis and management trainings among health 
workers to ensure that information about investigations and management is effectively 
passed on from one health care worker to another. In general, however, the majority of 
patients (78%) had visited the health facility ≤ 2 times before the diagnosis of TB was made, 
and this does suggest that the awareness and knowledge of TB is high among health workers 
in a high HIV-TB burden country like Zimbabwe. This high awareness may relate to the high 
burden of disease in Zimbabwe: in 2008 alone, TB cases contributed 30% of all chronic out-
patient disease conditions.35
Unlike other studies done in urban settings13,36,37 our study includes a heterogeneous 
population of TB patients in Zimbabwe coming from different levels of the healthcare 
system, from different regions and with a rural and urban mix, and therefore is representative 
of the overall TB programme in Zimbabwe. Limitations of our study include a possibility of 
recall bias of past events among respondents relating to when they first encountered TB 
symptoms. Health system delays may have shortened during the time of the survey since 
the structured questionnaires were administered by health workers from the selected health 
facilities. Our study could have failed to capture information on confirmed TB cases that 
were started on TB treatment but were not registered as shown in a study conducted in one 
province of Zimbabwe in which 43% of treated TB cases were not registered.38
There is also a possibility that our patient sample excluded vital information on 
those patients who may have been suspected of TB or diagnosed of TB in the private sector 
but did not go to public health facilities despite being referred. This is given the background 
that in Zimbabwe, TB treatment services are only offered in public health facilities hence 
those that are suspected of TB or diagnosed with TB in private health care facilities are 
referred to public health facilities which could either be missionary, local authority or 
government health facilities.
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CONCLUSION
This study has assessed the extent of TB treatment delays in a country with a high HIV-TB 
burden, an important issue that relates to individual patient outcomes and TB transmission 
in the community. Patient delays were found to be moderately high, suggesting the need for 
increased advocacy, communication and social mobilization efforts targeted at informing the 
general population to seek health services early when they experience symptoms suggestive 
of TB. There is also need for engagement and training of pharmacy staff so that they can 
accurately identify people with TB-like symptoms and effectively explain to them that TB 
diagnosis and treatment are offered for free at public health institutions. A programme of this 
nature has been piloted in Cambodia and has shown positive results.39
On the other hand, health system delays were not common, suggesting an efficient 
TB programme. Better understanding about why some patients have repeated visits to 
health facilities is needed. We also recommend more qualitative studies to elicit patient 
responses on why patient delays were associated with access to rural primary health facilities 
and also why health system delays where linked to older age and being female. Whilst our 
study findings are generalizable to those patients with microbiologically confirmed PTB, they 
are not representative of the HIV patient population which largely has smear negative TB 
and among whom delays are likely to be much more complex, longer, and more difficult to 
address. Hence a study specific to this population is also necessary.
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ABSTRACT
SETTING
All public health facilities in Chitungwiza District, Zimbabwe
Objective: To determine, in new tuberculosis (TB) patients registered in 2009 i) the proportion 
HIV tested, stratified by age, sex and type of TB, and ii) treatment outcomes in relation to type 
of TB and HIV status.
DESIGN
Retrospective cohort study 
RESULTS
Of 1800 TB patients, 1100 (61%) were HIV tested, of whom 877 (80%) were HIV-positive 
and 75 (9%) were documented as receiving antiretroviral treatment (ART). HIV-testing and 
HIV-positivity were similar between patients with different types of TB. For all TB patients 
regardless of HIV status, treatment success rate was 70% and 17% had transferred out. Being 
HIV-positive and on ART was associated with better treatment success, while age over 55 
years was associated with poor treatment outcomes. 
CONCLUSION
In a Zimbabwe district, less than two thirds of TB patients were HIV tested, and in the few 
patients documented HIV-positive and on ART there was better treatment success. Important 
lessons for improved TB control include increasing the uptake of HIV testing to ensure 
greater access to HIV treatment, more comprehensive recording practices on ART and better 
reporting on true outcomes of patients transferred out.
KEY WORDS
Zimbabwe; New tuberculosis; HIV; treatment outcomes
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INTRODUCTION
Zimbabwe is a country in central southern Africa with an estimated population of 13.5 million, 
and is currently suffering from a large epidemic of human immunodeficiency virus infection 
(HIV) and tuberculosis (TB). Zimbabwe is ranked 19th on the list of the 22 high TB burden 
countries in the world.1 In 1990 the country’s tuberculosis (TB) incidence rate was 329 cases 
per 100 000 population, but by 2009 this had increased to 742 cases per 100 000 population.1 
The overwhelming reason for the resurgence of TB has been the HIV/AIDS pandemic,2 which 
has been particularly devastating in Zimbabwe and other Southern African countries.3 The 
HIV-1 epidemic became established in Zimbabwe in the mid-1980s  and its subsequent 
spread was extremely rapid.4  HIV prevalence peaked in 1997 when it was estimated to be 
29% amongst the population aged ≥15 years.5  Since then, HIV prevalence has declined but 
was estimated to be 14% in the adult population in 2010.6 This decline has been attributed 
to behavioural change and the impact of mortality.7
According to national figures reported to the World Health Organization (WHO) for 
2009, 61% of TB patients received HIV testing and counselling of whom 78% were reported 
to be HIV-positive.1 For the 2008 cohort, 75% of HIV-positive TB patients were placed on 
cotrimoxazole preventive therapy (CPT) and 28% received antiretroviral treatment (ART) 
during anti-tuberculosis treatment.1 In 2008, the treatment success rate for new smear-
positive pulmonary tuberculosis (PTB) was reported at 74%.1 It is important that HIV-positive 
TB patients are identified and placed on CPT and ART, as these adjunctive therapies are 
crucial interventions in reducing case fatality.8 
In a country like Zimbabwe, TB patients who are not tested for HIV are likely to be 
co-infected, and yet without a confirmatory HIV test they do not have a gateway to HIV care 
and treatment. We hypothesised that TB patients who are not HIV-tested may have worse 
treatment outcomes when compared with those who are HIV-negative and those who are 
HIV-positive and on ART. Data in the national TB control programme have not been analysed 
to support or refute such a hypothesis. We therefore set out to determine the treatment 
outcomes of new TB patients registered over a 12-month period in relation to age, sex, type 
of TB and HIV status. Specific objectives were to determine i) the proportion of patients that 
were HIV tested, stratified by age, sex and type of TB, and ii) the treatment outcomes of these 
different types of TB patients in relation to HIV status.
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METHODS 
STUDY DESIGN: 
This was a retrospective cohort study of TB patients using routine programme data. 
SETTING: 
Chitungwiza, the study area, is a high density dormitory town situated approximately 20km 
from Zimbabwe’s capital city. It has a population of approximately 322,000.9 Chitungwiza is 
the third largest and fastest growing urban centre in Zimbabwe with most of its inhabitants 
commuting to the capital city for work. 
DIAGNOSIS AND MANAGEMENT OF TB IN CHITUNGWIZA:
All health institutions in the public sector in Chitungwiza that diagnose, register and treat 
TB patients were included in the study. These consisted of a government referral hospital, 
Chitungwiza Central Hospital, and four polyclinics which are under the city health department. 
While all facilities provide TB treatment services, it is only the central hospital that provides 
a TB diagnostic service and is the site to which all suspects were sent for sputum smear 
examination in 2009.  
All pulmonary TB (PTB) suspects first have sputum specimens examined by 
direct smear microscopy for acid-fast bacilli (AFB). Those with smears positive for AFB are 
diagnosed as smear-positive PTB, whilst those with negative smears or smears not done are 
referred for a chest radiograph. If the latter is suggestive of TB, the patients may be diagnosed 
as smear-negative PTB or PTB with smears-not-done. Extra-pulmonary TB (EPTB) is mainly 
diagnosed on clinical grounds and circumstantial evidence along with supporting specific 
diagnostic tests.10 Patients diagnosed as having TB are then referred back to their respective 
health centres for treatment. 
TB patients are registered in the district TB register and are treated with standardised 
anti-TB regimens.10 All new TB patients (patients who had never received anti-TB treatment 
in the past or had previously taken anti-TB drugs for less than 30 days) are treated with a 
standardised 6-month regimen consisting of 2-months initial phase of rifampicin, isoniazid, 
pyrazinamide and ethambutol followed by a 4-months continuation phase of rifampicin 
and isoniazid.10 Monitoring is done throughout anti-TB treatment. For patients with smear-
negative PTB and EPTB  the monitoring is clinical, but for those with smear-positive PTB 
sputum smears are tested at 2, 4 and 6 months. Smear-negative patients who complete 
treatment and smear-positive patients who complete treatment with or without negative 
smears are regarded as “successfully completing treatment”. Cohort analyses of registered 
TB patients are carried out to declare their standardised WHO TB treatment outcomes 12 
months after the start of TB treatment.1
Tuberculosis patients are routinely offered HIV counselling and testing at the time 
of TB diagnosis: in 2009, this was done using a parallel testing algorithm.11 HIV-infected TB 
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patients are counselled about safe sex practices and are meant to receive CPT for the whole 
duration of TB treatment. First-line ART is meant to be initiated usually within two to eight 
weeks after the start of anti-TB treatment irrespective of CD4 count and site of TB disease.12 
HIV-infected TB patients are referred to the ART centre at the government referral hospital, 
where they start efavirenz-based first line ART. 
PARTICIPANTS, DATA VARIABLES AND DATA COLLECTION:
All new adult TB patients (i.e., patients aged ≥ 15 years) registered in the District TB register 
kept at the government referral hospital for Chitungwiza from 1st January, 2009 – 31st 
December, 2009 were included in the study. Information was obtained from the TB register, 
which was examined between October 2010 and February 2011. Data variables abstracted 
into a structured report form included; TB registration number, age, sex, type of TB as 
determined by smear microscopy, HIVstatus (HIV test done or not done, HIV-positive and 
HIV-negative), and for those HIV-positive whether the patient was on ART.  Standardised 
TB treatment outcomes (treatment success, death, default, transfer out and failure) were 
recorded from the TB register.10 Data on ART for HIV-infected TB patients were not available 
in the TB register in 2009, and for this reason, information was obtained from the ART register 
for Chitungwiza district. 
ANALYSIS AND STATISTICS:
Patient data in the structured report form were coded and double entered by two 
independent data entry clerks into EpiData version 3.1 and cleaned for errors and analysed 
using STATA, version  10 (Stata Corporation, College Station, Texas). ). Associations between 
categorical variables were determined by the Chi-squared test and alternatively the Fischer’s 
Exact test. Poisson regression with robust error variance was used to calculate crude and 
adjusted relative risks for associations between HIV status, type of TB, age, sex and the 
primary outcome (TB treatment success). Relative risks were calculated since they are 
desirable for common outcome events in cohort studies.13 A Poisson regression model with 
the robust error variance option was chosen to minimize the 95% confidence interval widths 
for calculated relative risks.14
ETHICS AND APPROVAL:
Ethics approval was obtained from the Medical Research Council of Zimbabwe (MRCZ) and 
the Union Ethics Advisory Group in Paris, France.  
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RESULTS
CHARACTERISTICS OF PATIENTS WITH TB
There were 1800 adult patients who were registered with new TB, of whom 934 (52%) patients 
were female. The median age of all patients at the time of registration was 36 years (IQR 29-
44). Results of HIV testing and documented referral of HIV-infected TB patients to ART are 
shown in the Figure. Sixty-one percent of TB patients were HIV tested of whom 80% were 
HIV-positive, but less than 10% of these patients were documented as receiving ART. There 
were no data in the registers about initiation of CPT for HIV-positive TB patients.
Figure 1. HIV status and documented referral to antiretroviral treatment for new tuberculosis patients 
registered in Chitungwiza district, Zimbabwe (Jan – Dec 2009).
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The results of HIV testing in relation to type of TB, sex and age group are shown in Table 1. HIV 
testing and HIV-positivity were similar between patients with different types of TB; p=0.575 
and p=0.631 respectively. However, more females were tested (621/934, 66%) compared to 
males (479/866, 55%) – p <0.001. There was a significant association between age and being 
HIV tested (p<0.001): those ≥ 55 years (41%) were the least tested while those aged 25 to 44 
years (65%) were the most tested. The highest rates of HIV-infection were in those aged 45 to 
54 years (87%).
Table 1: HIV testing and HIV serostatus in relation to TB type, sex and age.
Variable Number 
registered
Number (%) 
HIV tested
ǂP-value Number (%) 
HIV-positive
P-value
All patients 1800 1100 (61) - 877 (80) -
Type of TB*
   Smear-positive PTB
   Smear-negative PTB
   Smear-not done PTB
   EPTB
533
587
459
220
  326 (61)
  365 (62)
  283 (62)
  126 (57)
0.575 263 (81)
 293 (80)
 226 (80)
   95 (75)
0.631
Sex
   Female
   Male
934
866
  621 (66)
  479 (55)
< 0.001 506 (81)
371 (77)
0.216
Age group
   < 25
   25 – 44
   45 – 54
   ≥ 55
180
1181
246
193
   93 (52)
  772 (65)
  155 (63)
    80 (41)
<0.001   56 (60)
635 (82)
135 (87)
  51 (64)
<0.001
*1 patient with unknown type of TB has been excluded from the table; ǂ Chi-squared test p-value for 
association.
TB = tuberculosis; PTB = pulmonary tuberculosis; EPTB = extrapulmonary tuberculosis;
HIV = human immunodeficiency virus.
TB TREATMENT OUTCOMES IN RELATION TO TYPE OF TB AND HIV STATUS
Treatment outcomes for all TB patients in relation to HIV status, types of TB, sex and age group 
are shown in Table 2, and outcomes by type of TB stratified in turn by HIV status are shown 
in Table 3. For all TB patients regardless of HIV testing status, the treatment success rate was 
70%. The proportion of patients with treatment outcome ‘transferred out’ constituted the 
majority (17%) of those with an adverse treatment outcome and of these, 153 (50%) were 
HIV positive with undocumented ART status. Most transfer out patients (210/307, 68%) were 
aged 25 to 44 years.
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Table 2: TB treatment outcomes for all TB patients in relation to HIV serostatus, TB type, sex 
and age.
Treatment outcome a
Variable Number 
Registered
Treatment 
success
n (%)
Death
n (%)
Defaulter
n (%)
Transfer 
Out
n (%)
Treatment 
failure
n (%)
All patients 1800 1263  (70) 105 (6)  118   (7) 307 (17) 1 (<1)
HIV Status b
  HIV-not done
  HIV-positivec
  HIV-positive on ART 
  HIV-negative 
  685
  877
    75
  197
  477  (70)
  615  (70)
    62  (83)
  137  (70)
  43 (6)
  52 (6)
    3 (4)
    9 (5)
   51   (7)
   50   (6)
     5   (7)
   15   (8)
110 (16)
158 (18)
    5  (7)
  35 (18)
1 (<1)
0   (0)
0   (0)
0   (0)
Type of TB d
  Smear-positive PTB
  Smear-negative PTB
  Smear-not done PTB
  Extra-pulmonary TB
  533
  587
  459
  220
  391  (73)
  423  (72)
  298  (65)
  150  (68)
  30 (6)
  30 (5)
  30 (7)
  15 (7)
   24   (5)
   34   (6)
   39   (9)
   21 (10)
  87 (16)
  98 (17)
  89 (20)
  33 (15)
1 (<1)
0   (0)
0   (0)
0  (0)
Sex
  Female
  Male
  934
  866
  665 (71)
  598 (69)
  42 (5)
  63 (7)
   67 (7)
   51 (6)
156 (17)
151 (17)
1 (<1)
0 (0)
Age group (in years)
  < 25
  25 – 44
  45 – 54
  ≥ 55
  180
1181
  246
  193
128 (72)
840 (71)
174 (71)
121 (63)
    9 (5)
  56 (5)
  18 (7)
  22 (11)
   18 (10)
   72 (6)
   14 (6)
   14 (7)
  23 (13)
210 (18)
  38 (15)
  36 (19)
0 (0)
0 (0)
1 (<1)
0 (0)
a 6 patients have missing treatment outcomes hence excluded; b 26 patients with HIV-indeterminate results 
and 15 patients with unrecorded HIV Testing & Counselling status have been excluded; c this includes those 
documented and not documented to be on ART; d 1 patient with unknown type of TB has been excluded. PTB 
= pulmonary tuberculosis.
Crude and sex and age adjusted relative risks for predictors of TB treatment success are 
shown in Table 4. Overall those HIV-positive TB patients documented to be on ART had a 
better treatment success compared to those not HIV-tested (adjusted RR 1.16 [95% CI, 1.02 – 
1.32]) while those over the age of 55 years had worse treatment success compared with those 
< 25 years (adjusted RR 0.79 [95% CI, 0.63 – 0.95]).
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Table 3: TB treatment outcomes in relation to type of TB and HIV serostatus.
Treatment outcome a
Type of 
TB c
HIV Status b Number 
registered
Treatment 
success
n (%)
Death
n (%)
Defaulter
n (%)
Transfer 
Out
n (%)
Treatment 
failure
n (%)
Smear-
positive 
PTB
All  patients
HIV-not done
HIV-positived
HIV-positive on ART
HIV-negative
533
202
263
  23
  53
  391  (73)
  159  (79)
  182  (69)
    19  (83)
    38  (72)
  30 (6)
    9 (4)
  18 (7)
    2 (9)
    3 (6)
   24   (5)
     8   (4)
   11   (4)
     1   (4)
     5   (9)
  87 (16)
  25 (12)
  52 (20)
    1   (4)
    7 (13)
1 (<1)
1 (<1)
0   (0)
0   (0)
0   (0)
Smear-
negative 
PTB
All patients
HIV-not done
HIV-positived
HIV-positive on ART
HIV-negative
587
215
293
  29
  60
  423  (72)
  152  (71)
  215  (73)
    24  (83)
    41  (68)
  30 (5)
  13 (6)
  12 (4)
    1 (3)
    4 (7)
   34   (6)
   10   (5)
   20   (7)
     1   (3)
     2   (3)
  98 (17)
  38 (18)
  46 (16)
    3 (10)
  13 (22)
0   (0)
0   (0)
0   (0)
0   (0)
0   (0)
Smear-not 
done PTB
All patients
HIV-not done
HIV-positiveb,d
HIV-positive on ART
HIV-negativeb
459
174
226
  16
  53
  298  (65)
  107  (61)
  147  (65)
    12  (75)
    38  (72)
  30 (7)
  16 (9)
  14 (6)
    0 (0)
    0 (0)
   39   (9)
   22 (13)
   14   (6)
     3 (19)
     3   (6)
  89 (19)
  29 (17)
  49 (22)
    1   (6)
  11 (21)
0   (0)
0   (0)
0   (0)
0   (0)
0   (0)
Extra-
pulmonary 
TB
All patients
HIV-not doneb
HIV-positived
HIV-positive on ART
HIV-negative
220
  93
  95
    7
  31
  150  (68)
    58  (62)
    71  (75)
      7 (100)
   20  (65)
  15 (7)
    5 (5)
    8 (8)
    0 (0)
    2 (6)
   21 (10)
   11 (12)
     5   (5)
     0   (0)
    5 (16)
  33 (15)
  18 (20)
  11 (12)
    0   (0)
    4 (13)
0   (0)
0   (0)
0   (0)
0   (0)
0   (0)
a 6 patients have missing treatment outcomes; b26 patients with HIV-indeterminate results and 15 patients with 
unrecorded HIV Testing & Counselling status have been excluded; c1 patient with unknown type of TB has been 
excluded. PTB = pulmonary tuberculosis. d this includes both those documented and not documented to be on ART.
Table 4: Adjusted Relative Risks for TB Treatment Success.
Variable Treatment 
success  
n(%)
RR (95% CI) Adjusted RR 
(95%CI)*
P – value
HIV status
   HIV –not done
   HIV-positive (ART not documented)
   HIV-positive (on ART)
   HIV-negative
477 (70)
553 (69)
  62 (83)
137 (70)
Ref.
0.97 (0.88 – 1.06)
1.16 (1.02 – 1.32)
1.01 (0.86 – 1.18)
Ref.
0.96 (0.87 – 1.06)
1.16 (1.02 – 1.32)
1.00 (0.85 – 1.18)
0.373
0.028
0.999
Type of TB
    Smear-positive PTB
    Smear-negative PTB
    Smear-not done PTB
    EPTB
    PTBND
391 (73)
423 (72)
298 (65)
150 (68)
Ref.
1.02 (0.94 – 1.12)
0.97 (0.86 – 1.09)
0.99 (0.85 – 1.14)
Ref
1.03 (0.94 – 1.13)
0.97 (0.86 – 1.10)
1.00 (0.87 – 1.15)
0.468
0.600
0.971
Sex
    Female
    Male
665 (71)
598 (69)
Ref.
0.97 (0.90 – 1.06)
Ref.
0.99 (0.91 – 1.08) 0.795
Age group
    < 25
   25 – 44
   45 – 54
   ≥ 55
128 (72)
840 (71)
174 (71)
121 (63)
Ref.
0.91 (0.75 – 1.09)
0.92 (0.74 – 1.12)
0.79 (0.63 – 0.99)
Ref.
0.91 (0.75 – 1.10)
0.92 (0.74 – 1.14)
0.77 (0.63 – 0.95)
0.316
0.450
0.015
* Relative risks are adjusted for sex and age using Poisson Regression with robust error variance. Relative risks 
greater than 1.0 indicate better treatment success.
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DISCUSSION
This study in Chitungwiza district showed a very high HIV prevalence in registered TB patients, 
irrespective of type of TB. Important significant findings with regards to treatment outcomes 
were a better treatment success rate in those few HIV-infected TB patients documented and 
known to be on ART and worse treatment success in those aged 55 years or more. 
 Apart from those HIV-infected patients known to be on ART, there were similar 
treatment outcomes in this study between patients who were not HIV-tested, those who 
were HIV-positive and those HIV-negative, and this finding differs from other studies where 
HIV-positive patients in general have worse treatment outcomes and higher death rates than 
HIV-negative patients.15 The reasons for our findings are not obvious. However, the main 
adverse treatment outcome was transfer-out, meaning that patients were transferred out to 
another health facility and no treatment outcomes were reported back to the referring and 
reporting unit. The true outcomes in the transfer-out groups could have varied between 
those with different HIV testing status, and could have included, for example, different case 
fatality rates between those HIV-negative and those with HIV status not known. Thus, the 
high rates of transfer out could have hidden varying mortality rates between the different 
HIV-status groups.  
There are four other important findings and implications from this study. First, only 
61% of patients registered with TB were HIV tested and, given the high HIV prevalence, it 
would be preferable to have a much higher testing uptake. HIV testing was more common in 
females compared with males, and better strategies to recruit males for HIV testing need to 
be found. 
Second, fewer than 10% of HIV-infected TB patients were documented as receiving 
ART during TB treatment from the ART facility in Chitungwiza, and this is well below the 
national average.1 Possible reasons for such a low uptake to ART include:- a) poor ART 
initiation in HIV-infected TB patients in Chitungwiza; b) the system that we used to collect 
ART data in this study missed patients who had been started on ART in another district, and 
thus there may be under-reporting of ART uptake. It would be much better to have ART data 
in all TB registers, and this in fact was initiated during 2010. Better integration of HIV and TB 
activities in health facilities may also improve linkages and ART uptake. 
Third, there was a high rate of transfer out of patients, and this adversely impacted 
on TB treatment outcomes and effectively means a high proportion of patients with an 
unknown outcome. Although there are difficulties in routinely and regularly reporting on 
transfer-out and transfer-in patients under programme settings,16 further studies should be 
done to trace the outcomes of these mobile patients since this mostly affects those that are 
HIV-positive who may have transferred to access ART in other districts. This is an area where 
improvement needs to be made. 
Fourth, almost 30% of patients with PTB had no sputum smears documented in the 
TB register. The high percentage of smears-not-done was attributed to a poor emphasis on 
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TB diagnosis by sputum smear examination in Chitungwiza district, with these patients being 
diagnosed by clinical findings and chest x-ray. This is of course contrary to international and 
national TB treatment guidelines which recommend sputum smear examination in all adults 
with suspected pulmonary TB.1, 10 The use of these guidelines is supported by a Kenyan study 
which showed that TB diagnosis by direct smear microscopy followed by chest x-ray is more 
cost-effective when compared to TB diagnosis by chest X-ray alone.17
 This was a district based study where data were collected for TB patients under 
routine programmatic conditions. A large number of patients were included in the study 
and we believe the results are representative of the national situation. The study also 
adhered to STROBE Guidelines for the reporting of observational data.18 However, there 
are limitations mainly related to the operational nature of the study and the fact that data 
were retrospectively collected from registers where completeness and accuracy of data is 
difficult to ensure. An important limitation of our study is the lower proportion of transferred 
out patients among HIV-positive patients on ART compared to other patient groups. This 
is probably due to the fact that these patients were registered in the Chitungwiza district 
register and therefore more likely to access TB treatment and ART locally. This may in part 
explain their better treatment outcomes in comparison to other patients. Our findings may 
also be limited by lack of data on TB treatment and ART compliance and HIV disease severity 
which may have confounded the relationship between HIV status and TB treatment success.
 In conclusion, there is a need to increase the HIV testing rate among TB patients, 
especially males, and if they are referred to HIV treatment and care this may improve their 
TB treatment outcomes. Better recording practices of ART access in the district TB registers 
are needed and this will enable better assessment of HIV care and treatment coverage. 
Strengthening the follow up of treatment outcomes in patients transferred out will also allow 
better analysis of the relationship between HIV status and TB treatment success. With respect 
to the national TB programme, there needs to be improvement in getting sputum smears 
examined in PTB suspects as this is more cost effective than diagnosis by chest x-ray. Further 
research should be conducted to establish the true TB treatment outcomes of transferred 
out patients. 
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ABSTRACT
BACKGROUND
Zimbabwe is a Southern African country with a high HIV-TB burden and is ranked 19th among 
the 22 Tuberculosis high burden countries worldwide. Recurrent TB is an important problem 
for TB control, yet there is limited information about treatment outcomes in relation to HIV 
status. This study was therefore conducted in Chitungwiza, a high density dormitory town 
outside the capital city, to determine in adults registered with recurrent TB how treatment 
outcomes were affected by type of recurrence and HIV status.
METHODS
Data were abstracted from the Chitungwiza district TB register for all 225 adult TB patients 
who had previously been on anti-TB treatment and who were registered as recurrent TB from 
January to December 2009. The Chi-square and Fischer’s exact tests were used to establish 
associations between categorical variables. Multivariate relative risks for associations 
between the various TB treatment outcomes and HIV status, type of recurrent TB, sex and 
age were calculated using Poisson regression with robust error variance.
RESULTS
Of 225 registered TB patients with recurrent TB, 159 (71%) were HIV tested, 135 (85%) were 
HIV-positive and 20 (15%) were known to be on antiretroviral treatment (ART). More females 
were HIV-tested (75/90, 83%) compared with males (84/135, 62%). There were 103 (46%) with 
relapse TB, 32 (14%) with treatment after default, and 90 (40%) with “retreatment other” TB. 
There was one failure patient. HIV-testing and HIV-positivity were similar between patients 
with different types of TB. Overall, treatment success was 73% with transfer-outs at 14% being 
the most common adverse outcome. TB treatment outcomes did not differ by HIV status. 
However those with relapse TB had better treatment success compared to “retreatment 
other” TB patients, (adjusted RR 0.81; 95% CI 0.68 – 0.97, p = 0.02).
CONCLUSIONS
No differences in treatment outcomes by HIV status were established in patients with 
recurrent TB. Important lessons from this study include increasing HIV testing uptake, a 
better understanding of what constitutes “retreatment other” TB, improved follow-up of true 
outcomes in patients who transfer-out and better recording practices related to HIV care and 
treatment especially for ART.
KEYWORDS
HIV, Recurrent tuberculosis, Treatment outcomes, Zimbabwe
TREATMENT OUTCOMES OF ADULT PATIENTS WITH RECURRENT TUBERCULOSIS 
IN RELATION TO HIV STATUS IN ZIMBABWE: A RETROSPECTIVE RECORD REVIEW
75
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
BACKGROUND
The global burden of tuberculosis (TB) is highest in the Sub-Saharan Africa region1 and this 
can be attributed to the high prevalence of human immunodeficiency virus infection (HIV) 
which is known to increase the risk of developing TB.2, 3 Tuberculosis cases are categorised 
as new and recurrent, the latter referring to patients who have been previously treated. 
Recurrence of TB can be attributed to relapse with a persistent Mycobacterium tuberculosis 
strain4 or reinfection with a different strain.5, 6 Several studies have shown that HIV infection 
increases the rate of TB recurrence after successful completion of TB treatment in high HIV 
endemic areas, with recurrence often being due to a reinfection.6 – 9
Despite evidence from clinical trial settings indicating that rates of recurrent 
TB can be reduced by administration of rifampicin-based treatment,10 there has been a 
steady increase in the number of tuberculosis (TB) case notifications that are categorised 
as recurrent or “retreatment”. Since 1995, when the global DOTS framework was launched, 
up to 2008, the annual number of retreatment cases globally has increased from 59,240 
to 775,403.1 In the WHO Africa region, the annual number of notified retreatment TB cases 
had increased from 15,133 in 1995 to 135,564 by the end of 2008, with 53,190 being relapse 
cases and 82,374 being registered in other retreatment categories.1 In general, the treatment 
outcomes of retreatment cases are not as good as with new cases of TB as shown by global 
statistics for the 2008 cohorts, whereby only 72% of retreatment cases (and 71% from the 
Africa region) successfully completed treatment.1
Zimbabwe is a country in Southern Africa with a population of 13 million and a 
large HIV-TB burden. Zimbabwe, which ranks 19th among the 22 Tuberculosis high burden 
countries, had a TB incidence rate of 762 cases per 100,000 population and an HIV co-infection 
prevalence of above 75% in 2008.1 There were 3631 (10%) notified retreatment cases out of 
a total of 36,650 cases registered in 2008, and these cases had a treatment success rate that 
was reported at 73% compared to 69% and 74% for new smear-positive TB cases and new-
smear negative/extra-pulmonary TB cases respectively.1
In 2008, the estimated number of retreatment TB cases with multi-drug resistant 
(MDR) TB (resistant to both isoniazid and rifampicin) was 8.3% (95% CI; 2.9-22). However, 
from 2005 to 2009, there were no notified retreatment cases that were actually tested for 
drug resistance,1 so this estimate cannot be confirmed. HIV-infected TB patients should 
now receive a package of cotrimoxazole preventive therapy (CPT) and antiretroviral therapy 
(ART), both of which can reduce case fatality and increase treatment success if administered 
early enough during anti-TB treatment.11 – 15 It is therefore important that TB patients | 
should undergo HIV testing as soon as TB is diagnosed, so that they can access these 
adjunctive therapies.
Given the high HIV prevalence in Zimbabwe and the growing importance of 
recurrent TB, we determined in one district in Zimbabwe (i) the type of tuberculosis in adult 
patients registered with recurrent TB, ii) the proportion that were HIV tested with their results 
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and (iii) the treatment outcomes of recurrent TB patients in relation to type of TB and HIV 
status.
METHODS
STUDY DESIGN
This was a retrospective record review of adult patients registered as “recurrent TB”.
STUDY SETTING
All public health facilities in Chitungwiza were selected for this study. Chitungwiza is a high 
density dormitory town which is situated about 20 km from Zimbabwe’s capital city, Harare, 
and has a population of 343 147.16 All health facilities consisting of a government central 
hospital and four polyclinics, which are under the Chitungwiza City Health Department, offer 
general health services including TB treatment services. However, TB laboratory diagnosis 
through direct smear microscopy examination is only carried out at the government central 
hospital where all collected sputum smears in the district are sent. All health facilities offer HIV 
counselling and testing services and cotrimoxazole prophylaxis free of charge for confirmed 
HIV-positive patients as recommended by the Zimbabwe National TB Control Programme 
(NTP). In 2009 ART initiation and HIV treatment and care services in Chitungwiza were only 
offered at an ART initiating facility at the government central hospital where all HIV-positive 
patients in the district were referred.
TB DIAGNOSIS AND DEFINITIONS: 
Patients with recurrent TB will have been previously treated for TB and are classified 
according to standard WHO case definitions as either a relapse case (a patient who completed 
treatment and presents again with smear-positive PTB), treatment after failure (a patient who 
failed first line treatment), treatment after default (a patient who defaulted from treatment 
and presents again with smear-positive PTB) or “retreatment other” (all other recurrent TB 
cases).2 In the Zimbabwe NTP, TB is diagnosed based on an initial clinical diagnosis and then 
a confirmative laboratory diagnosis through direct smear microscopy of sputum smears.17 
Those with smears positive for acid-fast bacilli are diagnosed as smear-positive PTB, whilst 
those with negative smears are referred for a chest radiograph. If the latter is suggestive of 
TB, the patient is diagnosed as smear-negative PTB. Extra-pulmonary TB (EPTB) is mainly 
diagnosed on clinical grounds, along with circumstantial evidence and supporting specific 
diagnostic tests.17
After TB diagnosis, health workers at each health facility complete notification 
forms and patient treatment cards for all recurrent TB patients indicating diagnosis, patient 
category, treatment regimen and monitoring indices. Patient information is then entered into 
the DOTS register at each health facility, which is then later compiled into the District TB 
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register for Chitungwiza. During the period of the study, HIV testing was routinely offered to 
all TB patients, using the parallel testing algorithm.18 However as from 2010 the serial testing 
algorithm was adopted.
After diagnosis and registration, all recurrent TB patients are given an 8-month 
standard re-treatment regimen with first line drugs (2SHRZE/1HRZE/5HRE) regardless of HIV 
status.17 In Chitungwiza, treatment was administered daily through health facility based DOT 
during the first 2 months of the intensive phase. Thereafter patients were given anti-TB drugs 
that ranged from weekly to monthly supplies until completion of the 8-month treatment 
period. Patients have their sputum specimens reviewed at 3 months, 5 months and at the 
end of treatment as recommended in the national guidelines.17 In Zimbabwe, cotrimoxazole 
preventive therapy (CPT) is recommended for the whole duration of TB treatment19 whilst 
ART is recommended between 2 and 8 weeks after commencing TB treatment.20 National 
TB treatment outcomes are in line with WHO guidelines and are classified as treatment 
success (cured plus treatment completed), defaulted, died, transferred out or treatment 
failure. Cohort analyses of the registered TB patients are done to declare their TB treatment 
outcomes 12 months after the start of TB treatment.
DATA COLLECTION
Data were collected for all adult TB patients registered in the District TB register for 
Chitungwiza between 1 January 2009 and 31 December 2009 who had previously been 
on TB treatment for more than one month. An adult was defined as a person 18 years and 
older. Patient data were abstracted from the District TB registers between October 2010 and 
February 2011 using a data collection form, and variables that were collected included:- TB 
registration number, age, sex, type and category of recurrent TB, HIV status (HIV test done 
or not done, HIV-negative or HIV-positive), treatment outcome (treatment success, died, 
defaulter, transferred out and failure) and cotrimoxazole use. For patients registered in 
2009, ART data were not available in the district TB registers, hence information about ART 
use in HIV-infected TB patients was obtained from the ART register at Chitungwiza Central 
hospital ART clinic were HIV-infected patients were referred for ART initiation in this district. 
TB registration numbers were collected as patient identifiers but however patient names had 
to be used to trace HIV-infected TB patients commenced on ART from the ART register.
STATISTICAL ANALYSIS
Patient information was coded, entered and cleaned using Epidata version 3.1 statistical 
software. Data were then imported and analysed using Stata 10 (Stata Corporation, College 
Station, Texas). The Chi-squared test or alternatively the Fischer’s Exact test was used to 
determine if there were associations between categorical variables. TB treatment outcomes 
were categorised into binary data with possible outcome events being treatment success, 
death, transfer-outs, defaulters and treatment failure. Poisson regression with error variance 
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was then used to estimate multivariate-adjusted relative risks for associations between the 
various TB treatment outcomes and HIV status, type of recurrent TB, sex and age.
The modified Poisson regression model with the robust error variance option was 
used as it is a better approach for estimating relative risks for cohort studies compared to 
using logistic regression.21 Assumptions of this statistical model were not violated as the 
model provides relative biases and percentages of confidence interval coverage which are 
reliable with a minimum sample size of 100.21 Relative risks for treatment failure, however, 
could not be calculated as there were no data in each subgroup to perform meaningful 
Poisson regression analysis. The 5% significance level was used in this study.
ETHICS
Access to data in the TB registers was granted by the Ministry of Health and Child Welfare 
whilst ethics approval was obtained from the Medical Research Council of Zimbabwe and the 
Union Ethics Advisory Group in Paris, France.
RESULTS
CHARACTERISTICS OF PATIENTS WITH RECURRENT TB
There were 225 registered patients with recurrent TB, of whom 135 (60%) were males. Results 
of HIV testing and documented referral of HIV-infected TB patients to ART are shown in 
Figure 1. Just over 70% of patients were tested for HIV and of these patients 85% were HIV-
positive, but only 15% were documented as being initiated on ART. There were no data in 
the registers about initiation of HIV-infected TB patients on CPT. Table 1 shows results of 
HIV testing and HIV serostatus in relation to type of TB, sex and age. Proportions of patients 
HIV tested were similar across all the different types of recurrent TB (p = 0.476). However, 
HIV-positivity had a borderline association with type of TB (p = 0.052) being highest among 
relapse cases (89%) compared to treatment after default patients (70%) – p = 0.037. Though 
more females were tested (75/90, 83%) compared to males (84/135, 62%) – p = 0.001, HIV-
positivity was similar between the 2 groups. HIV testing was highest in the 45 to 54 year age 
group (87%) compared to other age groups but HIV-positivity was similar (p > 0.99) across the 
age groups.
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Figure 1. HIV testing status and known referral to antiretroviral treatment for recurrent tuberculosis patients 
in Chitungwiza district, Zimbabwe (Jan – Dec 2009)
Table 1: HIV testing and HIV serostatus in relation to TB type, sex and age.
Variable Number 
registered
Number (%) HIV 
tested
ǂP-value Number 
(%) HIV-
positive
P-value
All patients 225 159 (71) - 135 (85) -
Type of TB*
   Relapse
   Treatment after default
   Retreatment other
  103
    32
    90
    72 (70)
    20 (63)
    67 (74)
   0.476    64 (89)
   14 (70)
   57 (85)
0.052
Sex
   Female
   Male
    90
  135
    75 (83)
    84 (62)
0.001    66 (88)
   69 (82)
0.357
Age group
   < 25
   25 – 44
   45 – 54
   ≥ 55
    16
  147
    39
    23
    11 (69)
    99 (67)
    34 (87)
    15 (65)
0.039    10 (91)
   83 (84)
   29 (85)
   13 (87)
>0.99
TB tuberculosis, HIV human immunodeficiency syndrome.
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TB TREATMENT OUTCOMES IN RELATION TO TYPE OF TB AND HIV STATUS
Treatment outcomes for all patients with recurrent TB in relation to HIV status, type of TB, sex 
and age group are shown in Table 2. The treatment success rate was 73% for all TB patients, 
regardless of HIV status. Patients who transferred out (14%) constituted the majority of those 
with adverse treatment outcomes, with 15 (49%) being HIV-positive with undocumented ART 
status. For all patients, treatment success rates were similar regardless of HIV status (HIV test 
done or not done, HIV test positive or negative). Treatment success rates were also similar 
when stratified by sex and age group, with transfer outs being the most common adverse 
outcomes. TB treatment success rate was however highest in those with relapse TB (80%) 
compared to “retreatment other” TB patients (adjusted RR 0.81; 95% CI 0.68 – 0.97, p = 0.02). 
For all other adverse treatment outcomes, there were no significant multivariate-adjusted 
relative risks for association with HIV status, type of TB, sex and age.
Table 2: TB treatment outcomes for all recurrent TB patients in relation to HIV status, type of 
TB, sex and age.
Treatment outcome b
Variable Number 
registered
Treatment 
success
n (%)
Death
n (%)
Defaulter
n (%)
Transfer 
Out 
n (%)
Treatment 
failure 
n (%)
All patients  225 163 (73) 13 (6) 14 (6) 32 (14) 1 (<1)
HIV statusa
HIV-negative
HIV-not done
HIV-positive (ART not documented)
HIV-positive (on ART)
   21
   64
 115
   20
15 (71)
44 (69)
87 (76)
14 (70)
2 (10)
2 (3)
6 (5)
2 (10)
2 (10)
5 (8)
5 (4)
2 (10)
2   (10) 
13 (20)
15 (13)
1   (5)
0   (0)
0   (0)
1   (1)
0   (0)
Type of TB
Relapse TB
Treatment after default
Retreatment other
 103
   32
   90
82 (80)
21 (68)
60 (67)*
4 (4)
2 (6)
7 (8)
6 (6)
3 (10)
5 (6)
11 (11)
5   (16)
16 (18)
0 (0)
0 (0)
1 (1)
Sex
Female
Male
  90
135
68 (76)
95 (71)
5 (6)
8 (6)
6 (7)
8 (6)
10 (11)
22 (16)
0 (0)
1 (1)
Age group (in years)
<25
25 – 44
45 – 54
≥ 55
  16
147
  39
  23
12   (80)
108 (74)
26   (67)
17   (74)
1  (7)
6  (4)
5 (13)
1   (4)
       
0   (0)
11 (8)
2   (5)
1   (4)
2   (13)
21 (14)
5   (13)
4   (17)
0 (0)
0 (0)
1 (3)
0 (0)
a 2 patient with unrecorded HTC status and 3 with HIV-indeterminate results have been excluded; b 2 patients have 
unrecorded TB treatment outcomes 
TB tuberculosis, ART antiretroviral treatment, HIV human immunodeficiency virus Significant statistical 
comparisons using multivariate Poisson regression: * p <0.05 compared with relapse TB.
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DISCUSSION
This study in Chitungwiza district in Zimbabwe showed a very high HIV prevalence in patients 
registered with recurrent TB, but we did not find significant differences in treatment outcomes 
in relation to HIV status, age or sex. However, relapse TB patients had better treatment 
success compared to “retreatment other” TB patients.
There are a number of important findings from our study. Although HIV testing 
should be offered to all registered patients with TB, nearly one third of those with recurrent TB 
had no HIV test done. We do not know the reasons for this, and this particular issue deserves 
further investigation. HIV testing uptake was much better in females than males, and better 
strategies of encouraging males to be HIV tested need to be found and assessed.
The majority of patients with recurrent TB were HIV-positive, yet only 15% were 
documented to be receiving ART. There may be several reasons for this that include poor 
referral and access to ART services by HIV-TB patients in Chitungwiza district or a poor 
recording and reporting system. For patients registered in 2009, the only way to find whether 
HIV-TB patients had accessed ART was to review the ART registers for Chitungwiza district 
and try to match the names of HIV-infected TB patients with those from the TB register – 
matching was not possible and this is therefore a limitation of the study. HIV-TB patients who 
had transferred out and started ART in another district would also not be identified by this 
method and therefore missed for the purposes of this study. Since 2010, HIV and TB activities 
have been integrated into TB registers, and there should now be better data on ART. There 
was also no record of CPT use in the TB register and this needs improvement as well.
Finally, there was a high transfer out rate which adversely impacted on treatment 
success. A transfer out is defined as a patient who has been transferred to a health facility 
in another district and the treatment outcome results have not been reported back to the 
referring treatment unit who have the duty to report on these patients. This is an area where 
the Zimbabwe NTP needs to improve and ensure that centres who receive transfer-in patients 
report back the treatment outcomes to the facilities that initiated TB treatment.
This was a district based study where data were collected for TB patients under 
routine programme conditions. Hence, it may be difficult to ensure completeness, consistency 
and accuracy of data. Our study sample was small therefore it may have reduced the power 
of the study. We also were unable to adjust for the potential confounding effect of ART and 
TB treatment compliance and disease severity when assessing the association between TB 
treatment outcomes and HIV status as the data were unavailable.
CONCLUSIONS
In conclusion, there are some important lessons to learn from the study. More attention 
should be paid to dissecting out the various categories of patients who are classified together 
under “retreatment other” to determine whether outcomes are similar or different. Relapse 
patients appear to do better, but the power of our sample may have been insufficient to detect 
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this. Improving the follow up of outcomes in transferred out patients coupled with better 
recording practices of HIV care and treatment will allow better analysis of the relationship 
between TB treatment outcomes and HIV status. Transfer outs may also be lessened by 
integration of TB treatment services and ART initiation in all health facilities.
There needs to be a higher uptake of HIV testing in TB patients, especially in males. 
If those found HIV-positive are followed up and given CPT and early ART, this may improve 
overall treatment outcomes. There needs to be much better recording practices of HIV care 
and treatment, especially with regard to CPT and ART. Future research of a prospective nature 
with a larger cohort of recurrent TB patients may more clearly establish the impact of HIV 
testing on TB treatment outcomes under programmatic conditions.
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ABSTRACT 
BACKGROUND 
In 2013, the tuberculosis (TB) mortality rate was highest in southern Zimbabwe at 16%. 
We therefore sought to determine factors associated with mortality among registered TB 
patients in this region. 
METHODOLOGY
This was a retrospective record review of registered patients receiving anti-TB treatment in 
2013.
RESULTS
Of 1,971 registered TB patients, 1,653(84%) were new cases compared with 314(16%) 
retreatment cases. There were 1,538(78%) TB/Human Immunodeficiency Virus (HIV) co-
infected patients, of whom 1,399(91%) were on antiretroviral therapy (ART) with a median 
pre-ART CD4 count of 133cells/uL (IQR,46-133). Overall, 428(22%) TB patients died. Factors 
associated with increased mortality included being ≥65 years old [adjusted relative risk 
(ARR)=2.48 (95% CI 1.35-4.55)], a retreatment TB case[ARR=1.34 (95% CI,1.10-1.63)], being 
HIV-positive [ARR=1.87 (95% CI,1.44-2.42)] while ART initiation was protective [ARR=0.25 (95% 
CI,0.22-0.29)]. Cumulative mortality rates were 10%, 14% and 21% at one, two and six months 
respectively after starting TB treatment.
CONCLUSION
There was high mortality especially in the first two months of anti-TB treatment, with 
risk factors being recurrent TB and being HIV-infected, despite a high uptake of ART. Late 
presentation with advanced HIV disease and drug-resistance in recurrent TB may be the 
reasons, and endorse the need for early ART initiation and use of molecular technology such 
as Xpert MTB/RIF.
KEYWORDS:
 HIV, Tuberculosis, Mortality, Zimbabwe, Operational research
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INTRODUCTION
Tuberculosis remains one of the world’s biggest public health threats and now ranks alongside 
HIV as the world’s leading infectious cause of death. In 2014, there were an estimated 9.6 
million people diagnosed with TB globally, of whom 1.5 million died from the disease in the 
same year (0.4 million were HIV-positive).  Despite this, TB incidence has slowly declined by 
18% since 2000 and it is estimated that 43 million lives were saved between 2000 and 2014 
through effective diagnosis and treatment.1 However, given that most deaths from TB are 
preventable, the death toll from the disease is still unacceptably high and efforts to combat 
this must be continuously accelerated beyond the Millennium Development Goal (MDG) 
targets, in line with the recently set Sustainable Development Goal (SDG) and End TB strategy 
targets.(2) By 2030, the ambition is to reduce TB mortality by 90% compared with 2015. Of 
the 6 million new cases of TB notified to World Health Organisation (WHO) in 2014, 21% 
were from the African region which had the highest burden of TB at 281 cases per 100,000 
population compared to the global average of 133 cases per 100,000 population. 1
Zimbabwe, which is in the Southern African region, is among the 30 high burden TB, 
HIV and MDR-TB countries in the world and it also has a high HIV prevalence of 15%.3 In 2014, 
Zimbabwe had an estimated TB incidence of 278 (193-379) cases per 100,000 population 
inclusive of HIV-positive TB cases, while TB prevalence in the same year was 292 (158-465) 
cases per 100,000 population.(1) Furthermore, the estimated TB mortality in 2014 stood at 
50 (34-68) cases per 100,000 population, although Zimbabwe was notably one of the only 11 
high-burden countries to meet the target of halving the TB mortality rate by 2015 compared 
to 1990.   The high burden of TB in Zimbabwe is mostly associated with HIV, with 69% of TB 
patients having HIV co-infection in 2014.(1) Thus, national ART guidelines state that all TB/
HIV co-infected patients are eligible for ART and co-trimoxazole preventive therapy-CPT in 
order to improve TB treatment success rates.4 
The TB treatment success rate for newly registered cases in 2012 was 81%,5 
which is below the 85% target recommended by WHO. According to national data, one of 
the contributors to this low treatment success rate was a high mortality rate of 8% among 
patients on TB treatment regardless of type and category of TB. Further analysis of this data 
showed that death rates were highest in the three southern region provinces of Zimbabwe 
which are Matabeleland North, Matabeleland South and Bulawayo, each recording case 
fatalities of 16%, 18% and 14% respectively (source – National TB Programme). Death rates 
in these three provinces have been consistently high in previous years. Given these high 
mortality rates, we set out to determine among TB patients registered in the three provinces in 
2013: i) their demographic and clinical characteristics, ii) factors associated with mortality, 
and iii) among those who died, their time from start of anti-TB treatment to death. 
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METHODS
STUDY DESIGN
This was a retrospective cohort study using routinely collected data on patients receiving TB 
treatment. 
SETTING – GENERAL AND STUDY SITE
Selected for this study were three districts from each of the three provinces with the 
highest TB mortality rates in Zimbabwe in 2013 (nine districts all together). Matabeleland 
South, Matabeleland North and Bulawayo provinces jointly constitute 16% of Zimbabwe’s 
population according to the Zimbabwe 2012 national census results,6 and have populations 
of 685,046, 743,871 and 655,675 respectively. Matabeleland South and North provinces 
are divided into 7 rural districts. Each of these districts has a district hospital and in some 
instances, there are also mission hospitals at the second level of the health delivery tiered 
system where there are medical doctors and laboratory facilities enabling the diagnosis of 
TB through direct smear microscopy and GeneXpert MTB/RIF. 
The three provinces each have a provincial hospital where referrals from district 
level are sent. Bulawayo city is Zimbabwe’s second largest city where three of the country’s 
central hospitals are located. In addition, there are number of polyclinics which fall under the 
Bulawayo City Health Directorate and which are responsible for TB treatment in Bulawayo 
city. All health facilities in the three provinces offer general health services including TB 
treatment services as part of an integrated care package. 
MANAGEMENT OF TB CASES AND HIV CO-INFECTION IN ZIMBABWE
In Zimbabwe, all public health facilities offer TB treatment services integrated with general 
health services. First, all presumptive pulmonary TB cases at each health centre have their 
sputum collected, and sputum specimens are sent to the nearest TB diagnosis laboratory 
for direct smear microscopy or GeneXpert MTB/RIF with results expected to return to their 
respective health centres within 2 days. Patients diagnosed with TB are then entered in the 
health facility DOT register and started on TB treatment. Those with smears positive for acid-
fast bacilli are diagnosed as smear-positive PTB, whilst those with negative smears or smears 
not done are referred for a chest radiograph. If the latter is suggestive of TB, the patients 
may be diagnosed as smear-negative PTB or PTB with smears-not-done. Extra-pulmonary 
TB (EPTB) is mainly diagnosed on clinical grounds and circumstantial evidence along with 
supporting specific diagnostic tests.7 
Patients are also classified and recorded by category of TB as: i) new case defined 
as a patient who has never had treatment for TB or who has taken anti-TB drugs for less than 
1 month, or ii) previously treated case defined as a patient who has received 1 month or more 
of anti-TB drugs in the past. Patients who are previously treated for TB (named as “retreatment 
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cases”) are further classified by the outcome of their most recent course of treatment as 
relapse, treatment after default, treatment after failure, transfer-in and retreatment others.8
Upon starting TB treatment patients take directly observed treatment (DOT) using 
standardised anti-TB regimens,8 regardless of HIV status. Monitoring is done bacteriologically 
for all forms of TB since all patients on anti-TB treatment are supposed to have their sputum 
tested at 2, 4 and 5 months. Smear-negative patients who complete treatment and smear-
positive patients who complete treatment with or without negative smears are regarded as 
“successfully completing treatment”.
All presumptive TB patients are offered HIV counselling and testing (opt-out 
provider-initiated)9 and if found to have TB/HIV co-infection, CPT is started together with 
anti-TB treatment, provided there is no contra-indication. After starting TB treatment, all 
HIV co-infected patients should be referred into HIV treatment and care for ART initiation 
and provision of HIV/AIDS care and support within that health facility or alternatively to the 
nearest ART initiating clinics within their district if ART services are not available on site.  
According to national guidelines, ART should be started at least two weeks after the 
start of TB therapy i.e. during the intensive phase when the patient has stabilized on anti-TB 
treatment regardless of the CD4 cell count status. However, for severely immunosuppressed 
patients (those with CD4<50 cells/uL), ART is initiated within the first two weeks of initiating 
TB treatment. In 2013, ART initiation services were found at all district, mission and rural 
hospitals and selected primary care facilities in the three provinces although as 2015, all 
health facilities are now offering ART services.
STUDY POPULATION
All TB patients who were registered in the district TB registers from the nine selected districts 
in the three provinces and started on TB treatment between 1 January and 31 December 
2013 were included in the study. 
DATA VARIABLES, SOURCES OF DATA AND DATA COLLECTION PROCEDURES
Sources of data included TB and ART registers, and in cases of missing data for ART initiation, 
the ART patient files. Data were abstracted from routinely existing health facility records into 
structured forms by three teams of trained and experienced data collectors, each consisting 
of 5 people. First, data were abstracted from district TB registers for each selected district 
and variables collected from this register included TB treatment start date, patient age and 
sex, TB category and type, TB treatment outcome, other co-morbidities, HIV status, pre-ART 
CD4 cell count, WHO stage and whether patient was on ART or not. Patient names were also 
collected and used to follow up and search for missing information about pre-ART CD4 cell 
count, WHO clinical staging and ART status. These names were used to search ART registers 
and individual ART care booklets from the respective health facilities in each district where 
these patients were registered and receiving anti-TB treatment.
CHAPTER 5
92
STATISTICAL ANALYSIS
Patient data collected in the structured report form was coded and single entered by six 
data entry clerks into EpiData version 3.1 (EpiData, Odense, Denmark) and later cleaned for 
errors and analysed using STATA, version 13.1 (Stata Corporation, College Station, Texas). 
Proportions and their 95% confidence intervals (CIs) were reported for categorical variables 
whilst medians and inter-quartile ranges were reported for continuous skewed variables. 
Associations between categorical variables were determined by the chi-square test and 
alternatively the Fischer’s Exact test. 
Univariate and multivariate-adjusted risk ratios together with their 95% CIs aimed 
at determining factors associated with mortality were calculated using generalized linear 
models with a log link and binomial distribution. If there was a convergence problem with 
the regression models, STATA’s “binreg” command was implemented.  Variables included in 
the multivariate generalised linear models were those with a p-value<0.25. The multivariate 
generalized linear model for HIV status, classification and category of TB included all study 
participants and were adjusted for age and level of health care facility. However, separate 
multivariate generalized linear models for the variables ART use recorded, ART initiation in 
relation to start of TB treatment, WHO staging and CD4 cell count at ART initiation whilst 
adjusting for age, level of health care and TB category were run separately to avoid collinearity 
and were also restricted to those HIV-positive since they did not apply to those HIV-negative. 
For survival analysis, we used date of starting TB treatment as time of entry and 
follow-up was censored at either date of death or date last seen or date of completing TB 
treatment. Time-to-event data were complete for 98% of all individuals who successfully 
completed TB treatment or who died after excluding those who were lost-to-follow-up, not 
evaluated and still on MDR-TB treatment. Whilst those excluded should have been included 
in the survival analysis as censored, this was not possible because their dates of last DOT visit 
were not recorded in the TB registers. Stratified Kaplan-Meier curves were used to graphically 
assess survival proportions and calculate the median survival time on TB treatment. A p 
value <0.05 was considered to indicate statistical significance.
ETHICAL CONSIDERATIONS
Ethics approval was granted locally by the Medical Research Council of Zimbabwe and the 
International Union Against Tuberculosis and Lung Disease (The Union) Ethics Advisory 
Group, Paris, France. Privacy and confidentiality of information drawn from the hospital 
registers was ensured by excluding patient names from the electronic data entry. All data 
abstracted were kept in a safe and secure place accessible only to the investigator.
RESULTS
There were 1,971 patients who were registered and started on TB treatment between 
1 January and 31 December 2013 in the selected districts of the three southern provinces. 
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Demographic and clinical characteristics of TB patients in the southern region provinces 
are shown in Table 1 and Table 2 respectively. Males constituted 1,075 (55%) of all patients 
whilst the overall median age of patients was 34 years (IQR, 28-34). Close to half of all patients 
were receiving anti-TB treatment at rural health clinics, whilst 436 (22%) and 341 (17%) were 
registered at district / provincial hospitals and mission / rural hospitals respectively. Only 63 
(3%) of all patients had a recorded history of travel outside Zimbabwe, and of these 57 (90%) 
had been to South Africa. 
Table 1: Demographic characteristics of TB patients in southern Zimbabwe, 2013.
Characteristics n N % (CI 95%)
Sex
Female
Male
Missing
891
1,075
5
1,966
1,966
1,971
45.3 (43.1 - 47.5)
54.7 (52.5 - 56.9)
0.3
Age (in years)
0-4
5-14
15-44
45-64
65+
Missing
Median (IQR)    34 (28 - 34)                                      
67
70
1,353
366
111
4
1,967
1,967
1,967
1,967
1,967
1,971
3.4 (2.7 - 4.3)
3.6 (2.8 - 4.5)
68.8 (66.7-70.8)
18.6 (16.9-20.4)
5.6 (4.7 - 6.8)
0.2
Type of health facility
Rural Health Clinic
Mission/Rural Hospital
Polyclinic
District/Provincial Hospital
Missing
922
341
266
436
6
1,965
1,965
1,965
1,965
1,971
46.9 (44.7 - 49.1)
17.4 (15.7 - 19.1)
13.5 (12.1 - 15.1)
22.2 (20.4 - 24.1)
0.3
Recorded history of travel outside Zimbabwe 
prior to TB treatment
Yes
No
63
1,908
1,971
1,971
3.2 (2.5 - 4.1)
96.8 (95.9 - 97.5)
IQR = Inter-quartile range; TB = Tuberculosis.
Table 2: Clinical characteristics of TB patients in southern Zimbabwe, 2013.
Characteristics n N Percentage (95% CI)
TB category
New
Retreatment
MDR-TB
Missing data
1,653
314
2
2
1,969
1,969
1,969
1,971
84.0 (82.3 - 85.5)
15.9 (14.4 - 17.6)
0.1 (0.0 - 0.4)
0.1
Type of new TB
Smear-positive PTB
Smear-negative PTB
EPTB
Smear not performed PTB
Missing
603
720
227
101
2
1,651
1,651
1,651
1,651
1,653
36.5 (34.2 - 38.9)
43.6 (41.2 - 46.0)
13.7 (12.2 - 15.5)
6.1 (5.1 - 7.4)
0.12
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Type of retreatment TB
Treatment after default
Retreatment others
Relapse
Treatment after failure
Missing data
29
191
78
10
6
308
308
308
308
314
9.4 (6.6 - 13.2)
62.0 (56.4 - 67.3)
25.3 (20.8 - 30.5)
3.2 (1.7 - 5.9)
1.9
HIV status
HIV-negative
HIV-positive
Unknown
419
1,538
14
1,971
1,971
1,971
21.3 (19.5 - 23.1)
78.0 (76.1 - 79.8)
0.7 (0.4 - 1.2)
WHO clinical staging at ART initiation*
I
II
III
IV
Missing data
30
75
494
39
900
638
638
638
638
1,538
4.7 (3.3 - 6.7)
11.8 (9.5 - 14.5)
77.4 (74.0 - 80.5)
6.1 (4.5 - 8.3)
58.5
CD4 count (cells/mL) at ART initiation*
≤ 50
51-200
201-350
351-500
> 500
Missing data
96
137
74
28
29
1,174
364
364
364
364
364
1,538
26.4 (22.1 - 31.2)
37.6 (32.8 - 42.8)
20.3 (16.5 - 24.8)
7.7 (5.4 - 10.9)
8.0 (5.6 - 11.2)
76.3
Median (IQR) 132.5 (46; 132.5)
ART use recorded*
No
Yes
139
1,399
1,538
1,538
9.0 (7.7-10.6)
91.0 (89.4-92.3)
ART initiation in relation to start of TB treatment*
>3 months pre-TB treatment
0-3 months pre-TB treatment
<2 weeks post-TB treatment
2-8 weeks post-TB treatment
Not recorded
412
172
543
15
257
1,399
1,399
1,399
1,399
1,399
29.4 (27.1-31.9)
12.3 (10.7-14.1)
38.8 (36.3-41.4)
1.1 (0.6-1.8)
18.4 (16.4-20.5)
CI = Confidence interval; TB = Tuberculosis; MDR-TB = Multi-drug resistant TB; PTB  = pulmonary TB; 
EPTB = Extra-pulmonary PTB HIV = Human Immunodeficiency Virus; WHO = World Health Organization; 
IQR = Inter-quartile range; ART = Antiretroviral therapy 
*These variables refer only to those who were diagnosed as HIV-positive.
Of all TB patients, 1,653 (84%) were newly registered TB patients, and of these the majority 
(44%) were smear-negative pulmonary TB cases whilst 37% were smear-positive PTB cases. 
Of the retreatment TB cases, 191 (62%) were “retreatment others” whilst 78 (25%) were 
relapse TB cases. Close to all patients had an HIV test result, of whom 1,538 (78%) were HIV-
positive. Of these, 1,399 (91%) were recorded as receiving ART.  More than half of all HIV-
positive patients had missing WHO clinical staging and baseline CD4 cell counts at ART 
initiation. Of those with recorded WHO clinical staging, 84% had advanced HIV disease while 
the median CD4 cell count was 133 cells/uL (IQR, 46-133). Of those patients with documented 
ART status, 584 (42%) were on ART prior to starting TB treatment while 543 (39%) initiated 
ART within 2 weeks of commencing TB treatment.
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As shown in Figure 1, 1,419 (72%) of all TB patients had a treatment success whilst death 
(22%) was the most common adverse TB treatment outcome.  Table 3 shows relative risks 
and their 95% CIs for factors associated with mortality. Patients aged 65 years and older 
compared to those <5 years old and having retreatment TB compared to newly treated TB 
were associated with higher risk of mortality in all multivariate regression models.. However 
accessing treatment from a polyclinic or higher level health centre and having CD4 count >50 
cells/mL versus ≤50 cells/mL were associated with lower risk of mortality. Being HIV-positive 
was associated with higher mortality compared to being HIV-negative [adjusted relative risk 
(ARR)=1.87 (95% CI, 1.44-2.42)], but among those who were HIV-positive, those on ART had 
lower mortality [ARR=0.25 (95% CI, 0.22-0.29)] compared with those not on ART. Compared to 
those who initiated ART > 3 months prior to starting TB treatment, those who initiated ART 
within 2 weeks [ARR=0.73 (95% CI, 0.54-0.98)] were less likely to die whilst those initiated on 
ART 0-3 months prior to TB treatment were more likely to die [ARR=1.80 (95% CI,1.34-2.43)].
Figure 1. Overall TB treatment outcomes among enrolled patient on TB treatment in southern Zimbabwe, 
2013.
TB = Tuberculosis
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The overall mortality incidence rate was 49.1(44.5 - 54.2) per 100 person-years.  Figure 2 
shows the overall Kaplan-Meier survival estimates for all patients enrolled on TB treatment. 
The mortality rate increased rapidly in the first two months of TB treatment from 10% at 
one month to 14% at two months and eventually increased slowly over time to 21% at the 
6-month end-point. Kaplan-Meier survival estimates for the HIV-negative compared to those 
HIV-positive on ART and those HIV-positive not documented on ART are shown in Figure 3: 
10% of the respective cohorts had died by 13 weeks, by 7 weeks and by less than one week 
respectively (p<0.001). In relation to median survival time, this could not be estimated for 
those HIV-negative and those HIV-positive on ART. However, median survival time among 
those HIV-positive and not on ART was 3.3 weeks (95% CI, 2.3-5.4).
Figure 2. Overall Kaplan-Meier survival estimates among patients on TB treatment 
TB = Tuberculosis
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Figure 3. Kaplan-Meier survival estimates stratified by HIV status and ART initiation.
TB = Tuberculosis; HIV = Human Immunodeficiency Virus; ART = Antiretroviral therapy
NB: The numbers of HIV-negative patients and those HIV-positive on ART and not on ART differ from those 
presented in Table 1 because some patients were excluded from survival analysis because of missing outcome 
status dates.
DISCUSSION
We conducted a retrospective review of data collected on patients receiving anti-TB 
treatment in a routine programme setting in the southern region of Zimbabwe where the 
TB mortality rate is the highest in the country. This region, where the average TB mortality 
rate is more than double that of the national average of 10%1, is a cause for concern and 
attention is needed to address this huge problem. We observed that TB co-infection with HIV 
among patients on anti-TB treatment was eleven percent higher than the national average 
in Zimbabwe.5 This correlates with HIV prevalence figures in this region which are the highest 
in the country at  21%, 18% and 19% for Matabeleland South, Matabeleland North and 
Bulawayo respectively compared to the national HIV prevalence of 15.2% according to the 
2010-11 Zimbabwe Demographic and Health survey.3 
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Whilst only a quarter of TB/HIV co-infected patients had a documented CD4 cell count, we 
observed that these patients presented late with low CD4 cell counts and this is similar 
to previous local findings.10 These late presentations occur despite national guidelines 
recommending over the years an increased CD4 cell count eligibility for starting ART: from a 
CD4 cell count threshold of <200 cells/mL before 2010,  to <350 cells/mL from 2011 to 2013 
and eventually to <500 cells/mL from 2014 onwards in accordance with WHO guidelines.11, 12, 
13 We also observed, that the elderly, those with recurrent TB, those diagnosed HIV-positive, 
those HIV-positive with no documentation of ART and those HIV-positive presenting with 
lower CD4 cell counts were more likely to die during anti-TB treatment. Of particular note 
was the fact that mortality was most common in the intensive phase of anti-TB treatment 
particularly for those who were HIV-positive without documented ART initiation.
A major strength of this study is that data were an exhaustive sample of all registered 
cases on anti-TB treatment in the high mortality burden districts of the three highest TB death 
rate provinces, and hence this study was well powered. Data were obtained from routinely 
existing programme data which make the study representative of TB patients receiving 
treatment in public health facilities in southern Zimbabwe. Study limitations include access 
to few variables that may not exhaustively provide information on mortality-associated 
factors and also possibilities of incomplete recording of important patient information such 
as whether an HIV-positive patient was on ART and when they initiated ART, dates of death 
and the presence or absence of other co-morbidities (such as diabetes mellitus) which 
may account for mortality among patients who received anti-TB treatment. Another study 
limitation was that there were no post-mortem facilities or access to sophisticated laboratory 
diagnostic facilities and therefore the exact cause(s) of death could not be determined.
Being HIV-positive was the most common risk factor for mortality whilst on anti-
TB treatment and this has been reported in studies from different parts of the world such 
as in Cameroon14, the United States15, South Africa16 and Ghana17. HIV-positive individuals 
with latent TB are known to be approximately 20-30 times more likely to develop TB disease 
than those who are HIV negative, at a rate of 8-10% per year,1 because of their suppressed 
immune system which can result in an increase odds of mortality with further progression 
of the HIV disease killing 1 in 3 patients.18  Starting TB treatment with a low CD4 cell count, 
particularly those with CD4 cell counts <50 cells/mL, was associated with higher mortality 
and this is a well-established risk factor for early mortality.19 The declining CD4 cell count 
influences both the frequency and severity of active TB disease,20  and active TB disease may 
be associated with a higher HIV viral load and more rapid progression of HIV disease.21 Such 
cases presenting for TB treatment with advanced HIV infection are also likely to present with 
other AIDS-defining diseases which further add to the risk of dying.22 
In this study we observed a reduction in mortality among HIV-positive TB patients 
who had documented ART use and this clearly highlights the protective effects of ART from 
mortality. Similar findings by Agbor et al14 showed that those who were HIV co-infected 
and not receiving antiretroviral therapy were more than two-fold likely to die. Among those 
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HIV-infected, starting ART in the intensive phase of TB treatment was also associated with 
lower mortality compared to those who were previously on ART. These findings concur 
with SAPiT(23), CAMELIA24 and STRIDE25 clinical trials which informed WHO guidance 
and collectively demonstrated that early initiation of ART can reduce mortality and AIDS 
progression, notwithstanding the risk of increased immune reconstitution inflammatory 
syndrome (IRIS) in patients with active TB and with very low CD4 cell counts (i.e., <50 cells/
mm3). Those who had started TB treatment within 3 months of ART initiation had an almost 
two-fold higher risk of mortality during anti-TB treatment and this may be attributed to 
late presentation for ART initiation with advanced HIV disease which is associated with 
“unmasking” TB-IRIS26  and early mortality within the first three months of ART initiation.19 It 
is also possible that there are delays in laboratory diagnosis and start of TB treatment among 
presumptive TB patients identified through intensified TB-case finding using the 4-symptom 
TB checklist within ART clinics and this requires further investigation in future studies.
Late presentation with advanced HIV disease and low CD4 cell counts at the time of 
starting anti-TB treatment are often anecdotally reported by health workers in these southern 
regions of Zimbabwe as the major reason for the high mortality rates. Many of these patients 
are said to reside as migrant workers in neighbouring South Africa where they do not seek 
HIV-testing and HIV treatment and care services and commonly return to their homes to seek 
treatment when they are sick and bed-ridden. Whilst this record review study also sought to 
determine the proportion of patients who had a history of travel to South Africa as a proxy 
indicator of these HIV late presentation cases, less than five percent had this information 
documented and we also did not find it to be a significant risk factor for mortality. It is likely 
that this information may have been under-reported since TB and HIV data collection tools 
are not standardized to collect this data.
Whilst male gender has commonly been reported as a risk factor for mortality 
among TB patients in other studies16, 15, 27, this was not the case in our study. As with other 
studies, in Sub-Saharan Africa, there was higher mortality among those with pulmonary 
TB for which sputum smear status was unknown 17 and smear-negative pulmonary PTB.16 
In addition to most smear-negative PTB cases being HIV-positive, there are potential time 
delays in diagnosis, after receipt of negative sputum smears, which include undergoing a 
chest radiograph (CXR), that is performed, read and interpreted by a clinician, and a clinical 
assessment. These diagnosis delays,28 can be associated with progression of disease and 
worse treatment outcomes. Smear not-performed PTB cases did not follow national 
guidelines which recommend TB diagnosis with two sputum smear examinations, and this 
may result in over-diagnosis of TB disease and under-diagnosis of other respiratory diseases 
thus increasing mortality risk.  
Mortality was also notably higher among patients with recurrent TB29, 16, 27 who have 
a strong association with HIV infection, whether on ART or with unknown ART status30. Such 
patients are also more likely to be non-compliant to TB treatment and hence linked with 
drug resistant TB31. Multidrug-resistant (MDR-TB) poses a threat to TB control worldwide, and 
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globally an estimated 3.5% (95% CI: 2.2–4.7%) of new cases and 20.5% (95%CI: 13.6–27.5%) 
of previously treated cases have MDR-TB. In 2013, neighbouring South Africa was one of the 
countries with the highest number of notified MDR-TB or Rifampicin-resistant TB (RR-TB) 
cases who were eligible for MDR-TB treatment. Only 41% of those diagnosed were enrolled 
to treatment,5 and this is of great concern given that Zimbabwe had the largest number 
of registered immigrants in South Africa from the Africa region in 201332. The incidence of 
multidrug- MDR-TB is also increasing in high human immunodeficiency virus (HIV) prevalence 
settings, with high associated mortality. A recent meta-analysis of treatment outcomes for 
HIV and MDR-TB co-infected adults and children showed that treatment success rates were 
low, mortality was 38% in adults (95%CI 28-48.1) and 11.4% (95%CI 5.8-17.1) in children and 
loss to follow-up was also higher among adults (16.1%, 95%CI 9-23.2) than among children 
(3.9%, 95%CI 0.9-6.9).33 In our setting, it is possible that mortality among TB patients may be 
partly driven by undiagnosed drug-resistant TB and hence it is important to scale up the use 
of Xpert MTB/RIF assays for TB diagnosis especially in HIV settings.
Mortality was also notably higher in those aged >65 years and this could possibly 
be attributed to diabetes mellitus which is common among the elderly and causes 
immunosuppression thus increasing the risk of TB disease.34 The prevalence of diabetes 
mellitus (DM) in adults for Zimbabwe is unexplored and therefore requires investigation. 
The association between diabetes mellitus and TB has been well documented, and some 
studies report that smear-negative PTB is more common in people with diabetes, although 
this association may require rigorous studies to prove an association.35 This may pave 
way for interventions such as active case finding and treatment of latent TB and efforts to 
diagnose, detect, and treat DM may have a beneficial impact on TB control. It is also possible 
that rifampicin, isoniazid and pyrazinamide-containing regimens led to anti-TB drug-
induced liver disease in these elderly patients36, and this in turn can lead to drug-induced 
acute liver failure which is associated with high mortality.37 This also will require further 
exploration in future studies.
There are a number of programmatic implications from this study. First it is 
important to continue doing HIV testing for all presumptive TB patients given the high 
HIV co-infection in these settings and subsequently ensuring that all TB patients who are 
HIV-infected are started on ART as soon as possible after anti-TB treatment. Second, with 
most clinical management and initiation on ART and TB treatment being done by nurses, 
it is important to ensure that there is continued clinical mentorship and training of these 
cadres to manage any arising drug interactions in the treatment of HIV-associated TB or TB-
related IRIS given the complexities of patients presenting for TB treatment with advanced 
HIV disease. Third, it is necessary to scale up the use of the Xpert MTB/RIF assay technology 
to diagnose TB among HIV-infected patients in order to identify drug-resistant TB so that 
these patients receive appropriate treatment. This will reduce reliance on the use of sputum-
smear microscopy which is also less sensitive among HIV-infected TB patients with low CD4 
cell counts. Finally, it may be worthwhile exploring the burden of DM among TB patients, 
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particularly amongst the elderly who are at higher risk of non-communicable diseases, in 
order to enable appropriate management.
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ABSTRACT
SETTING
All public health facilities in 2 provinces of Zimbabwe 
OBJECTIVE
To determine among tuberculosis (TB) patients with human immunodeficiency virus (HIV) 
registered in 2010, 1) the proportion started on antiretroviral treatment (ART), 2) the timing 
of ART in relation to start of anti-TB treatment, and 3) whether timing of ART influenced TB 
treatment outcomes. 
DESIGN
Retrospective cohort study 
RESULTS
Of the 2,655 HIV-positive TB patients, 1,115 (42%) were documented as receiving ART. 
Of those with documented ART, 178 (16%) started prior to TB treatment. Of those started 
after TB treatment, 17% started within 2 weeks, 43% between 2-8 weeks and 40% after 8 
weeks. Treatment success in the cohort was 82% with 14% dying before completing anti-TB 
treatment. Not receiving ART during TB treatment was associated with lower TB treatment 
success (adjusted RR=0.70; 95%CI, 0.53-0.91) and more deaths (adjusted RR=3.43; 95%CI, 2.2-
5.36). There were no differences in TB treatment outcomes by timing of ART initiation. 
CONCLUSION
Uptake of ART is low given the high prevalence of HIV co-infection and the improved TB 
treatment outcomes in those initiated on ART during TB treatment. Better integration of HIV 
and TB services is needed to ensure increased coverage and earlier ART uptake. 
KEYWORDS: 
HIV; tuberculosis, Zimbabwe; antiretroviral therapy
ANTIRETROVIRAL TREATMENT UPTAKE, ITS TIMING AND RELATION 
TO TB TREATMENT OUTCOMES AMONG HIV-INFECTED TB PATIENTS
111
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
INTRODUCTION
Zimbabwe like other Sub-Saharan African countries has a high burden of HIV infection with 
75% of TB patients having HIV co-infection.1 Such HIV-associated TB is associated with high 
case fatality and low treatment success rates.2 A recent review of mortality data in two large 
cities in Zimbabwe indicated that TB and HIV were responsible for 70% of deaths in the 15 
to 44 year age group from the early 1990s with a gradual decline in deaths being noted from 
2004 onwards,3 which coincided with the introduction of antiretroviral treatment in public 
health sector facilities. 
ART initiated during TB treatment4,5 and the additional use of cotrimoxazole 
preventive therapy (CPT) reduces TB case fatality.6 Three randomized clinical trials have 
clarified the question about when best to start ART in relation to start of TB treatment: in 
patients with advanced immunosuppression (whose CD4 counts are < 50 cells /uL) early 
initiation of ART within 2- 4 weeks of start of anti-TB treatment significantly reduces death 
rates compared with a later start of ART, while in patients with higher CD4 counts, the benefit 
of early ART initiation is less clear and hence can be deferred to between 2-8 weeks.7,8,9 
Despite WHO recommendations in 2010 10 about initiation of ART within the initial 
phase of anti-TB treatment among HIV-infected TB patients regardless of CD4 count, these 
guidelines were only implemented in Zimbabwe in April 2011, 11 and up until this time the 
previous 2006 WHO Guidelines were used. 12 Routine National TB Programme data in 2010 
showed that a small proportion of eligible HIV-infected TB patients were accessing this life 
saving therapy. 1 The NTP needs more data to determine the extent and timing of ART access 
and whether ART administered in the routine setting influences TB treatment outcomes. 
The objectives of this current study were to use routinely collected data to determine in two 
provinces countrywide:- 1) the proportion of HIV-infected TB patients who were started on 
ART, 2) the timing of ART in relation to start of anti-TB treatment, and 3) whether the timing of 
ART influenced TB treatment outcomes.
METHODS
STUDY DESIGN
This was a retrospective cohort study using routinely collected programme data.
SETTING
A one-stage cluster sampling technique was used to randomly select 2 of the 10 provinces 
in Zimbabwe which are Mashonaland West and Matebeleland South. From these selected 
provinces, all TB patients registered between 1 January and 30 June 2010 were included in 
the study. Mashonaland West which is situated in northern Zimbabwe consists of 7 districts 
and has a population of 1,300,011, whilst Matebeleland South which is in the southern region 
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consists of 6 districts and has a population of 693,230. 13 Mashonaland West has 128 health 
facilities and Matebeleland South has 105 health facilities, of which 85% in each province 
are rural health facilities. Each province has a designated provincial hospital whilst each 
district has a district hospital and all of these facilities offer smear microscopy TB diagnostic 
services and ART initiation services. 13 All public health facilities countrywide offer general 
health services integrated with TB treatment services whilst ART initiating clinics are situated 
at central, provincial and district level hospitals and other selected faith-based hospitals. 
Follow-up ART clinics are situated at selected primary healthcare clinics as static follow-up or 
outreach clinics to which stable ART patients are transferred out, as part of decentralisation.14 
In 2010, there were 12 ART-initiating sites and 39 ART follow-up sites in Mashonaland West, 
and 10 ART-initiating sites and 51 ART follow-up clinics in Matebeleland South. 15
Diagnosis and Management of HIV-infected TB patients: In Zimbabwe, TB is 
diagnosed according to national guidelines 16 which are based on WHO TB treatment 
guidelines 17 and they were made available in 2010. Patients with new TB are treated with a 
standardised 6-month regimen consisting of 2-months initial phase of rifampicin, isoniazid, 
pyrazinamide and ethambutol followed by a 4-months continuation phase of rifampicin 
and isoniazid, regardless of HIV status. Patients with recurrent or previously treated TB are 
treated according to national 16 and international guidelines. 17  Monitoring is done clinically 
for smear-negative PTB and EPTB patients whilst those with new smear-positive PTB have 
sputum specimens examined for acid-fast bacilli at 2, 5 and 6 months. Those with previously 
treated smear-positive PTB have sputum examined at 3, 5 and 8 months. Smear-negative 
patients who complete treatment and smear-positive patients who complete treatment with 
or without negative smears are regarded as “successfully completing treatment”.
Patients are offered HIV counselling and testing (opt-out provider-initiated testing) 
upon diagnosis of TB. 18 CPT is started together with anti-TB treatment for HIV-infected TB 
patients, provided there is no contra-indication. These patients are then referred to their 
nearest ART initiating clinics within their districts, where a clinician initiates ART and provides 
HIV/AIDS care and support. 19 In 2010, based on the previous 2006 WHO Guidelines, ART was 
recommended between 2 to 8 weeks after commencing TB treatment for all HIV-infected 
TB patients with CD4 counts ≤ 350cells/mm 3, all those with extra-pulmonary TB regardless 
of CD4 count and those with pulmonary TB with unavailable CD4 counts. Those with PTB 
and no other WHO stage 3 or 4 event whose CD4 > 350 cells/mm 3 had ART deferred, and 
they were re-evaluated for ART after 8 weeks from commencing TB treatment and also after 
completing TB treatment. 19 In 2010, the preferred first-line regimen during TB treatment was 
one containing efavirenz.
STUDY POPULATION
All HIV-infected TB patients who were registered in the district TB registers for Mashonaland 
West and Matebeleland South provinces between 1 January and 30 June 2010 were included 
in the study. The minimum required sample size was 912 patient records assuming a 28% 
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proportion of HIV-infected TB patients accessing ART, a significance level of 5% and a 
precision of 1%.
DATA COLLECTION AND VALIDATION
Data on HIV-infected TB patients were abstracted from district TB registers and ART initiating 
facility ART registers into data abstraction forms by 2 trained data collectors between October 
and November 2011. Data drawn from district TB registers included TB registration date, TB 
treatment commencement date, age, sex, type and category of TB, TB diagnosing centre, 
TB DOT centre, use of CPT, and, if recorded, the baseline pre-ART CD4 cell count, ART use 
and ART initiation date. To verify or record undocumented ART use and ART initiation dates 
for those patients abstracted from TB registers per district, we abstracted and line-listed all 
patients initiated or substituted to an Evafirenz-containing first –line ART regimen at all ART 
initiating facilities in each district between 1 January 2010 and 30 June 2011. Data were then 
matched using patient names, their sex and age.
DATA ANALYSIS
Data were single-entered into an electronic database, EpiData version 3.1 (The EpiData 
Association, Odense Denmark) and later cleaned for errors and analysed using Stata, version 
10 (Stata Corporation, College Station, Texas). Frequencies and proportions were generated 
for categorical variables whilst medians (interquartile ranges) were used to summarise 
skewed continuous variables. Multivariate adjusted relative risks were used to establish 
associations between timing of ART initiation among other variables and TB treatment 
outcomes (treatment success and death) using poisson regression with error variance. 20
ETHICS APPROVAL
Ethics approval was granted locally by the Medical Research Council of Zimbabwe and the
International Union Against Tuberculosis and Lung Disease (The Union). Privacy and 
confidentiality of information drawn from the hospital registers was ensured by excluding 
patient names in the electronic data entry. All data abstractions were kept in a safe and 
secure place accessible only to the investigator.
 
RESULTS
There were 2,655 HIV-positive TB patients registered between 1 January and 30 June 2010 
from the two selected provinces: their median age was 35 years (IQR, 28-42). There were 1,394 
(54%) females and 1,219 (46%) males, with gender data missing for 42 patients. Males were 
older than females; 36 years (IQR, 30-44) versus 33 years (IQR, 27-41), p<0.001. There were 
1,461 (55%) patients from Mashonaland West province and 1,194 (45%) from Matebeleland 
South province. Clinical and immunologic characteristics of HIV-positive TB patients are 
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shown in Table 1. The majority of patients, 2,296 (87%) had new disease and of these, 1,578 
(69%) had negative sputum-smears or smears not done. Of those with previously treated TB, 
157 (45%) were classified as “retreatment others”. Cotrimoxazole uptake was documented 
in 1,778 (67%) patients. Only 146 (6%) patients were documented as having had CD4 counts 
measured at baseline prior to starting ART. Of those with CD4 counts done, the median count 
was 128 cells/mm3 (IQR, 59-210), with no differences between males and females.
Table 1: Clinical characteristics among HIV-infected TB patients in Zimbabwe.
Characteristic (N = 2,655) N % (95% CI)
TB Category, n (%) New
Retreatment
Missing data
2,296
351
9
86.5 (84.2 – 88.5)
13.2 (11.2 – 15.5)
0.3 (0.1 – 0.7)
Type of new TB, n (%) Smear-positive PTB
Smear-negative PTB
EPTB
Smear not performed PTB
Missing data
444
937
271
641
3
19.3 (17.2 – 21.7)
40.8 (32.6 – 49.6)
11.8 (8.9 – 15.6)
28 (19.7 – 38)
0.1 (0.0 – 0.5)
Type of retreatment 
PTB, n (%)
Relapse
Treatment after default
Treatment after failure
Retreatment others
Missing data
45
11
3
157
135
12.8 (4.4 – 31.9)
3.1 (0.9 – 10.5)
0.9 (0.2 – 4.0)
44.7 (32.2 – 58.0)
38.5 (22.4 – 57.5)
Type of DOT centre, 
n (%)
District hospital
Rural clinic
Faith-based (mission)
Private facility
Rural hospital
Central/provincial hospital
Municipal clinic
Missing data
287
1,413
207
5
125
181
353
84
10.8 (4.7 – 23)
53.2 (41.3 – 64.8)
7.8 (3.5 – 16.4)
0.2 (0.0 – 1.0)
4.7 (2.3 – 9.2)
6.8 (1.4 – 27.3)
13.3 (6.2 – 26.1)
3.2 (0.9 – 10.3)
CPT use, n (%) Yes
No
Missing data
1,778
11
866
67.0 (44.5 – 83.7)
0.4 (0.2 – 1.0)
32.6 (16.0 – 55.2)
Documented baseline 
pre-ART CD4 count
Yes
No
146
2,509
5.5 (2.1 – 13.7)
94.5 (86.3 – 97.9)
Baseline pre-ART CD4 
count level (cells/mm3)
<50
51-200
>200
30
75
41
20.6 (11.7 – 33.7)
51.4 (40.3 – 62.3)
28.1 (21.5 – 35.7)
*Percentages may not always add to 100 due to rounding errors
TB = tuberculosis; PTB = pulmonary tuberculosis; EPTB = extra-pulmonary TB; DOT = directly observed 
treatment; CPT = cotrimoxazole prophylaxis; ART = antiretroviral therapy.
The documentation of ART uptake and the timing of ART in relation to start of anti-TB 
treatment among HIV-positive TB patients is shown in Table 2. Overall, 1,115 (42%) 
patients had any documentation about whether ART had been given or not. Of those 
where there was documentation, 16% had started ART prior to TB treatment. Of those 
starting ART after TB treatment, 17% started within 2 weeks, 43% started between 2-8 
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weeks and 40% started after 8 weeks. Table 3 shows the timing of ART after starting TB 
treatment in relation to ART eligibility. Of those eligible for ART with EPTB or PTB with 
CD4≤350 and those with PTB but undocumented CD4 counts, 85 (48%) and 186 (38%) 
respectively delayed ART initiation to the continuation phase of TB treatment
Table 2: ART use and timing in HIV-infected TB patients.
ART usage in relation to TB treatment Number % (95% CI)
ART initiation status 
ART use documented
No ART used
ART use not documented
1,115
37
1,503
42.0 (31.6 – 53.2)
1.4 (0.7 – 2.8)
56.6 (45.2 – 67.3)
ART use documented 
ART started before TB treatment
ART started after TB treatment
ART timing not indicated
178
670
267
16.0 (10.2 – 24.1)
60.1 (49.9 – 69.5)
24.0 (17.5 – 31.8)
ART started after TB treatment 
<2 weeks after start of TB treatment
2-8 weeks after start of TB treatment
>8 weeks after start of TB treatment
112
287
271
16.7 (8.9 – 29.1)
42.8 (29.1 – 57.8)
40.5 (29.0 – 53.1)
*Percentages may not always add to 100 due to rounding off error
ART = antiretroviral therapy; TB = tuberculosis; HIV = Human Immunodeficiency Virus.
Table 3: Timing of ART after starting TB treatment in relation to ART eligibility.
ART eligibility (n (%))
Timing of ART initiation EPTB/PTB & 
CD4≤350
(n=178)
PTB & no CD4 
count
(n=489)
PTB & CD4>350
(n=1)
ART started <2 weeks after start of 
TB treatment
31 (17.4) 80 (16.4) 0 (0)
ART started 2-8 weeks after start of 
TB treatment
62 (34.8) 223 (45.6) 1 (100)
ART started >8 weeks after start of 
TB treatment
85 (47.8) 186 (38.0) 0 (0)
NB: 2 patients have been excluded from this analysis as they had missing information on type of TB.
Of the 2,655 patients who started anti-TB treatment, treatment outcomes were as follows: 
treatment success (N=2,159, 82%), death (N=370, 14%), lost to follow-up (N=55, 2%), 
transferred-out (N=49, 2%), failure in 4 (<1%) patients and in 18 no data were available. 
Table 4 shows multivariate-adjusted relative risks for associations between patient 
characteristics and ART status with treatment success or death during anti-TB treatment. 
There was a lower treatment success rate among those > 15 years compared to those ≤15 years 
old. Treatment success rate was higher for new TB patients compared to those previously 
treated for TB (adjusted RR=0.94, 95% CI 0.88-1.00, p=0.034). Of note, those HIV-positive TB 
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patients documented as not starting ART had lower TB treatment success (Adjusted RR=0.70, 
95% CI 0.53-0.91, p=0.008) and significantly more deaths (adjusted RR=3.43, 95% CI 2.2-5.36, 
p<0.001). Whilst those with undocumented ART status had lower treatment success (adjusted 
RR=0.94, 95% CI 0.90-0.97, p=0.001) and more deaths (Adjusted RR=1.39, 95% CI 1.13-1.72, 
p=0.002) when compared to those documented to be on ART.
Table 4: Patient characteristics in relation to TB treatment outcomes (TB treatment success 
and Death).
TB treatment outcome
Treatment success* Death*
Variables ₸ n (%) ARR (95% CI) n (%) ARR (95% CI)
Sex
Female
Male
1,151 (82.8)
980 (80.9)
ref.
0.98 (0.95-1.02)
181 (13.0)
182 (15.0)
Ref.
1.13 (0.94 – 1.37)
Age group (in years)
<15
15-25
26-44
45-54
>55
193 (88.1)
157 (78.9)
1,376 (82.1)
260 (80)
163 (79.1)
ref.
0.89 (0.82-0.97)
0.92 (0.88-0.98)
0.90 (0.84-0.97)
0.89 (0.82-0.97)
23 (10.5)
30 (15.1)
229 (13.7)
53 (16.3)
33 (16.0)
Ref.
1.50 (0.90 - 2.50)
1.36 (0.90 - 2.05)
1.60 (1.00 - 2.55)
1.62 (0.98 - 2.68)
TB category
New
Previously treated
1,886 (82.6)
270 (77.1)
ref.
0.94 (0.88-1.00)
308 (13.5)
62 (17.7)
Ref
1.28 (1.0 - 1.64)
New TB type
Smear-positive PTB
Smear-negative PTB
EPTB
Smear not-done PTB
370 (84.1)
755 (80.8)
216 (80.6)
542 (84.8)
ref.
0.95 (0.90-1.00)
0.95 (0.89-1.02)
0.99 (0.93-1.04)
57 (13.0)
140 (15.0)
42 (15.7)
69 (10.8)
Ref.
1.22 (0.91 - 1.62)
1.26 (0.87 - 1.83)
0.93 (0.66 - 1.30)
Retreatment TB type
Relapse
Treatment after default
Treatment after failure
Retreatment others
Missing data
38 (84.4)
8 (72.7)
2 (66.7)
122 (77.7)
100 (74.6)
ref.
0.96 (0.68-1.34)
0.70 (0.31-1.59)
0.92 (0.79-1.06)
0.89 (0.76-1.04)
6 (13.3)
1 (9.1)
1 (33.3)
31 (19.8)
23 (17.2)
Ref.
0.43 (0.12 - 1.54)
5.0 (0.66 - 37.9)
1.76 (0.69 - 4.50)
1.45 (0.54 - 3.85)
ART initiation status
ART use documented
No ART used
ART use not documented
956 (85.9)
22 (59.5)
1,181 (79.4)
ref.
0.70 (0.53-0.91)
0.94 (0.90-0.97)
117 (10.5)
14 (37.8)
239 (16.1)
Ref.
3.43 (2.2 – 5.36)
1.39 (1.10 – 1.70)
ART use documented
ART started before TB treatment
ART started after TB treatment
ART timing not indicated
150 (84.3)
593 (88.5)
213 (80.4)
ref.
1.03 (0.96-1.11)
0.96 (0.87-1.04)
25 (14)
48 (7.2)
44 (16.6)
Ref.
0.56 (0.35 - 0.88)
1.19 (0.71 - 1.78)
ART started after TB treatment
<2 weeks after start of TB treatment
2-8 weeks after start of TB treatment
>8 weeks after start of TB treatment
96 (85.7)
245 (85.4)
252 (93.0)
ref.
0.99 (0.91-1.09)
1.08 (1.00-1.17)
11 (9.8)
21 (7.3)
16 (5.9)
Ref
0.76 (0.38 - 1.52)
0.60 (0.28 - 1.28)
* 18 patients with missing TB treatment outcomes were excluded from this analysis
₸ Denominators for each variable differ since they exclude those with missing data for each respective
variable including the 18 patients with missing TB treatment outcomes.
ARR = Adjusted relative risk; ART = antiretroviral therapy; TB = tuberculosis; PTB = pulmonary TB;
EPTB = extra-pulmonary TB.
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Those starting ART after commencing TB treatment had fewer deaths (adjusted RR=0.56, 95% 
CI 0.35-0.88, p=0.012) compared to those started on ART prior to TB diagnosis however there 
were no difference in treatment success. There also were no differences in treatment success 
rates by timing of ART initiation after commencing TB treatment. Successful TB treatment 
was better (adjusted RR=1.13, 95%CI 1.08-1.18 p<0.001) and deaths fewer (adjusted RR=0.24, 
0.09-0.64, p=0.004) for those with documented pre-ART CD4 counts compared to those 
without CD4 count tests done.
DISCUSSION
This study raises the important programmatic issue of poor ART uptake during anti-TB 
treatment among HIV-infected TB patients. Over half of HIV-infected TB patients, had no 
documentation about whether ART had been started, and this was also a problem for the 
documentation of CPT. Potential reasons include poor record keeping, poor ART coverage or 
indeed poor integration of TB and ART services. 21 Half of these patients accessed DOT at rural 
clinics which in Zimbabwe are not ART initiating clinics, and therefore a lack of colocation 
or integration of TB and HIV services may have been a barrier to initiation of ART. Elsewhere, 
non-integrated TB and ART services have been associated with low acceptance of ART 22 or 
delays in ART initiation among HIV-infected TB patients. 23, 24  Likewise, very few patients were 
recorded as having their baseline CD4 counts measured, which may indicate poor patient 
access to CD4 testing services given that only 15 out of all 22 ART initiating clinics in both 
provinces had a CD4 machine.25 The few data on HIV-positive TB patients with documented 
CD4 counts indicate that HIV-TB patients present late for treatment with very low CD4 counts, 
and thus according to the current scientific evidence they should be starting ART at an early 
stage of anti-TB treatment. 7, 8, 9 
Among ART eligible patients that started ART after anti-TB treatment, less than 
one fifth commenced ART within 2 weeks, whilst about half delayed ART initiation until the 
continuation phase of anti-TB treatment. Data from South Africa shows that even when there 
is a national policy to start ART early, unless there is integration of TB and HIV services early 
start of ART is very difficult to achieve. 21
In terms of treatment outcomes, young patients and those with new rather than 
previously treated TB had better treatment success. Those documented to be on ART had 
better treatment success and lower death rates than those not started on ART, reinforcing 
the point that ART for HIV-infected TB patients is important for TB treatment outcomes.26, 27 
The routine data showed little difference in treatment success in relation to when ART was 
started. The data from this study differ from recent data showing that earlier initiation of ART 
saves lives in HIV-infected patients with TB, particularly those with CD4 cell counts < 50 cells /
uL in whom the risk of death is minimised by starting ART within the first 2-4 weeks of anti-TB 
treatment.7, 8, 9 This is one of the limitations of programme data, as those patients starting ART 
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later may be less sick compared to those severely immune suppressed who may already have 
died before the end of the initial phase of anti-TB treatment. 26 This limitation is augmented 
by challenges with completeness and accuracy of routinely collected programme data and 
lack of any data on disease severity. However, the strengths of this study were that it was 
done within a programme setting using a large patient sample and hence findings can be 
generalised to the whole country.
In conclusion, there is urgent need to scale up the provision of ART for all HIV-
positive patients initiated on TB treatment through expansion of decentralisation or 
integration of TB and HIV treatment and care services at all health facilities. The programmes 
also need to focus on better and more complete data collection, and this probably requires 
education and most importantly supervision. 28 Despite ART eligibility of all HIV-infected 
TB patients regardless of CD4 count, provision of affordable CD4 count testing technologies 
such as the PIMA Point-of-Care CD4 may be considered additional criteria, 29 that can assist 
clinicians in deciding whether to initiate ART early or late in resource limited settings. Finally, 
further research is also necessary to establish the accuracy and proper classification of TB 
diagnosis among smear-not done PTB, unclassified retreatment TB cases and ‘retreatment 
other’ TB cases.
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ABSTRACT 
SETTING
Zimbabwe has an HIV-driven tuberculosis (TB) epidemic with antiretroviral therapy (ART) 
being scaled up in the public sector since 2004. 
OBJECTIVE
To determine whether national ART scale-up was associated with annual national TB case 
notification rates, stratified by disease type and category, between 2000 and 2013. 
DESIGN
A retrospective study was undertaken using aggregate data from global reports. 
RESULTS
The number of people living with HIV and retained on ART from 2004 to 2013 increased from 
8400 to 665299, with ART coverage increasing from <0.5% to 48%. TB case notification rates, 
all types and categories, increased from 2000 to 2003, and thereafter declined from 2004 to 
2013. The decreases in annual TB notifications between the highest rates (before 2004) and 
lowest rates (2013) were: all forms of TB (56%); new TB (60%); previously-treated TB (53%); 
new smear-positive pulmonary TB (40%); new smear-negative/smear-unknown pulmonary 
TB (58%); and extra-pulmonary TB (58%).
CONCLUSION
Significant declines in TB case notification rates were observed during ART scale–up, 
especially for smear-negative PTB and extra-pulmonary TB. These encouraging national 
trends support the continued scale-up of ART to people living with HIV as a way of tackling 
the twin epidemics of HIV/AIDS and TB in Zimbabwe.
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INTRODUCTION
HIV is the most important risk factor for developing tuberculosis (TB), with that risk also 
dependent on the CD4 cell count of the HIV-infected person and the amount of transmission 
of Mycobacterium tuberculosis in the community. Antiretroviral therapy (ART) reduces the 
risk of TB in people living with HIV, with the main risk reduction being at lower CD4 cell 
counts, although benefit is also seen in those with CD4 cell counts > 350 cells/mL. 1 
Southern Africa is the region most heavily burdened with the HIV-TB epidemic, and TB is 
largely driven by HIV in the affected countries.2 However, in this region there has been 
a tremendous scale up of ART in the last decade and one might therefore expect to see a 
reduction in TB case notification rates. In Malawi and Swaziland, the scale up of ART has 
been associated with a marked decline in TB case notifications, especially with types of TB 
associated with HIV such as smear-negative pulmonary disease and recurrent TB. 3,4,5 
Zimbabwe is one of the Southern African countries with a largely HIV-driven TB epidemic, 
given the HIV/TB co-infection rates of nearly 70% among TB patients in 2014. 2 We were 
therefore interested to see whether there has been any association between ART scale-
up and annual TB case notification rates, stratified by type and category of disease, in the 
country between 2000 and 2013. 
 
METHODS
STUDY DESIGN
This was an ecological study design using aggregate programme data. 
SETTING
General: Zimbabwe is a Southern African country with a population of 13 million 6 has a 
high HIV prevalence rate of 15%. The total number of adults and children living with HIV was 
estimated at 1.4 million according to the 2013 national HIV estimates.7 
The National ART Programme in Zimbabwe: ART was first offered in public health facilities in 
2004 under the National ART programme at 5 central level hospitals, and, with national scale 
up, ART became available at 1,459 out of 1,560 health facilities by December 2014 (source – 
National ART programme). Since inception of the ART programme, the ART initiation criteria 
among adults has shifted from a CD4 cell count threshold of <200 cells/mL, to <350 cells/
mL from 2011 to 2013 and eventually to <500 cells/mL from 2014 onwards in accordance 
with WHO guidelines. 8,9,10 During these periods, ART has also been available for those with 
advanced clinical HIV disease. Towards the end of 2013, there was also a shift in eligibility 
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for lifelong ART in Zimbabwe under Option B+, whereby all HIV-infected pregnant and 
breastfeeding women irrespective of their CD4 count or World Health Organisation (WHO) 
clinical staging could be initiated on treatment for life. Over this same period, ART regimens 
have become simpler and less toxic, moving from stavudine+lamivudine+nevirapine in 
the first 6 years of the ART progamme to tenofovir+lamuvidine+nevirapine, and as of 2013, 
to tenofovir+lamuvidine+efavirenz which is administered as a single pill of fixed-dose 
combinations  to be taken once daily. 
The National TB Programme in Zimbabwe: Zimbabwe has a well-established WHO 
recommended DOTS 11 (directly observed treatment short course) national TB programme 
(NTP) whereby TB treatment services are integrated with general health services at all 
health facilities countrywide. This DOTS model ensures good structures for bacteriological 
detection of TB mostly through sputum smear microscopy followed by treatment using 
WHO standardized TB regimens. These services are provided in conjunction with supervision 
and patient support whilst ensuring an effective drug supply and management system and 
monitoring and evaluation structures for routine assessment of treatment outcomes from 
district to national level.11 National TB treatment outcomes are defined in line with WHO 
guidelines and are classified as treatment success (cured plus treatment completed), loss-
to-follow-up (defaulted), died, transferred out or treatment failure.11
TB patients are classified as either new or previously treated: new cases are those who have 
never received anti-TB treatment or have previously received anti-TB drugs for <30 days while 
previously treated TB cases are those who have previously received anti-TB drugs for >1 
month. New TB cases are divided into smear-positive pulmonary (PTB), smear-negative PTB 
or extra-pulmonary TB (EPTB) cases. As of 2013, new pulmonary bacteriologically-confirmed 
TB cases have been added to account for the expansion of Xpert MTB/RIF machines in the 
country. These new pulmonary bacteriologically-confirmed TB cases include all smear-
positive, culture-positive or positive TB cases diagnosed with molecular techniques such as 
Xpert MTB/RIF. As of 2013, this also includes pulmonary bacteriologically-confirmed cases 
with unknown previous TB treatment history. Previously treated TB patients are categorised 
as either i) relapse cases ii) treatment after failure iii) treatment after default (loss-to-follow-
up) or iv) “retreatment other”. The NTP also ensures that these TB patients are prescribed 
a standardized treatment regimen of six months for new TB cases or eight months for 
previously treated TB cases which is observed by a healthcare worker or community health 
worker for at least the first two months.
STUDY POPULATION
All people (adults and children) with HIV who were recorded as alive and retained on ART at 
the end of each year and all patients (adults and children) registered nationally each year 
with TB between 2000 and 2013 in Zimbabwe were included. 
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DATA VARIABLES AND SOURCES OF DATA
Aggregate numbers of HIV-infected people started on ART were obtained from global reports 
for the Joint Programme on HIV and AIDS (UNAIDS). Data on the estimated total population 
living with HIV (PLHIV) were also obtained from the UNAIDS website. 12 These data are 
generated annually using the Estimation and Projection Package and Spectrum software13 
from UNAIDS based on primary collected data from census reports, antenatal clinic 
surveillance, population based surveys and programme data. Data on TB case notifications 
stratified by category, type of new TB and HIV status were obtained from the WHO website.14 
To calculate TB case notification rates, national population figures for 2002 and 2012 were 
obtained from national census reports for the respective years. 15, 6 The population figures for 
the years in between 2002 and 2012 were based on the annual average inter-census growth 
rate for 2002 to 2012 of 1.1% 6 and the 2013 national population was obtained from official 
national population projection statistics. 16
ANALYSIS AND STATISTICS
Data were analysed descriptively mainly by plotting line and bar graphs of the various 
indicators over time from 2000 to 2013. Due to changing ART eligibility criteria over the years, 
ART coverage was calculated by dividing the total number of HIV-infected persons started and 
retained on ART by year by the estimated number of PLHIV. Annual TB case notification rates 
were calculated by dividing annual TB case notifications by national population figures to 
obtain case notifications per 100,000 people. Changes in TB notification rates between 2000 
and 2013 were determined by comparing the highest and lowest annual TB case notification 
rates using tests for proportions in Stata version 13.0 (Stata Corporation, College Station, TX, 
USA). Levels of significance were set at 5%.    
ETHICS APPROVAL
Ethics approval was sought and obtained from the Ministry of Health and Child Care and the 
Union Ethics advisory group, Paris, France.
RESULTS
Figure 1 shows the number and coverage of patients with HIV infection alive and retained on 
ART in Zimbabwe from 2000 to 2013. There was a rapid exponential increase in the number 
of HIV-infected patients receiving ART from 8,400 in 2004 to 665,299 in 2013. This is equivalent 
to an increase in ART coverage of the estimated HIV-infected population from <0.5% in 2004 
to 48% in 2013. 
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Figure 1. Numbers and coverage of patients with HIV infection alive and retained on ART in Zimbabwe, 
2000 – 2013. ART coverage was calculated using the total HIV population as the denominator from national 
projections obtained from Joint United Nations Programme for HIV/AIDS (UNAIDS) Spectrum software; 
ART = antiretroviral therapy.
Figure 2A shows TB case notification rates for all patients and stratified by new and 
previously treated TB from 2000 to 2013. For all TB cases, there was a sharp increase in case 
notification rates from 450 per 100,000 in 2000 to 600 per 100,000 in 2003 after which there 
was steep decline to approximately 300 per 100,000 in 2008. From 2009 to 2010 there was a 
slight increase in case notification rates after which there was a steady decline to an all-time 
low over the 13-year period in 2013 of approximately 250 per 100,000. New cases, constituting 
the majority of all TB cases, followed the same trend as for all TB cases. Previously treated TB 
case notification rates increased slightly from zero in 2000 to approximately 60 per 100,000 
before decreasing slowly over time to approximately 30 per 100,000 in 2013.
In Figure 2B there were observed declines in case notification rates for all types of new TB 
from 2000 to 2013 though more pronounced for extra-pulmonary PTB and smear-negative/
smear-unknown PTB cases combined. Smear-negative PTB cases alone declined between 
2000 to 2008, before increasing up to 2010 and eventually declined to 110 cases per 100,000 
population in 2012. Table 1 shows TB case notification rates declined significantly among 
those with new TB compared with previously treated TB whilst new smear-unknown PTB, 
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Figure 2A. Notification rates of all TB cases in Zimbabwe from 2000-2013 stratified by TB category, 
2000-2013. TB = tuberculosis.
Figure 2B. Notification rates of new TB cases in Zimbabwe stratified by type of TB, 2000-2013. PTB = 
pulmonary TB cases; TB = tuberculosis.
EPTB, and smear-unknown/smear-negative PTB cases had significantly higher declines 
compared with new smear-positive PTB cases.
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Table 1: Comparisons of TB case notification rates, stratified by type and category prior to 
2004 (at start of ART scale up) and after ART roll-out in Zimbabwe.
Type of TB Highest 
notification 
rate
(per 100,000)
(year) Lowest 
notification 
rate
(per 100,000)
(year) Decrease 
(%) between 
highest and 
lowest
P-value*
All TB 603 2003 264 2013 56.2% -
New TB 590 2003 237 2013 59.8%
Previously treated 
TB
58 2004 27 2013 53.4% p<0.001‡
New smear-
positive PTB
142 2002 85 2013 40.1% -
New smear-
negative PTB
160 2001 86 2008 46.3% p=0.278†
New EPTB 79 2002 33 2013 58.2% p=0. 01ǂ
Smear-unknown 
PTB
129 2004 23 2012 82.1% p<0.001 ɸ
New smear-
negative & smear-
unknown PTB 
combined
283 2002 118 2013 58.3% P<0.001Ï
*Test of proportions; ‡ comparison of percentage decreases between new TB and previously-treated 
TB cases †comparison of percentage decreases between smear-positive PTB and smear-negative PTB 
cases; ǂ comparison of percentage decreases between smear-positive PTB and extra-pulmonary TB cases. 
ɸ comparison of percentage decreases between smear-positive PTB and smear-unknown PTB cases. 
Ï comparison of percentage decreases between smear-positive PTB and smear-negative and smear-unknown 
PTB cases combined. TB = tuberculosis; PTB = pulmonary tuberculosis; EPTB = extra-pulmonary TB.
Figure 3 shows total TB case notification rates from 2000 to 2013 transposed against 
percentage ART coverage were there was an observed inverse trend in the declining total 
number of TB case notification rates with increasing coverage of ART.
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Figure 3. Trends in notification rates of all TB cases versus antiretroviral therapy coverage, 2000-2013. ART 
coverage was calculated using the total HIV population as the denominator from national projections obtained 
from Joint United Nations Programme for HIV/AIDS (UNAIDS) Spectrum software.
ART = antiretroviral therapy; TB = tuberculosis.
DISCUSSION
This study shows the rise and fall of TB in the pre-ART and ART scale up periods respectively 
in Zimbabwe. First, there was a sharp increase in TB case notification rates in the pre-ART 
scale-up era which was more pronounced for new TB cases and, in particular, for new extra-
pulmonary PTB cases and smear-negative and smear-unknown PTB cases combined. The 
resurgence of TB in much of sub-Saharan African in the last two decades before the advent 
of ART was attributed largely to the HIV/AIDS epidemic. 17 There was a particular increase in 
cases of smear-negative PTB largely due to the effects of severe immune suppression on the 
development of tuberculosis pathology in the lungs.18 In Zimbabwe the strong association 
between HIV and TB was manifested in high co-infection rates that reached a peak of 79% in 
2009 and were still maintained at 68% in 2013. 2
Second, from 2004 to 2013, there was a decline in all categories and types of TB 
as ART coverage in the public sector increased, and, although causality cannot be proven in 
an ecological study such as this, the decline in TB burden is likely to be due to the protective 
effects of ART on HIV-infected individuals. The impact of ART in reducing TB incidence among 
HIV-infected persons has been observed in high-income countries19 and resource-limited 
settings with a high HIV burden. In Zimbabwe as in other African countries, the indicated 
CD4 cell count threshold for starting ART has increased over the past decade from <250 
CHAPTER 7
132
cells/mL to the current threshold of <500 cells/mL, and this has the potential for more HIV-
infected persons starting ART with less advanced HIV disease and thus further reducing their 
risk of developing TB. Another plausible explanation for the significant decline in TB case 
notification rates in this period may be the large decline in HIV prevalence in Zimbabwe from 
a peak of 29.6% in 1999 to a low of 17% in 2013 according to the 2014 UNAIDS Spectrum HIV 
estimates.20 Going forward, the recent international support for a 90-90-90 approach21 which 
could pave way for an HIV test and treat approach could result in an even sharper decline in 
TB case notifications and TB incidence. 
Despite the overall decline in all forms of TB case notifications; there was a 
slight increase in all TB case notification and smear-negative PTB cases from 2008 to 2010 
before further declining to a 13-year and 12-year low in 2013 and 2012 respectively. With 
the exponential increase in ART coverage since start of ART public roll-out in 2004, this 
increase in TB notification rates may be explained by the prevailing socio-economic turmoil 
in Zimbabwe at that time whereby the nation experienced the worst hyperinflation in the 
21st century of 2600.2 percent according to the country’s Central Statistics Office between 
2007 and 2009.22 This period resulted in declining production and severe food shortages 
which may have contributed to immunosuppression among those HIV-infected and hence 
the resurgence of new TB cases particularly those with smear-negative PTB. 22 The 2008-
2010 increase in smear-negative PTB cases can be also be attributed to significant declines 
in smear-unknown PTB cases given improving availability of smear-microscopy laboratory 
services in the country. These smear-unknown PTB cases are likely to have added smear-
negative cases given that approximately one in four TB patients in Zimbabwe are HIV/TB 
co-infected likely to have smear-negative PTB. 
A significant decline was observed since 2004 in the number of previously treated 
TB cases. ART will lead to an increase in the CD4 cell count in TB patients who are already on 
treatment or have completed treatment, and their enhanced immunity would provide some 
protection against recurrent TB. This has been found elsewhere with two Malawian studies 
showing a reduction in the incidence of recurrent TB in association with ART. 23, 24 The effects 
of ART in reducing recurrent TB may be further evident as there has been a continued increase 
in ART initiations among HIV-infected TB patients from 23% in 2007 to 77% by 201314 and 
therefore attaining 100% uptake of ART for all HIV-infected TB patients could further decrease 
recurrent TB case notifications. 
There are two other considerations. First, ART, on its own, may not do the job. 
While ART can greatly reduce the risk of developing TB, it has been shown in an eight-year 
follow-up study of an ART cohort in a South African community that those with a CD4 cell 
count >700cells/mL still have about four-fold higher incidence rates of developing TB when 
compared to those HIV-uninfected in the community. 25 It may thus require the national ART 
programme to scale up isoniazid preventive therapy (IPT) which, alone26 and in combination 
with ART27, 28 has a more profound effect on reducing TB incidence among HIV-infected 
populations. From 2013, IPT was provided to HIV-infected people in ART clinics in Zimbabwe, 
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although uptake is still in its infancy and only 10,926 (<1%) HIV-positive people were provided 
with this prophylactic treatment in 2013. 29 Thus, at a population level IPT is unlikely yet 
to have had any additional effect on reducing TB case notifications. Second, the study is 
dependent on accuracy of TB  case notifications and these may be affected by the sensitivity 
of smear microscopy in peripheral laboratories resulting in possible under-diagnosis of 
bacteriologically confirmed PTB and the well understood difficulties in excluding other HIV-
related diseases resulting in possible over-diagnosis of smear-negative PTB. However, the 
country has been scaling up the use of Xpert MTB/RIF technology for screening active TB 
among PLHIV in HIV treatment and care settings with a total of 108 instruments currently 
in use countrywide. This is likely to increase the accurate detection of some of the smear 
negative TB cases. 
In conclusion, this study shows encouraging national trends of decreasing TB case 
notification rates that support the continued scale-up of ART to PLHIV as a means of tackling 
the twin epidemics of HIV/AIDS and TB in Zimbabwe. 
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SUMMARY OF THE STUDY FINDINGS 
The studies presented in this thesis highlight and provide information on important 
programmatic challenges faced by Zimbabwe in its response to the dual epidemic of HIV 
and TB. 
The study in Chapter 2 found that approximately half of all microbiologically-confirmed TB 
patients encountered patient delays, defined as more than one month between the date of 
onset of TB symptoms and first contact with a health worker.1, 2 In contrast, only three in ten 
TB patients experienced health system delays, defined as more than 4 days from date of first 
contact with a health worker to date of starting TB treatment. Not surprisingly, starting TB 
treatment at rural primary health care facilities compared to district/mission facilities and 
taking self-medication were associated with patient delays, while being diagnosed using 
Xpert MTB/RIF reduced patient delays compared with sputum smear microscopy. The use of 
Xpert MTB/RIF in sub-Saharan Africa has been shown to shorten the time to TB diagnosis and 
treatment, although this has yet to make any difference with respect to mortality reduction.3, 4 
In the studies described in Chapters 3 and 4, and contrary to what was expected, 
HIV testing among new TB cases was low (particularly among males) with less than two-thirds 
knowing their status. Among those with recurrent TB, three in ten patients also did not know 
their HIV status. Among those who did receive HIV-testing, HIV-TB coinfection rates were at 
80% or higher for both new and recurrent TB. Despite this high TB-HIV coinfection rate, a low 
proportion (less than 20%) of both new and recurrent TB cases received ART. Not surprisingly, 
given the low uptake of ART, treatment success was poor in both categories of patients, with 
about one third having unfavourable treatment outcomes. Transfer-out (where patients are 
transferred to another facility and no outcomes are reported back to the referring facility) was 
the most common type of unfavourable outcome for both new and recurrent TB patients. 
Those who were found to be HIV-positive and not documented as being on ART and those 
who were not HIV-tested had poor outcomes which were also inferior on all counts compared 
with those who were HIV-positive and on ART. Age was a factor in determining treatment 
outcomes, with older patients (≥55 years) having lower treatment success compared 
with other age groups. 
The study in Chapter 5, assessing factors associated with high case fatality in 
the southern region of Zimbabwe, documented a high mortality especially in the first two 
months of anti-TB treatment, with cumulative mortality rates being 10%, 14% and 21% at 
one, two and six months respectively after starting TB treatment. HIV-testing uptake in this 
study was high, and of those tested four in every five TB patients were HIV co-infected. ART 
uptake in HIV/TB co-infected patients was high, with only 10% not being on ART. Risk factors 
for high mortality included being elderly (>65 years old), being a retreatment TB case, being 
HIV-positive and being severely immunosuppressed (<50 cells/mL), while ART initiation was 
protective. The precise causes of the high early mortality were therefore not clear from the 
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study findings, with the authors speculating on other reasons such as late presentation with 
advanced disease, associated co-morbidity in the elderly, drug resistance in recurrent TB and 
late initiation of ART. 
The study in Chapter 6 looked more in depth at ART initiation in two provinces. 
The key findings were that in those starting ART, 16% were on ART prior to starting anti-
tuberculosis treatment, whilst among those who started ART after anti-tuberculosis 
treatment, 17% started within 2 weeks, 43% between 2 and 8 weeks and 40% after 8 weeks. 
Treatment success in the whole cohort was 82%, with case fatality being at 14% during the 
course of anti-tuberculosis treatment. Not receiving ART during anti-tuberculosis treatment 
was associated with lower anti-tuberculosis treatment success and higher mortality. 
However, there were no differences in TB treatment outcomes in relation to when ART was 
started. 
The final study in Chapter 7 documented that the number of people living with 
HIV (PLHIV) and retained on ART in the country from 2004 to 2013 increased dramatically 
and rapidly, with national ART coverage increasing from less than 1% to nearly 50%. In the 
four years prior to ART scale up, TB case notification rates for all types and categories of TB 
increased but from 2004 onwards they declined. The decreasing trend in TB case notification 
rates between the highest (before 2004) to the lowest (2013) levels were of the following order 
of magnitude: all forms of TB (56% decrease), new TB (60% decrease), previously treated 
TB (53% decrease), new smear-positive pulmonary TB (40% decrease), new smear-negative/
smear-unknown PTB (58% decrease) and extra-pulmonary TB (58% decrease). The declines 
in TB case notification rates among new TB cases were largest among patients with smear-
negative or smear-unknown PTB and extra-pulmonary TB, a finding that is to be expected 
given the strong associations between HIV-positive status and these two types of TB. 
HOW THE STUDY FINDINGS RELATE TO THE PREVIOUS LITERATURE. 
Chapter 2 focused on the important issue of delays in diagnosis and treatment. It is known 
that symptomatic patients with TB can infect up to 10–15 other people in the community 
through close contact over the course of a year.5 Given the high prevalence of HIV in 
Zimbabwe, currently estimated at about 14%,6, 7 delayed presentation by infectious TB 
patients can expose a large number of immunosuppressed persons in the general population 
to TB infection and this may be one important explanation for the high HIV coinfection rate 
of 75% in TB patients in the country.8 Children who are contacts of adults with infectious 
TB who delay seeking anti-TB treatment are also at high risk of acquiring TB disease. A 
modelling study by Dodd and colleagues suggested that in 2010 a median of 15.3 million 
children in the 22 high burden TB countries, including Zimbabwe, shared a household with 
an index adult TB patient, thus placing considerable numbers of children at risk of TB.9 If 
adults presented earlier for diagnosis, this would reduce exposure time and enable children 
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in at-risk households to potentially be screened and offered isoniazid preventive therapy. 
However, the practice of screening childhood contacts and giving protection with isoniazid 
preventive therapy leaves much to be desired in many sub-Saharan African countries.10, 11, 12 
This is an area where programmes need to step up to the plate and improve performance 
if the End TB targets and Sustainable Development Goal targets are to be achieved with 
respect to reducing TB incidence. 
Precise reasons for delayed presentation to health services, which were not explored 
in our study, have been well studied elsewhere and vary between and within countries. 
In Viet Nam, for example, many men exhibit denial and concealment attitudes towards 
TB disease and often neglect progressive symptoms until the disease is far advanced.13 
It is possible that this also applied in our setting. A study in rural South Africa found that 
being a migrant, consuming alcohol and having a prior history of TB were associated with 
delays in presentation and women in this setting were more at risk compared with men.14 
Self-medication is important and has been frequently identified with delayed presentation 
to health services.15, 16, 17 In much of Africa, patients with TB symptoms also first present to 
traditional healers, where they may take traditional medicine for several weeks before 
then seeking orthodox care.18, 19, 20 Advocacy campaigns within general communities and 
education, training and collaboration with traditional healers are therefore needed if patients 
with TB symptoms in high TB burden countries like Zimbabwe are to seek orthodox care in a 
more timely fashion. Engagement of political leaders to rally communities to present earlier 
to health facilities if they exhibit TB-like symptoms may also help in preventing TB disease 
progression which is associated with delays in seeking health care among those with latent 
TB infection. 
It was reassuring to see that health system delays were relatively minor in our study, 
with about two thirds of patients staying within the four day target. This suggests that there 
is a fairly efficient turn-around time from sputum collection, transportation, examination 
and results to the sending of results back to the care givers and hence the patients. Patients 
with smear-positive or bacteriologically confirmed TB are the most infectious and the most 
likely to transmit infection to their communities.21 They are therefore the programmatic 
focus for infection control, hence requiring as early a diagnosis as possible and start of 
anti-TB treatment in accordance with national and international TB guidelines.22, 23 Sputum 
transportation delays are often the key component of health system delays when peripheral 
health facilities have to send specimens to hospital-based laboratories for smear microscopy 
or Xpert MTB/RIF. These delays have been widely documented in African countries,24, 25, 26 as 
well as in India.16 Innovative approaches or more investment in health service transportation 
services might improve the challenging issue of sputum result turn-around times.27, 28
In Chapter 3 and 4, it was disappointing to find sub-optimal HIV-testing among 
TB patients. By 2009, it was well established that the TB epidemic in Sub-Saharan Africa 
was largely driven by HIV, with the African region constituting 80% of the global estimated 
incident HIV-TB cases.29 In Zimbabwe alone, the burden of TB disease more than doubled 
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between 1990 and 2009 from 329 to 742 cases per 100,000 population,29 while HIV prevalence 
in the general population increased from 15% in 1990 to a peak of 26% in 1996-1997 before 
declining to 15.7% in 2009.30 However, on a slightly more encouraging note, although HIV-
testing rates were low, they were higher than in 2007 when the proportion of TB patients 
knowing their HIV status was just 27%.29 
With HIV testing, males had a lower uptake compared with females. This finding 
aligns with what is found in the general population.31, 32 The reasons for low HIV testing rates 
amongst males in the general population include stigma and fear of discrimination for having 
an HIV-positive result.33 However, why HIV testing was lower in male TB patients compared 
with women is not clear, because provider-initiated testing is offered to all patients at 
registration, so access and opportunity are probably equally shared between the sexes. One 
study among TB patients in South Africa found that low testing rates among men were due 
to fear of testing HIV-positive, a perception of being at low risk of HIV infection and a desire 
first to deal with TB 'on its own', before considering HIV/AIDS,34  and these reasons might have 
been similar in Zimbabwe. The South African study also found that health workers were 
reluctant in some cases to offer HIV testing to males.34 A study in Eastern India also attributed 
low HIV-testing uptake in males with TB to higher losses in the referral process among those 
whose TB and HIV-disease were being managed at different locations  (fragmented care),35 
and this might partially explain some of our results in Zimbabwe where long waiting times 
between different services might have affected male perceptions of quality of care and good 
treatment. 36, 37, 38 
The low uptake of HIV testing during this period meant that many HIV-positive 
patients whose status remained unknown and who could have benefited from CPT and ART 
were denied adjunctive therapy. However, even in those diagnosed as being HIV-positive, ART 
uptake was reported to be low and unfortunately no information was available on adjunctive 
CPT as it was not recorded at that time.  
Adjunctive CPT is important. In 1999, a randomised controlled trial in the Ivory Coast 
found that CPT given to adults with HIV-associated TB substantially reduced severe clinical 
events and mortality.39 This seminal study paved the way for a number of observational and 
randomised studies to assess efficacy, effectiveness and safety of CPT in people living with 
HIV-associated TB, especially in sub-Saharan Africa. A recent systematic review and meta-
analysis, that included these studies, showed that across all global regions, CPT reduces 
morbidity and mortality when given to HIV-infected persons and these beneficial effects are 
augmented when the medication is combined with ART.40  
ART administered to those with HIV-associated TB results in excellent immunological 
and virological responses and a reduction in mortality risk of 64% -95%.41, 42 Timing of ART is 
important with the issue of when to start ART in relation to start of anti-TB treatment being 
clarified several years ago by three randomised controlled studies: CAMELIA,43 STRIDE,44 and 
SAPIT.45 While all three trials were slightly different, collectively one clear message emerged, 
namely that earlier initiation of ART saves lives in HIV-infected patients with TB, with the 
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benefits being particularly evident for those with CD4 cell counts < 50 cells/µL. It is also well 
established through two systematic reviews that ART results in significantly lower rates of 
recurrent TB, most probably by increasing the immune status of the patient during and after 
the end of anti-TB treatment.46, 47
Given the significant benefits of ART, the low uptake of this therapy during the 
study period was of concern. The exact reasons remain speculative but a likely cause was 
poor integration of TB and HIV services in the country at this time. Decentralisation of ART 
services in Zimbabwe started in 2008, and by December 2009 only 20% of health facilities in 
the country were offering ART.48 These health facilities were usually at tertiary or secondary 
levels where ART was administered by medical doctors. Thus, HIV-positive patients from 
peripheral centres had to be referred, limiting access and the chances of being able to start 
HIV treatment. It is possible that many HIV-positive TB patients sought ART and further 
continuation of TB treatment elsewhere and this may have contributed to the high rates of 
transfer-out. Poor integration of TB and HIV services may have also led to poor recording and 
reporting, and in fact more patients starting ART than was documented. 
There was higher mortality among older patients (≥55 year olds) and this might 
have been due to their lower uptake of HIV-testing in comparison to other age groups. HIV-
testing is the gateway to HIV care and thus older patients may have been denied such services. 
There are also a number of studies reporting poorer TB treatment outcomes among elderly 
populations. 49, 50, 51 There are several reasons for poor outcomes in this age group, none of 
which were investigated in our two studies. Older people are at risk of diabetes mellitus, 
which is associated with TB and is known to adversely affect TB treatment outcomes. 52, 53, 54 
Other comorbidities such as end-stage renal disease and malignancy in elderly people have 
also been associated with an increased risk of adverse TB outcomes and might have been 
factors in our study.53 
In Chapter 5, the observed early mortality in the intensive phase of TB treatment 
was similar to that reported from the Malawi National TB Programme several years previously, 
before the advent of ART, where 40% of patients who died did so in the first one month of 
treatment.55  Whilst being elderly (>65 years old), being a retreatment TB case, being HIV-
positive and being severely immunosuppressed (<50 cells/mL) were identified as mortality 
risk factors, the study did not explore why these mortality-associated risk factors caused 
death and the reasons remain speculative. Older age as a risk factor for mortality is intuitive 
and has already been discussed with respect to the first two studies. Recurrent TB as a risk 
factor for mortality may be due to progressive tubercular destruction of lung parenchyma 
leading to restrictive or obstructive lung disease, possible misdiagnosis especially if there is 
no bacteriological confirmation of TB or drug- resistance which may not be identified due to 
deficiencies in culture and drug sensitivity testing services. 
Patients who are diagnosed with TB within three months of starting ART have a 
high risk of dying which is a finding also reported from several other African countries.56, 57, 58, 
59 TB occurring at this time is either prevalent or incident TB, where the diagnosis depends 
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on levels of awareness, expertise and diagnostic resources. Mortality is high because of 
difficulties in diagnosing TB and presentation with severe tuberculosis disease and/or 
advanced HIV disease with high HIV viral load and severe immunosuppression. Working 
strategies to address these difficult issues are needed and these include point-of-care 
sensitive and specific diagnostic tests for TB.60 Having a high index of suspicion for TB, close 
follow-up and training of health staff on managing the immune reconstitution inflammatory 
syndrome (IRIS) and opportunistic infections which get unmasked during ART in patients with 
advanced HIV disease might also help. Many HIV-infected patients also die in sub-Saharan 
Africa in these first three months of ART because of undiagnosed and untreated TB, the point 
clearly made in a systematic review of autopsy studies in HIV-infected adults dying in health 
care facilities both on and off ART.61, 62 
Chapter 6 provided some encouraging findings about ART. When compared with 2007 when 
only 26% of TB patients knew their HIV status and 23% of those HIV-positive were started 
on ART,29 by 2010 significant progress had been made in the country. ART uptake has also 
continued to improve with over 90% of HIV/TB patients documented as starting ART three 
years later in 2013. Since the adoption of the WHO 2012 guidance on collaborative TB/HIV 
activities,63 there has been increasing HIV testing uptake and initiation of ART in the country 
as a result of integration of both TB and HIV services which are delivered in a one-stop shop 
approach. This has been facilitated by rapid expansion and decentralisation of ART services 
in the country, which saw ART services increase from less than seven sites (<1% of health 
facilities) in 2004 to 1,106 (67% of health facilities) by the end of 2013. The decentralisation 
has been facilitated by task-shifting from doctor-led to nurse-led ART initiation, which has 
also ensured that HIV-infected TB patients at peripheral level health facilities no longer have 
to wait for a doctor to come to their health facility for ART initiation nor do they have to be 
referred to higher-level health facilities for ART initiation. Nurse-led ART initiation works not 
only in Zimbabwe but in other similarly resource-constrained countries. 64
In 2010, only 6% of the HIV/TB co-infected patients had a CD4 count measured prior 
to ART initiation. Amongst those who were assessed, the median CD4 count was 128 cells/uL, 
with the majority of these patients severely immunosuppressed. The advanced HIV-disease 
at the time of registration for treatment probably explains the high numbers of patients being 
diagnosed with smear-negative PTB and EPTB, conditions which are both closely associated 
with low CD4 cell counts and severely depressed immunity.65, 66 In 2010,67 and since then in 
2013,68 and 2015,69 the WHO has recommended that all HIV-infected TB patients start ART 
regardless of the CD4 cell count, so at the programmatic level these laboratory tests are not 
needed for initiation of ART. Nevertheless, if they are done, they provide useful information 
about when HIV-infected TB patients are presenting for care. Despite a progressive relaxation 
over the last decade about the CD4 cell count threshold for starting ART, the actual CD4 cell 
count at which patients actually start ART in Africa has remained stubbornly unchanged at 
around 150 cells / uL for the last ten years.70 Low CD4 cell counts at ART initiation are a proxy 
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of delayed presentation and are associated with high risks of morbidity and mortality. A 
concerted effort needs to be made to change this practice of patients presenting late. 
Although early start of ART in HIV-infected TB patients is what is recommended, 
less than one fifth of patients studied in Chapter 6 started within 2 weeks and 40% started 
after 8 weeks. Why earlier start of ART in our study was not associated with better treatment 
outcomes is not clear. The lack of association may have several methodological reasons 
such as challenges with completeness and accuracy of routinely collected data, especially 
for dates, and no data about disease severity. For example, at the individual patient level, the 
very sick patient started early on ART may well fare badly compared with the moderately sick 
patient in whom ART initiation has been delayed. The three trials, CAMELIA,43 STRIDE,44 and 
SAPIT 45 showed that earlier initiation of ART saved lives, with the benefits being particularly 
evident for those with CD4 counts < 50 cells/uL. A randomised controlled trial in Zambia 
published in 2014, however, found no mortality benefit for early start of ART in HIV-infected 
TB patients with CD4 counts above 220 cells/ uL, with the authors making a controversial 
recommendation that ART could be delayed in this group of patients until after completion 
of 6 months of anti-tuberculosis treatment.71 A systematic review and meta-analysis 
published in 2015 found that while survival was indeed improved by early ART in HIV-infected 
TB patients with CD4 counts < 50 cells/uL, the evidence was insufficient to support or refute a 
survival benefit for early ART in those with higher CD4 counts > 50 cells/uL.72 
Most of the published studies show that early start of ART is associated with an 
increased risk of IRIS,72, 73 and this requires attentive clinical management. However, the 
programmatic benefits of commencing ART as soon as possible, which include getting 
patients into structured care, reducing the risk of recurrent TB once the current TB therapy 
is finished and preventing HIV transmission by suppressing viral load, outweigh these 
management challenges. Since the current study was conducted in 2010, seven years have 
elapsed and a repeat study with similar methodology and more attention to IRIS needs to be 
conducted in Zimbabwe to get up to date information on current practice. 
In Chapter 7, the decline in TB case notifications were dependent on the diagnosis of TB 
which may have been affected by laboratory performance of smear microscopy over the 
14 years as well as the recognised difficulties in countries like Zimbabwe of establishing 
accurate diagnoses of smear-negative PTB and EPTB. The decrease in case notifications 
may also have occurred due to other factors such as improved socio-economic status of 
the population or scale up of isoniazid preventive therapy. However, there is no evidence 
of improved socio-economic status in Zimbabwe and, although there are currently plans to 
scale up isoniazid preventive therapy, this was not implemented to any degree during the 
time period of the study. The study findings are in line with estimates in the 2016 WHO Global 
TB report showing that Zimbabwe had the highest decline in TB incidence in the fifteen years 
from 2010 to 2015.8 There is further confirmation of a decline in TB burden from the recently 
concluded national TB prevalence survey in 2014,74 which showed that the prevalence 
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of bacteriologically-confirmed TB was 344 cases (275-430) per 100,000 people leading to 
revisions in TB incidence by WHO from 278 to 242 cases per 100,000 between 2014 and 2015.5 
While ecological studies like this cannot prove causality, the decline in the burden 
of TB is likely to be due to the protective effects of ART against TB. With initiation of ART 
there is rapid functional recovery of mycobacteria-specific immune responses which results 
in enhanced capacity to restrict mycobacterial growth. 75, 76 As a result, ART has a potent TB 
preventive effect. A systematic review and meta-analysis of 11 studies from 2002 to 2011 
showed that ART was associated with a 65% reduction in TB incidence across all baseline CD4 
counts in PLHIV.77 The effects of ART were stronger in those with more advanced HIV-disease 
or with the lowest CD4 cell counts, but were also apparent in patients with CD4 counts > 350 
cells/µL. The evidence of benefits of early ART initiation at high CD4 cell counts has been 
further strengthened by results from two randomised controlled studies published in 2015 
(INSIGHT START and TEMPRANO).78, 79 These data on individual patients are further supported 
by mathematical models that predict the enormous benefit that early ART initiation might 
have on TB prevention at the population level. Using data from the southern African HIV/AIDS 
epidemic, a strategy of universal and annual HIV testing of adults with immediate start of ART 
in those diagnosed HIV-positive might be expected to halve the incidence of HIV-associated 
TB within a 5 year period.80 
Despite PLHIV routinely initiating ART at low CD4 counts, in Zimbabwe there 
has been a marked decline in TB case notifications at the population level. The findings 
in Zimbabwe have been mirrored in other countries in Southern Africa. In Swaziland, a 
decline in TB case notifications has been observed since 2009, especially for smear-negative 
TB.81 There have been several studies from Malawi documenting this decline in TB case 
notifications, noting similar large decreases in smear-negative TB and recurrent TB, all of 
which are strongly associated with HIV infection.82, 83, 84  In the latest Malawi study,84 there was 
a decline in HIV-negative as well as in HIV-positive TB cases, suggesting that a reduction in 
HIV-positive TB cases has a beneficial effect on transmission of Mycobacterium tuberculosis 
in the community and thus fewer cases of TB in the HIV uninfected population. Similar 
findings have also been reported from a 15-year observational study in Kenya where there 
was a 28-44% decrease in HIV-positive TB and 11-26% decrease in HIV-negative TB.85 
LESSONS LEARNT, CONTINUING GAPS AND NEEDED RESEARCH PRIORITIES
From the studies conducted as part of this thesis, there are some lessons to be learnt. First 
and foremost, there is the value of operational research in providing evidence of how policies 
that are adopted in alignment with global guidance are operationalized within the routine 
health setting in resource-constrained countries such as Zimbabwe. These findings often 
reveal how there are deviations in the implementation of policies and guidelines which 
impact negatively on the desired programme outcomes. Operational research provides the 
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data and the knowledge for evidence-based decision making which can guide programmes 
to recalibrate identified problematic areas in order to improve on the quality of services 
provided and/or increase the coverage of health service delivery. More attention, however, 
needs to be paid to use the data and information obtained in operational research to affect 
policy change, and a systematic approach has been recently proposed,86 which could work 
in the Zimbabwe setting. 
Second, is the subject of patient-related delays, which from our studies are more 
prevalent than health system delays when it comes to patients accessing a proper diagnosis 
and treatment. A greater focus on qualitative research is therefore needed to better understand 
these issues as well as better advocacy within communities to ensure that those with HIV 
and TB symptoms seek health facility screening and diagnosis in a timely manner. Most TB 
Programmes in Africa use a passive case finding strategy, namely waiting for symptomatic 
patients to seek health care. There seems no doubt that this is inadequate, and NTPs need 
to move to an active case finding approach, using different models in order to identify 
missing TB cases in an earlier fashion. WHO has provided guidelines for the systematic and 
active screening of high-risk groups and these guidelines should be strongly considered for 
adoption by the Zimbabwe NTP.87, 88 In one review, the yield of newly diagnosed TB through 
active case finding in PLHIV was 0.7% in population-based community surveys, 2.2% in 
contact-tracing studies, 2.3% in mines, 2.5% in prisons, 8.2% in medical and ART clinics and 
8.5% in HIV voluntary and counselling services.89
Third, it is apparent from our studies that HIV testing is the gateway for care and 
treatment of HIV-TB patients and that ART has a hugely important impact on TB treatment 
outcomes. While there is positive progress in these two areas, Zimbabwe needs to be more 
ambitious and aim for 100% HIV testing uptake and 100% of those HIV-positive receiving CPT 
and ART. Lessons learnt are that patients still present late with advanced disease and there 
are vulnerable groups that need to be identified such as the elderly. The country also needs 
to understand through qualitative research why patients present late and why the elderly are 
more severely impacted and it needs to put in place innovative and feasible solutions that 
probably involve a more community-based approach
Finally, there was the important observation that national ART scale-up was 
associated with a decrease in the national burden of TB. There are some important lessons 
from this study. HIV testing and ART scale up must be maintained and even increased in 
order for the HIV-infected population to benefit from the individual TB protective effect of 
ART. Results from the recently concluded ZIMPHIA study translate to ART coverage of 64% 
and viral suppression of 56% among all PLHIV. 33 While this is encouraging news, Zimbabwe 
also needs to implement the WHO’s recent guidance of starting all PLHIV on ART regardless 
of clinical stage or CD4 cell count, the so called “HIV test and treat approach”.69 While there 
are undoubted short to medium term benefits of this approach, caution is also required as 
longer term projections over 20 years or so raise the possibility of a rebound in TB incidence.90 
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It is clear though that ART on its own will not completely eliminate the risk of TB. 
At the laboratory level, ART is associated with incomplete long-term recovery of TB-specific 
immune function. At the individual patient level, the beneficial TB preventive effects increase 
with length of time on ART and with ART-induced immune recovery, but the risk of TB 
never decreases to levels seen in patients without HIV-infection in the same community.91 
Additional interventions are therefore needed and isoniazid preventive therapy is one that 
should be considered. Two randomised controlled studies in the Ivory Coast and South Africa 
have demonstrated that adding isoniazid preventive therapy to ART in PLHIV can lead to 
additional reductions in TB cases of 30% or more.79, 92 This intervention will therefore add 
to the TB preventive effect of ART and Zimbabwe needs to consider its widespread scale up 
within HIV treatment and care services. 
Zimbabwe also needs to repeat this ecological study and assess whether ART scale 
up is having an effect on HIV-negative TB as is the case in Malawi and Kenya. This is important 
as a serious attack on the burden of TB requires not forgetting about the basics of sound TB 
control, and this includes good infection control measures to minimise the risk of multidrug-
resistant TB and the provision of regular structured supportive supervision to all the TB 
management units in the country.93 In doing this the country needs to start recognising and 
addressing other factors that increase the risk of TB such as undernutrition, smoking, alcohol 
and diabetes mellitus as these may work independently or together with HIV to drive the 
TB epidemic in the country.94 Rapid uncontrolled urbanization together with major lifestyle 
changes among populations in sub-Saharan Africa are driving a rapidly increasing epidemic 
of diabetes mellitus,95 and there is increasing evidence to show that this poses a risk for TB 
control in terms of rising case numbers and worse treatment outcomes for people on anti-TB 
treatment.96
THE ROLE OF OPERATIONAL RESEARCH IN THE ZIMBABWE TB AND HIV 
PROGRAMME: PAST, PRESENT AND FUTURE
All the presented studies in this thesis were operational research (OR) studies, carried out 
within the routine services of the Zimbabwe HIV/AIDS and TB Programmes. OR has several 
overlapping and sometimes contradictory definitions, but the one used to oversee the 
conduct of OR in Zimbabwe has been “the search for knowledge on interventions, strategies 
or tools to enhance the quality, effectiveness or coverage of programmes in which the 
research is being conducted”.97 Ultimately, OR is done to improve programme implementation 
and performance with the ultimate aim of improving health outcomes for the people and 
communities in need. 
With the new Sustainable Development Goals focused on ending the epidemics 
of HIV and TB by 2030,98 through a marked reduction in incidence and mortality, there is a 
need for the development of new tools for both diseases (diagnostics, drugs and vaccines). 
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However, there is also an urgent need to know more about how to deliver these once they 
are developed and importantly how to deliver the existing tools much more efficiently than is 
currently the case. The “Know-Do” gap is large and there is a need for much more collaborative 
operational research that especially includes national programmes, field-based staff and 
communities in order to ensure optimal delivery of health services for patients. 
In this regard, the placement of an OR fellow (KCT) in the Zimbabwe HIV/AIDS and 
TB Programmes has led to the production of much useful OR and this has provided the 
programme with valuable information that is not easily accessible just from programme 
registers, reports or reviews. The benefit of having an OR fellow embedded in the Ministry of 
Health has been recognised at the national level, and an additional OR fellow has recently 
been appointed within the National TB Programme to help build important critical mass. 
In moving forward, sustained funding will be required to maintain these two positions. The 
OR fellows will also need to move beyond just using routinely collected secondary data and 
begin to engage with more mixed methods research, both quantitative and qualitative in 
nature, so that they can better answer some of the “why” in addition to the “what” questions 
asked by the programme leadership. Capacity building will be required to undertake this 
more intensive and demanding research methodology. 
In terms of moving the operational research agenda forward, there is a need to 
explore the extent of MDR-TB and the treatment outcomes of these patients in relation to the 
management of HIV infection. There are opportunities of exploring the extent of utilization of 
the Xpert MTB/RIF assay in screening for drug-susceptible TB and MDR-TB among high-risk 
groups such as PLHIV and retreatment TB cases as well as challenges around the use of this 
technology. Given the higher adverse outcomes among elderly patients, there is a need to 
further assess the true burden of TB in this age group using more accurate diagnostic tests 
such as Xpert MTB/RIF. 
In a developing country such as Zimbabwe, the co-existing burden of non-
communicable diseases must be addressed. A recent national nutritional and vulnerability 
assessment survey among HIV-infected patients revealed that the burden of over-nutrition 
(≥25kg/m2) affected approximately one in four patients enrolled in HIV treatment and 
care and this was higher among those aged ≥ 45 years.99 The high adverse TB treatment 
outcomes observed in chapters 5 and 6 may be related to comorbidities such as diabetes 
mellitus and hypertension which are also associated with obesity and older age.100 Given the 
notable patient-level delays in seeking TB treatment, there are also opportunities to conduct 
operational research on innovative active TB-case finding strategies aimed at shortening 
these patient delays. This includes investigating TB screening and treatment among child 
household contacts of microbiologically-confirmed TB cases and following up uptake of 
isoniazid preventive therapy in those without TB. 
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IMPACT OF RESEARCH FINDINGS ON POLICY AND PRACTICE
There are some implications from the studies conducted in this thesis for policy and practice 
change and these are shown in the Table in relation to the research question and the 
methodology used. The broad principal recommendations include: better advocacy and 
communication at the community level about HIV-TB to facilitate earlier patient presentation; 
feasible, timely and cost-effective ways of increasing HIV testing uptake and ART for those 
diagnosed HIV-positive so that no one is denied the gateway to HIV care and treatment; 
working with the National AIDS Programme to ensure continued ART scale-up in PLHIV using 
the WHO recommended “Test and Treat” approach and strongly considering the additional 
use of isoniazid preventive therapy. 
DISCUSSION AND CONCLUSION
151
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
R
es
ea
rc
h 
qu
es
ti
on
M
et
ho
do
lo
gy
R
es
ea
rc
h 
fin
di
ng
s
Im
pl
ic
at
io
ns
 fo
r 
po
lic
y 
an
d 
pr
ac
ti
ce
 
ch
an
ge
 a
t n
at
io
na
l a
nd
 in
te
rn
at
io
na
l 
le
ve
l
To
 d
et
er
m
in
e 
tre
at
m
en
t d
el
ay
s a
nd
 th
ei
r 
as
so
ci
at
ed
 fa
ct
or
s i
n 
pa
tie
nt
s w
ith
 tu
be
rc
ul
os
is 
re
gi
ste
re
d 
w
ith
in
 th
e 
Zi
m
ba
bw
e 
na
tio
na
l 
tu
be
rc
ul
os
is 
co
nt
ro
l p
ro
gr
am
m
e 
(C
ha
pt
er
 2
)
K
C
 T
ak
ar
in
da
, A
D
 H
ar
rie
s, 
B 
N
ya
th
i e
t a
l. 
Tu
be
rc
ul
os
is 
tre
at
m
en
t d
el
ay
s a
nd
 a
ss
oc
ia
te
d 
fa
ct
or
s w
ith
in
 th
e 
Zi
m
ba
bw
e 
na
tio
na
l 
tu
be
rc
ul
os
is 
pr
og
ra
m
m
e.
 
BM
C
 P
ub
lic
 H
ea
lth
 2
01
5;
 1
5:
29
.
Pa
tie
nt
 e
xi
t
in
te
rv
ie
w
s a
nd
 re
tro
sp
ec
tiv
e 
re
co
rd
 re
vi
ew
• 5
0%
 o
f a
ll 
m
ic
ro
bi
ol
og
ic
al
ly
-
co
nfi
rm
ed
 T
B 
pa
tie
nt
s e
nc
ou
nt
er
ed
 
pa
tie
nt
 d
el
ay
s
• O
nl
y 
30
%
 e
xp
er
ie
nc
ed
 h
ea
lth
 
sy
ste
m
 d
el
ay
s. 
• R
isk
 fa
ct
or
s f
or
 p
at
ie
nt
 d
el
ay
s w
er
e 
i) 
ac
ce
ss
in
g 
ca
re
 in
 ru
ra
l p
rim
ar
y 
he
al
th
 c
ar
e 
an
d 
ii)
 se
lf-
m
ed
ic
at
io
n.
 
R
isk
 fa
ct
or
s f
or
 h
ea
lth
 fa
ci
lit
y 
de
la
ys
 w
er
e 
i) 
ac
ce
ss
in
g 
tre
at
m
en
t 
at
 p
er
ip
he
ra
l h
ea
lth
 fa
ci
lit
ie
s, 
ii)
 >
 4
 
he
al
th
 fa
ci
lit
y 
vi
sit
s p
rio
r t
o 
sta
rt
 o
f 
T
B 
tre
at
m
en
t a
nd
 ii
i) 
T
B 
di
ag
no
sis
 
us
in
g 
sm
ea
r m
ic
ro
sc
op
y 
ra
th
er
 th
an
 
X
pe
rt
 M
T
B/
R
IF
 
• A
dv
oc
at
e 
fo
r t
im
el
y 
T
B 
sc
re
en
in
g 
am
on
g 
th
os
e 
w
ith
 p
re
su
m
pt
iv
e T
B
• E
ng
ag
e 
in
 m
or
e 
co
m
m
un
ity
-b
as
ed
 
an
d 
de
ce
nt
ra
lis
ed
 a
ct
iv
e 
ca
se
 fi
nd
in
g.
• B
as
ed
 o
n 
th
e 
stu
dy
 fi
nd
in
gs
, t
he
 
Zi
m
ba
bw
e 
N
T
P 
th
ro
ug
h 
Th
e 
U
ni
on
 
ha
s s
ta
rt
ed
 a
n 
ac
tiv
e T
B 
ca
se
 fi
nd
in
g 
co
m
m
un
ity
 p
ro
je
ct
 in
 2
1 
pr
io
rit
y 
di
str
ic
ts 
of
 Z
im
ba
bw
e.
 E
nc
ou
ra
ge
 
ex
pa
nd
ed
 u
se
 o
f X
pe
rt
 M
T
B/
R
IF
 
fo
r T
B 
di
ag
no
sis
To
 d
et
er
m
in
e 
tre
at
m
en
t o
ut
co
m
es
 o
f a
du
lt 
pa
tie
nt
s w
ith
 n
ew
 a
nd
 re
cu
rr
en
t t
ub
er
cu
lo
sis
 
in
 re
la
tio
n 
to
 H
IV
 st
at
us
 in
 Z
im
ba
bw
e 
(C
ha
pt
er
s 3
 a
nd
 4
).
K
C
 T
ak
ar
in
da
, A
D
 H
ar
rie
s, 
S 
Sr
in
at
h 
et
 a
l. 
Tr
ea
tm
en
t o
ut
co
m
es
 o
f a
du
lt 
pa
tie
nt
s w
ith
 
ne
w
 T
ub
er
cu
lo
sis
 in
 re
la
tio
n 
to
 H
IV
 st
at
us
 in
 
Zi
m
ba
bw
e.
 P
ub
lic
 H
ea
lth
 A
ct
io
n.
 2
01
1;
 1
(2
): 
34
-3
9.
 d
oi
: 1
0.
55
88
/p
ha
.1
1.
00
01
.
K
C
 T
ak
ar
in
da
, A
D
 H
ar
rie
s, 
et
 a
l. 
Tr
ea
tm
en
t 
ou
tc
om
es
 o
f a
du
lt 
pa
tie
nt
s w
ith
 re
cu
rr
en
t 
tu
be
rc
ul
os
is 
in
 re
la
tio
n 
to
 H
IV
 st
at
us
 in
 
Zi
m
ba
bw
e:
 a
 re
tro
sp
ec
tiv
e 
re
co
rd
 re
vi
ew
. 
BM
C
 P
ub
lic
 H
ea
lth
 2
01
2;
 1
2:
12
4.
Re
tro
sp
ec
tiv
e 
re
co
rd
 re
vi
ew
 
us
in
g 
ro
ut
in
e 
pr
og
ra
m
m
e 
da
ta
• P
oo
r u
pt
ak
e 
of
 H
IV
 te
sti
ng
 in
 n
ew
 
an
d 
re
cu
rr
en
t T
B
• P
oo
r u
pt
ak
e 
of
 A
RT
 in
 H
IV
-p
os
iti
ve
 
T
B 
pa
tie
nt
s 
• P
oo
r t
re
at
m
en
t o
ut
co
m
es
 w
ith
 o
ne
 
th
ird
 h
av
in
g 
un
fa
vo
ur
ab
le
 re
su
lts
 
w
ith
 tr
an
sfe
r-
ou
t b
ei
ng
 p
ar
tic
ul
ar
ly
 
co
m
m
on
• R
isk
 fa
ct
or
s f
or
 p
oo
r o
ut
co
m
es
 
in
cl
ud
ed
 u
nd
oc
um
en
te
d 
H
IV
 o
r 
AR
T
 st
at
us
 a
nd
 o
ld
er
 a
ge
 
• S
ca
le
 u
p 
H
IV
 te
sti
ng
 a
nd
 A
RT
 
in
iti
at
io
n 
an
d 
ai
m
 fo
r 1
00
%
 te
sti
ng
 
up
ta
ke
 a
nd
 1
00
%
 o
f H
IV
-T
B 
pa
tie
nt
s s
ta
rt
in
g 
AR
T
 
• E
ns
ur
e 
th
er
e 
is 
co
m
pl
et
e 
• m
on
ito
rin
g 
of
 o
ut
co
m
es
 a
nd
 
es
pe
ci
al
ly
 d
oc
um
en
t e
nd
 o
f 
tre
at
m
en
t s
ta
tu
s f
or
 th
os
e 
w
ho
 
tr
an
sfe
r o
ut
. 
• C
on
sid
er
 o
th
er
 c
o-
m
or
bi
di
tie
s i
n 
el
de
rly
 p
at
ie
nt
s s
uc
h 
as
 D
ia
be
te
s 
m
el
lit
us
 
IM
PA
CT
 O
F 
RE
SE
AR
CH
 F
IN
DI
N
GS
 O
N
 P
O
LI
CY
 A
N
D 
PR
AC
TI
CE
CHAPTER 8
152
To
 a
ss
es
s c
as
e 
fa
ta
lit
y 
am
on
g 
pa
tie
nt
s o
n 
an
ti-
T
B 
tre
at
m
en
t i
n 
th
e 
so
ut
he
rn
 re
gi
on
 
of
 Z
im
ba
bw
e 
an
d 
th
e 
as
so
ci
at
ed
 fa
ct
or
s 
(C
ha
pt
er
 5
)
K
C
 T
ak
ar
in
da
, C
 S
an
dy
, N
 M
as
uk
a 
et
 a
l. 
Fa
ct
or
s a
ss
oc
ia
te
d 
w
ith
 m
or
ta
lit
y 
am
on
g 
pa
tie
nt
s o
n 
T
B 
tre
at
m
en
t i
n 
th
e 
so
ut
he
rn
 
re
gi
on
 o
f Z
im
ba
bw
e,
 2
01
3.
 
Tu
be
rc
ul
os
is 
Tr
ea
tm
en
t a
nd
 R
es
ea
rc
h 
20
17
; 
20
17
: 6
23
20
71
.
Re
tro
sp
ec
tiv
e 
re
co
rd
 re
vi
ew
 
us
in
g 
ro
ut
in
e 
pr
og
ra
m
m
e 
da
ta
• B
et
te
r u
pt
ak
e 
of
 H
IV
 te
sti
ng
 a
nd
 
AR
T
 u
se
 c
om
pa
re
d 
w
ith
 3
 y
ea
rs
 
pr
ev
io
us
ly
 (C
ha
pt
er
s 2
 a
nd
 3
) 
• h
ig
h 
m
or
ta
lit
y 
es
pe
ci
al
ly
 in
 th
e 
fir
st 
tw
o 
m
on
th
s o
f t
re
at
m
en
t 
• R
isk
 fa
ct
or
s f
or
 h
ig
h 
m
or
ta
lit
y 
in
cl
ud
ed
: i
) b
ei
ng
 e
ld
er
ly,
 ii
) 
ha
vi
ng
 re
tre
at
m
en
t T
B,
 ii
i) 
be
in
g 
H
IV
-p
os
iti
ve
 a
nd
 se
ve
re
ly
 
im
m
un
os
up
pr
es
se
d 
an
d 
 iv
) A
RT
 
in
iti
at
io
n 
≤ 
3 
m
on
th
s v
er
su
s ≤
2 
w
ee
ks
• N
ee
d 
fo
r t
im
el
y 
AR
T
 in
iti
at
io
n 
am
on
g 
H
IV
 c
o-
in
fe
ct
ed
 p
at
ie
nt
s 
w
ith
 a
dv
an
ce
d 
H
IV
 d
ise
as
e
• N
ee
d 
to
 u
nd
er
sta
nd
 b
et
te
r w
hy
 o
ld
er
 
pa
tie
nt
s a
nd
 th
os
e 
w
ith
 re
cu
rr
en
t T
B 
fa
re
 b
ad
ly
To
 d
oc
um
en
t u
pt
ak
e 
of
 A
RT
 in
 p
at
ie
nt
s w
ith
 
T
B/
H
IV
 c
o-
in
fe
ct
io
n,
 th
e 
tim
in
g 
of
 A
RT
 
in
 re
la
tio
n 
to
 st
ar
t o
f a
nt
i-T
B 
tre
at
m
en
t a
nd
 
ho
w
 A
RT
 in
flu
en
ce
s T
B 
tre
at
m
en
t o
ut
co
m
es
 
(C
ha
pt
er
 6
)
K
C
 T
ak
ar
in
da
, A
D
 H
ar
rie
s, 
T
 M
ut
as
a-
Ap
ol
lo
 e
t a
l. 
An
tir
et
ro
vi
ra
l t
re
at
m
en
t u
pt
ak
e,
 
its
 ti
m
in
g 
an
d 
re
la
tio
n 
to
 T
B 
tre
at
m
en
t 
ou
tc
om
es
 a
m
on
g 
H
IV
-in
fe
ct
ed
 T
B 
pa
tie
nt
s. 
Pu
bl
ic
 H
ea
lth
 A
ct
io
n 
20
12
; 2
(3
): 
50
–5
5.
Re
tro
sp
ec
tiv
e 
re
co
rd
 re
vi
ew
 
us
in
g 
ro
ut
in
e 
pr
og
ra
m
m
e 
da
ta
• 1
6%
 o
f p
at
ie
nt
s o
n 
AR
T
 p
rio
r t
o 
sta
rt
in
g 
an
ti-
tu
be
rc
ul
os
is 
tre
at
m
en
t
• A
m
on
g 
th
e 
AR
T-
na
ïv
e,
 1
7%
 st
ar
te
d 
≤2
 w
ee
ks
, 4
3%
 b
et
w
ee
n 
2-
8 
w
ee
ks
 
an
d 
40
%
 >
8 
w
ee
ks
 fr
om
 st
ar
t o
f T
B 
tre
at
m
en
t. 
• O
ve
ra
ll 
ca
se
 fa
ta
lit
y 
of
 1
4%
 
• R
isk
 fa
ct
or
s f
or
 a
dv
er
se
 o
ut
co
m
es
 
in
cl
ud
ed
 i)
 n
ot
 re
ce
iv
in
g 
AR
T
 
• N
o 
di
ffe
re
nc
es
 in
 T
B 
tre
at
m
en
t 
ou
tc
om
es
 in
 re
la
tio
n 
to
 ti
m
in
g 
of
 
AR
T
 in
iti
at
io
n
• N
ee
d 
fo
r m
or
e 
tim
el
y 
ac
ce
ss
 to
 A
RT
 
am
on
g 
H
IV
 c
o-
in
fe
ct
ed
 T
B 
pa
tie
nt
s
To
 re
po
rt
 o
n 
tu
be
rc
ul
os
is 
ca
se
 n
ot
ifi
ca
tio
n 
ra
te
s i
n 
re
la
tio
n 
to
 th
e 
sc
al
e 
up
 o
f A
RT
 in
 
Zi
m
ba
bw
e 
(C
ha
pt
er
 7
)
K
C
 T
ak
ar
in
da
, A
D
 H
ar
rie
s, 
C
 S
an
dy
 e
t a
l. 
D
ec
lin
in
g 
tu
be
rc
ul
os
is 
ca
se
 n
ot
ifi
ca
tio
n 
ra
te
s 
w
ith
 sc
al
e-
up
 o
f a
nt
ire
tro
vi
ra
l t
he
ra
py
 in
 
Zi
m
ba
bw
e.
 
Pu
bl
ic
 H
ea
lth
 A
ct
io
n 
20
16
; 6
(3
): 
16
4–
16
8
Ec
ol
og
ic
al
 st
ud
y
• A
RT
 c
ov
er
ag
e 
in
 Z
im
ba
bw
e 
in
cr
ea
se
d 
ex
po
ne
nt
ia
lly
 fr
om
 <
0.
5%
 
to
 4
8%
 b
et
w
ee
n 
20
04
 a
nd
 2
01
3
• T
B 
ca
se
 n
ot
ifi
ca
tio
ns
 (a
ll 
fo
rm
s)
 
de
cr
ea
se
d 
by
 m
or
e 
th
an
 5
0%
 
be
tw
ee
n 
20
04
 a
nd
 2
01
3 
• N
ee
d 
fo
r c
on
tin
ue
d 
sc
al
e 
up
 o
f 
AR
T,
 e
sp
ec
ia
lly
 u
sin
g 
th
e 
“T
es
t a
nd
 
Tr
ea
t”
 a
pp
ro
ac
h,
 to
 h
el
p 
m
ee
t t
he
 
U
N
AI
D
S 
90
-9
0-
90
 ta
rg
et
s. 
Sc
al
e 
up
 
ha
s c
on
tin
ue
d 
an
d 
1,
13
0,
45
3 
(8
7%
) 
of
 th
e 
es
tim
at
ed
 1
.3
 m
ill
io
n 
PL
H
IV
 
w
er
e 
on
 A
RT
 b
y 
M
ar
ch
 2
01
8 
• N
ee
d 
to
 c
on
sid
er
 a
dd
iti
on
al
 sc
al
in
g 
up
 o
f i
so
ni
az
id
 p
re
ve
nt
iv
e 
th
er
ap
y. 
Th
is 
is 
no
w
 a
lre
ad
y 
ha
pp
en
in
g 
in
 Z
im
ba
bw
e 
af
te
r a
 p
ilo
t s
tu
dy
 
an
d 
fu
rt
he
r o
pe
ra
tio
na
l r
es
ea
rc
h 
co
nd
uc
te
d 
in
 2
01
3 
 
DISCUSSION AND CONCLUSION
153
Ch
ap
te
r 1
Ch
ap
te
r 6
Ch
ap
te
r 2
Ch
ap
te
r 7
Ch
ap
te
r 3
Ch
ap
te
r 8
Ch
ap
te
r 4
Ch
ap
te
r 5
CONCLUSION
The body of work contained in this thesis demonstrates what can be done as a result 
of rigorous analysis of secondary data collected in the routine setting of a national TB 
Programme. Important programmatic challenges, as well as encouraging progress, were 
identified. Delays in presentation to health services were identified as important patient-
related factors that need to also be addressed if TB control and reduced transmission of 
infection in the community are to be maximised. There were, and continue to be, high 
rates of TB/HIV coinfection in the country. HIV testing rates were low in 2009, especially 
amongst males, but these improved considerably by 2010 and 2013. ART uptake was also 
low in 2009 and this also increased significantly by 2013. Contrary to some of the previous 
published literature, there was no evidence that timing of ART made any difference to 
treatment outcomes: this may, however, have been related to methodological issues of using 
secondary data and this requires further study. Risk factors for mortality were identified, 
important issues being the development of TB shortly after the start of ART and increasing 
age. Finally, there is encouraging information that ART scale up is having a beneficial effect 
on TB case notifications in the country, but further work is needed to better understand the 
interactions and to assess if additional interventions such as isoniazid preventive therapy 
can produce extra benefit.    
Conducting the research within the context of the National AIDS and TB Control 
Programmes and the involvement of programme managers and staff in the design, conduct 
and publication of the studies meant that the findings had a good chance of impacting on 
policy and practice. Indeed since the completion of the thesis, the Zimbabwe Ministry of 
Health has begun to scale up and decentralise Xpert MTB/RIF, scale up isoniazid preventive 
therapy along with ART and shown more interest in operational research by appointing a 
second operational research officer to the NT Programme and taking on SORT IT courses 
to build operational research capacity within its public health workforce. This will help the 
country better tackle the HIV-TB epidemic and meet the milestones and targets within the 
WHO End TB Strategy. 
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SUMMARY
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are the twin epidemics of our 
time. In 2016, TB was the ninth leading cause of death worldwide and the leading cause 
from a single infectious agent, ranking above HIV/AIDS. In 2016, there were an estimated 
1.3 million TB deaths among HIV-negative people (down from 1.7 million in 2000) and an 
additional 374 000 TB deaths among HIV-positive people whilst an estimated 10.4 million 
people fell ill with TB in that year. Of the incident cases estimated in 2016, a quarter of these 
occurred in Sub-Saharan Africa which also bears the biggest burden of HIV as the continent 
had approximately 69% of all people living with HIV (PLHIV) in 2016. Within Sub-Saharan 
Africa, the world’s most affected region is Eastern and Southern Africa which comprises 54% 
of the global total for PLHIV. HIV is the most important risk factor for the development of TB in 
persons infected with Mycobacterium tuberculosis. Given the higher risk of TB among PLHIV, 
Sub-Saharan Africa has the world’s highest TB incidence at 254 cases per 100,000 people 
compared to the global incidence of 140 cases per 100,000 people. 
Zimbabwe, in Southern Africa, also has a high burden of TB with a TB incidence of 
208 (152–273) cases per 100,000 people.. This has been fuelled by the HIV epidemic which 
stands at 14.6% in the general population, whilst the TB/HIV co-infection rate has stood at 
about 70% over the last ten years or more. The advent of the Sustainable Development Goals 
and the World Health Organization (WHO) End TB strategy led to the reclassification of the 
high burden countries for TB, HIV/TB and MDR-TB and Zimbabwe is one of the 14 countries 
that is classified in the top 30 high priority burden countries for all three categories. Anti-TB 
treatment coverage was estimated at 72% (55%-97%) in 2015, meaning that about three in 
every ten TB cases went undiagnosed and untreated. 
In line with the WHO 2004 interim policy on TB/HIV collaborative activities, the 
country has over the years routinely monitored the prevalence of HIV/TB co-infection among 
patients receiving TB treatment. HIV testing rates of TB patients have increased from 26% 
in 2007 to 96% in 2015 whilst the HIV/TB co-infection rate has consistently stood at 70%, 
although it did peak in 2009 at 79% before gradually coming down to 70%. Uptake of 
antiretroviral therapy (ART) among co-infected TB/HIV cases has also been scaled up over 
the years from a low of 23% in 2007 to 72% in 2015. The revised WHO 2012 policy on TB/HIV 
collaborative activities brought increased emphasis on integrating TB and HIV services and 
offering these as a “one-stop shop” as well as initiating ART in a timely way among HIV/TB 
co-infected patients. 
Despite this progress, there have been existing challenges for TB/HIV collaborative 
care from 2010 onwards that were encountered by the national HIV/AIDS and TB programmes 
in Zimbabwe. First, it was known anecdotally that there were often delays in patients starting 
anti-TB treatment and more information was needed on this particular challenge. There 
were reports of problems with the sputum specimen transportation system due to lack 
of vehicles or shortages of fuel affecting the timely movement of sputum specimens from 
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peripheral primary health care centres to centralised TB diagnosing centres. These problems, 
which could lead to individual progression of disease and on-going TB transmission in the 
community, led to delays in starting treatment. This became a high priority research area for 
the NTP and therefore the research question was pursued in Chapter 2. Findings showed 
that patient delays from symptom onset to seeking health care were more prevalent and 
longer compared with health system delays encountered from the first health care visit 
to onset of TB treatment. Associated with patient-related delays was the seeking of self-
medication, suggesting the important need for promoting timely and appropriate health-
seeking behaviour among those with presumptive TB. Associated with health system delays 
were several health facility visits prior to TB diagnosis and these may be indicative of missed 
opportunities for TB screening which could be related to a low index of TB suspicion among 
some health workers.
Second, despite HIV testing among TB patients increasing to 86% with a TB/HIV 
coinfection rate of 78%, there was little information in the country about whether HIV testing 
uptake and HIV-status differed amongst those with different types and categories of TB or 
whether anti-TB treatment outcomes differed significantly in terms of HIV status (HIV-positive, 
HIV-negative or HIV-not known). This became an area of research interest for the National 
TB Programme (NTP) and was pursued in Chapter 3 and 4. HIV testing uptake was poor in 
both categories of patient. Those who were found to be HIV-positive and not documented 
as being on ART and those who were not HIV-tested had poor outcomes which were also 
inferior on all counts compared with those who were HIV-positive and on ART. 
Third, TB treatment success rates at the national level were consistently below 
the 85% target set by the WHO; this was particularly the case in 2013, when the national 
TB treatment success rate was 81% among newly registered TB cases and the case fatality 
rate was 8% regardless of type and category of TB. In Chapter 5 we therefore set out to 
assess factors associated with mortality in the high-mortality Southern region of Zimbabwe. 
Findings showed that mortality was especially prevalent in the first two months of anti-TB 
treatment, with risk factors being recurrent TB and being HIV-infected, despite a high uptake 
of ART. This high mortality was attributed to late presentation of patients with advanced HIV 
disease and likely drug-resistance in recurrent TB which needs to be verified through future 
studies. Overall, the findings endorse the need for early ART initiation and the early use of 
molecular technology such as Xpert MTB/RIF to detect rifampicin resistance as a proxy for 
multidrug-resistant TB (TB that is resistant to at least isoniazid and rifampicin). 
Fourth, amongst the TB/HIV co-infected patients there was a relatively low uptake 
of ART of about 45% in 2012. Furthermore, although the global guidance from the 2012 policy 
on TB/HIV collaborative activities to initiate ART within 2- 8 weeks of starting TB treatment 
had been adopted in the country, there was little information through the routine monitoring 
system about how well this was being implemented. Both national ART and TB programmes 
wanted to know more detail about this issue and whether ART and timely initiation was 
having any impact on TB treatment outcomes for new and for previously treated TB. This 
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was answered in Chapter 6. Just over 40% of HIV-positive TB patients were documented 
as receiving ART. Of these, 16%  were on ART prior to starting anti-tuberculosis treatment, 
whilst among those who started ART after anti-tuberculosis treatment, 17% started within 
2 weeks, 43% between 2 and 8 weeks and 40% after 8 weeks. Not receiving ART during anti-
tuberculosis treatment was associated with lower anti-tuberculosis treatment success and 
higher mortality. However, there were no differences in TB treatment outcomes in relation to 
when ART was started. 
Finally, while the TB preventive effects of ART in PLHIV were recognised at the 
individual level, there was little information in Zimbabwe about whether ART scale up at the 
national level was having any effect on TB case notifications at the population level. Using 
data from the southern African HIV/AIDS epidemic, mathematical models had predicted that 
a strategy of universal and annual HIV testing of adults with immediate start of ART in those 
diagnosed HIV-positive might be expected to halve the incidence of HIV-associated TB within 
a 5 year period.  No such information using programme data had been collected or analysed 
in Zimbabwe, and both national programmes for HIV/AIDS and TB wanted to document 
the effects of ART scale up on the national TB burden. This hypothesis was therefore tested 
in Chapter 7. Findings showed that national ART coverage increased exponentially over 
a decade from <1% to approximately 50% and was associated with halving of overall TB 
case notification rates, particularly among those with smear-negative and extra-pulmonary 
TB. The findings therefore supported the scale-up of ART as a strategy for mitigating the TB 
epidemic in Zimbabwe.
In conclusion, the above studies have highlighted important interventions that are 
needed to mitigate the TB epidemic in Zimbabwe. There is also need to promote awareness 
of early and appropriate health seeking behaviour among presumptive TB patients so that 
there is timely TB treatment initiation. Health system delays, although less of a problem than 
patient-related delays, need to be shortened through quicker identification and diagnosis of 
TB, thus lessening frequent hospital visits. The findings also indicate the need for continued 
HIV testing in this setting of high TB/HIV coinfection followed by the need for universal and 
timely initiation of ART among those co-infected in line with national and WHO guidelines 
so as to improve TB treatment outcomes. Overall, the national scale up of ART has had an 
impact beyond improving TB treatment outcomes at the individual level by decreasing TB 
case notification rates and thereby lowering TB transmission at the population level.
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SAMENVATTING
Tuberculose (tbc) en het humaan immunodeficiëntievirus (hiv) zijn de twee grote epidemieën 
van onze tijd. In 2016 was tbc de negende doodsoorzaak wereldwijd en de belangrijkste 
oorzaak op basis van één enkele infectieuze stof, op de voet gevolgd door hiv/aids. In 2016 
overleden er naar schatting 1,3 miljoen hiv-negatieve mensen aan tbc (tegenover 1,7 miljoen 
in 2000) en er overleden ook nog eens 374.000 hiv-positieve mensen aan tbc, terwijl naar 
schatting 10,4 miljoen mensen in dat jaar besmet werden met tbc. Van de in 2016 geraamde 
incidentie vond een kwart van de gevallen plaats in Afrika bezuiden de Sahara, dat ook de 
grootste hiv-last draagt, aangezien het continent in 2016 ongeveer 69% van alle mensen met 
hiv tevens tbc had. In Afrika bezuiden de Sahara ligt de zwaarst getroffen regio ter wereld, 
namelijk oost- en zuidelijk Afrika, dat 54% van het wereldwijde totaal van mensen met 
hiv uitmaakt. Hiv is de belangrijkste risicofactor voor de ontwikkeling van tuberculose bij 
personen die besmet zijn met Mycobacterium tuberculosis. Gezien het hogere risico van tbc 
onder mensen met hiv heeft Afrika bezuiden de Sahara de hoogste tbc-incidentie ter wereld 
met 254 gevallen per 100.000 mensen, vergeleken met de wereldwijde incidentie van 140 
gevallen per 100.000 mensen. 
Zimbabwe, in zuidelijk Afrika, heeft ook een hoge tbc-last met een tbc-incidentie 
van 208 (152-273) gevallen per 100.000 mensen. Dit werd gevoed door de hiv-epidemie, die 
14,6% van de bevolking heeft getroffen, terwijl het aantal gevallen van co-infectie met tbc en 
hiv in de afgelopen tien jaar en meer ongeveer 70% bedroeg. De formulering van de Duurzame 
Ontwikkelingsdoelen van de VN en de ‘End TB’-strategie van de Wereldgezondheids-
organisatie (WGO) heeft geleid tot een herindeling van de landen met een hoge tbc-, hiv/tbc- 
en multiresistente tbc-last en Zimbabwe is een van de 14 landen die in de top 30 van landen 
met een hoge prioriteit voor alle drie de categorieën zijn ingedeeld. De dekking van de anti-
tbc-behandeling werd geschat op 72% (55%-97%) in 2015, wat betekent dat ongeveer drie 
op elke tien tbc-gevallen niet gediagnosticeerd werden en onbehandeld bleven. 
In overeenstemming met het tussentijdse beleid van de WGO voor 2004 op het 
gebied van tbc/hiv-samenwerking, heeft het land in de loop der jaren routinematig de 
prevalentie van coïnfectie met hiv/tbc bij patiënten die een tbc-behandeling ondergaan, 
gemonitord. Het aantal hiv-testen bij tbc-patiënten is gestegen van 26% in 2007 tot 96% in 
2015, terwijl het percentage coïnfecties met hiv/tbc constant op 70% is uitgekomen, hoewel 
het in 2009 een piek bereikte van 79% en daarna geleidelijk terugviel tot 70%. De toepassing 
van antiretrovirale therapie (ART) onder gecoïnfecteerde tb/hiv-gevallen is in de loop der 
jaren ook opgeschaald van een dieptepunt van 23% in 2007 naar 72% in 2015. Het herziene 
WGO-beleid uit 2012 inzake samenwerkingsactiviteiten op het gebied van tbc/hiv bracht 
meer nadruk op de integratie van tbc- en hiv-diensten en het aanbieden van deze diensten 
als "one-stop-shop" en het tijdig initiëren van ART bij patiënten gecoïnfecteerd met hiv en 
tbc. 
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Ondanks deze vooruitgang werden de nationale hiv/aids- en tbc-programma's 
in Zimbabwe vanaf 2010 geconfronteerd met zaken die een bedreiging vormden voor de 
samenwerking op het gebied van de tbc/hiv-zorg. Ten eerste waren er naar verluid vaak 
vertragingen in het opstarten van een anti-tbc-behandeling. Hierover was meer informatie 
nodig. Er waren meldingen van problemen met het transportsysteem voor sputummonsters 
als gevolg van een gebrek aan voertuigen of brandstoftekorten die de tijdige verplaatsing van 
sputummonsters van perifere centra voor eerstelijnsgezondheidszorg naar gecentraliseerde 
centra voor de diagnose van tuberculose beïnvloedden. Deze problemen, die zouden 
kunnen leiden tot individuele progressie van de ziekte en voortdurende tbc-overdracht 
in de gemeenschap, leidden tot vertragingen bij het opstarten van de behandeling. Dit 
werd een prioritair onderzoeksgebied voor het nationaal tbc-programma (NTP) en wordt 
daarom als onderzoeksvraag in hoofdstuk 2 behandeld. De bevindingen toonden aan 
dat vertragingen bij patiënten vanaf het begin van de symptomen tot aan het zoeken naar 
gezondheidszorg vaker voorkwamen en langer waren in vergelijking met vertragingen in het 
gezondheidszorg-systeem vanaf het eerste bezoek tot aan het begin van de behandeling van 
tbc. Patiëntgerelateerde vertragingen werden in verband gebracht met zelfmedicatie, wat 
het belang van tijdig en passend gezondheidszorg-zoekend gedrag bij vermoedelijke tbc-
patiënten te bevorderen duidelijk maakte. Vertragingen gerelateerd aan het gezondheidszorg- 
systeem ontstonden doordat verscheidene bezoeken aan gezondheidszorgfaciliteiten 
werden afgelegd voorafgaand aan de tbc-diagnose. Deze kunnen indicatief zijn voor gemiste 
kansen voor tbc-screening die verband zouden kunnen houden met een lage index van tbc-
verdenking bij sommige gezondheidswerkers.
Ten tweede, ondanks het feit dat het aantal hiv-testen onder tbc-patiënten is 
gestegen tot 86% met een tb/hiv-coïnfectiegraad van 78%, was er weinig informatie in het 
land over de vraag of het aantal hiv-testen en de hiv-status verschilden tussen patiënten met 
verschillende soorten en categorieën tbc of dat de resultaten van de anti-tbc-behandeling 
significant verschilden in termen van hiv-status (hiv-positief, hiv-negatief of hiv-status 
onbekend). Dit werd een aandachtsgebied voor het nationaal tbc-programma en wordt 
belicht in hoofdstuk 3 en 4. Het testen op hiv was in beide categorieën patiënten beneden 
peil. Voor hen die hiv-positief werden bevonden en volgens de documenten geen ART kregen 
en zij die niet op hiv werden getest, waren de uitkomsten slecht en op alle punten inferieur 
aan die van degenen die hiv- positief waren bevonden en wel ART kregen. 
Ten derde lag het succespercentage van de tbc-behandeling op nationaal niveau 
constant onder het door de WGO vastgestelde streefgetal van 85%; dit was met name het 
geval in 2013, toen het succespercentage van de nationale tbc-behandeling onder de nieuw 
geregistreerde tbc-gevallen 81% en de letaliteit 8% bedroeg, ongeacht de soort en categorie 
tbc. In hoofdstuk 5 hebben we daarom getracht de factoren te beoordelen die verband 
houden met de mortaliteit in de zuidelijke regio van Zimbabwe, waar veel sterfgevallen 
voorkomen. De bevindingen toonden aan dat sterfte vooral voorkwam in de eerste twee 
maanden van de anti-tbc-behandeling, met risicofactoren als terugkerende tbc en infectie 
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met hiv, ondanks een hoge inzet van ART. Deze hoge mortaliteit werd toegeschreven aan 
de late klinische presentatie van patiënten met een gevorderde hiv-ziekte en waarschijnlijk 
geneesmiddelenresistentie bij terugkerende tbc, hetgeen dient te worden geverifieerd 
in toekomstige studies. Globaal genomen, bevestigen de bevindingen de behoefte aan 
vroege initiatie van ART en vroege inzet van moleculaire technologie zoals Xpert MTB/RIF 
om resistentie tegen rifampicine te detecteren als indicatie voor multiresistent tbc (tbc die 
resistent is tegen minstens isoniazide en rifampicine). 
Ten vierde was er bij de met tb/hiv gecoïnfecteerde patiënten sprake van een 
relatief lage toepassing van ART van ongeveer 45% in 2012. Hoewel de wereldwijde 
beleidsrichtlijn voor samenwerkende tb/hiv-activiteiten uit 2012 om binnen 2 tot 8 weken 
na de start van de tbc-behandeling met ART te starten in het land is overgenomen, was er via 
het gangbare monitoringssysteem weinig informatie over hoe goed dit in de praktijk werd 
uitgevoerd. Zowel de nationale ART- als tbc-programma’s vroegen om meer details over 
deze kwestie en wilden weten of ART en het tijdig starten van de behandeling enig effect 
had op de behandelingsuitkomsten voor nieuwe en eerder behandelde tbc-gevallen. Hierop 
wordt ingegaan in hoofdstuk 6. Iets meer dan 40% van de hiv-positieve tbc-patiënten werd 
gedocumenteerd als zijnde ART-patiënten. Hiervan kreeg 16% ART vóór het begin van de 
behandeling tegen tuberculose. Van de patiënten die na de behandeling tegen tuberculose 
met ART begonnen, begon 17% met ART binnen 2 weken, 43% tussen 2 en 8 weken en 40% 
na 8 weken. Het niet ontvangen van ART tijdens de anti-tbc-behandeling werd geassocieerd 
met een lager succes van de anti-tbc-behandeling en een hogere mortaliteit. Er waren echter 
geen verschillen in de resultaten van de tbc-behandeling met betrekking tot het tijdstip 
waarop met ART werd begonnen. 
Tot slot, hoewel de preventieve effecten van ART tegen tbc bij mensen met hiv op 
individueel niveau werden erkend, was er in Zimbabwe weinig informatie beschikbaar over 
de vraag of opschaling van ART op nationaal niveau enig effect had op het aantal gemelde 
tbc-gevallen op bevolkingsniveau. Op basis van gegevens over de hiv/aids-epidemie in 
zuidelijk Afrika hadden de wiskundige modellen voorspeld dat een strategie gericht op het 
grootschalig en jaarlijks testen op hiv van volwassenen, waarbij direct werd begonnen met ART 
bij hen die hiv-positief werden bevonden, de incidentie van met hiv geassocieerde tbc binnen 
een periode van 5 jaar zou kunnen halveren. Gegevens op basis van dergelijke informatie 
waren in Zimbabwe niet verzameld of geanalyseerd en de twee nationale programma's 
voor hiv/aids en tbc wilden de effecten van de opschaling van ART op de nationale tbc-last 
documenteren. Deze hypothese is daarom getest in hoofdstuk 7. De bevindingen toonden 
aan dat de nationale dekking van ART in tien jaar tijd exponentieel was toegenomen van <1% 
naar ongeveer 50% en gepaard ging met een halvering van de totale meldingspercentages 
voor tbc, met name onder mensen met sputum-uitstrijknegatieve en extrapulmonale tbc. De 
bevindingen ondersteunen daarom de opschaling van ART als strategie om de tbc-epidemie 
in Zimbabwe te beperken.
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Concluderend kan worden gesteld dat bovenstaande studies belangrijke 
interventies hebben aangetoond die nodig zijn om de tbc-epidemie in Zimbabwe te 
beperken. Er is ook behoefte aan het bevorderen van tijdig en passend gezondheidzorg-
zoekend gedrag onder vermoedelijke tbc-patiënten, zodat tijdig met de tbc-behandeling 
kan worden begonnen. De vertragingen gerelateerd aan het gezondheidszorgsysteem, 
hoewel die niet zo’n probleem vormen als de patiëntgerelateerde vertragingen, moeten 
door snellere identificatie en diagnose van tbc verkort worden, zodat uiteindelijk minder 
ziekenhuisbezoeken nodig zijn. De bevindingen wijzen ook op de behoefte aan voortzetting 
van de hiv-testen in deze situatie waarin sprake is van hoge coïnfectie met tbc en hiv en 
op de behoefte aan grootschalige en tijdige initiatie van ART bij gecoïnfecteerde patiënten 
overeenkomstig de nationale en WGO- richtlijnen om de uitkomsten van de tbc-behandeling 
te verbeteren. De opschaling van ART op nationaal niveau heeft geleid tot een verlaging van 
de tbc-meldingspercentages en daarmee ook tot een verlaging van de tbc-overdracht op het 
bevolkingsniveau en heeft daardoor over het geheel genomen een effect gehad dat verder 
reikt dan het verbeteren van de tbc-behandelresultaten op individueel niveau.
Hieronder worden de papers genoemd waarop dit proefschrift is gebaseerd in de 
volgorde waarin ze zijn verschenen.
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• report to the Director of Research, the Director of the National TB Programme and the Country 
 Director of the Union Office in Zimbabwe as appropriate
• Actively participate in Technical Working Groups set up for Monitoring and Evaluation and for 
 ongoing surveys within the AIDS and TB Department.
• Junior Lecturer: Department of Community Medicine, UZ Medical School 
[Feb 2009 – April 2010]
 Duties: 
• Teaching subjects: Biostatistics and Research Methods 
• Supervision of projects and dissertations for undergraduate students.
• One of the judges at the 2009, 2010 and 2011 Annual Medical Research Days.
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